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Abstract 
These proceedings contain thirty-one papers presented at the 
"Third International Heeting on the Toxicity of Thorotrast". The 
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Epidemiological Surveys including Human and Experimental Carcino-
genesis. 
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Introduction 
by 
J.S.Nitchall 
Addenbrookc's Hospital, Cambridge, England. 
8 
After aore than 40 years, one can talk about history. 
Colloidal thorlua dioxide was Introduced as a radiological 
contrast aediua in about 1928. The aost important 
preparation is Thorotrast which was developed for 
intravenous injection and has been used widely since 1931. 
The story of Thorotrast is a sad and salutary one, 
but I suggest very relevant to aedicine at the present 
tine. Thorotrast was obviously an outstandingly good 
radiological contrast aediuB with practically no iaaediate 
toxicity. Nevertheless, despite warnings about the risks 
of the late effects of its radioactivity, its use in 
diagnostic radiology spread widely and continued for 
•any years apparently everywhere. In the J.A.N.A. 
of Deceaber 24th 1932 (Vol.99, pp.2183-2185) an 
unambiguous report was published by the Council on 
Pharmacy and Cbenlstry. After considering the available 
evidence including that of H.S.Martland on radius 
poisoning and specifically aentioning "the short period 
during vnicb patients have been kept under observation", 
"the Council voted that Thorotrast be not accepted for 
intravenous administration". It also expressed 
reservations about its uses in retrograde pyelography 
and for outlining various body cavities. Further, In 
1934 and 1936 in Paris, Roussy, Oberling and Ouerln 
showed that Thorotrast produced sarceaas easily In 
white rats at the site of injection, both intraperitoneal 
and subcutaneous. This was an accidental finding In 
rats surviving about a year after injections of Thorotrast, 
which had produced regression of transplanted Jensen 
sarcoma and Flexner-Jobling carcinoma. Some of the 
tumours arose in relation to Thorotrast granulomata. 
Many experiments vere carried out, which established a 
causal relationship, the frequency of sarcoma induction 
increasing with the amount of Thorotrast injected. 
Since then and mainly since the War, a large number 
of reports have appeared of late deaths usually 20 years 
and longer after administration of Thorotrast, mainly 
including single cases or a few cases of malignant liver 
tumours - not only malignant haemangio-endothelioma but 
also malignant cholangioma and hepatoma -, malignant tumours 
of some other organs and fatal blood dyscrasias, chiefly 
leukaemias and aplastic anaemias, together with local 
granulomata. A very good bibliography haa been published 
by the International Atomic Energy Agency (1964). 
The Finsen Laboratory in Copenhagen has played a 
leading part in the systematic epidemiological study of 
Thorotrast. In 1948, the question was raised whether 
some esses of obscure illness were due to the late toxic 
effects of Thorotrast. The Director, the late 
Or.O.H.Henriques, realized the importance of the 
Thorotrast problem and must be given great credit for 
organizing the first collection and Investigation of a 
large number, 234, patients who had received Thorotrast 
injections, with a view to Ions-term follow-up. He 
emphasized the relevance of the uptake of the colloidal 
10 
tborlua dioxide into the reticulo-endothelial system after 
Intravenous and lntra-arterlal injection and in 1953 
presented a Finsen Laboratory Report entitled 'Radiation 
induced dysaemia - Review of 234 patients vlth deposits of 
0.5 - 5* C lb". He said in the Introduction These 
investigations are not only a teaa work, they are part of 
an Olympic race ... Ve Bust hope that our basic work nas 
been sufficiently accurate, comprehensive and extensive 
for our successors to win when carrying the torch the 
last siles". Soon sfterwards on 2nd August 1953 
Oscar Henriques died. The good work has certainly been 
carried on at the Finsen Laboratory by Professor Hogens Faber. 
In 1966 be reported "A follow-up of 1000 Tborotrast esses in 
Denmark" (Faber, 1968) and much more evidence has been 
collected since then. 
It may be of interest to say a few words about 
the work here in the early days. Dr.Henriques with 
characteristic enthusiasm obtained help and collaboration 
from the British Medical Research Council and the 
U.K.Atonic Energy Research Establishment, Harwell. At 
his request, I spent some time here under thsauspices of 
the H.R.C. My wife, Dr.L.Mary Mitchell, and I bad the 
privilege of Joining the team and ve certainly worked 
very hard. I wrote a 58 page report (MRC 51/548). Kost 
of the staff could devote only part-time work 
to the Thorotrast investigation. The 
11 
pathologist and haeaatologist was Dr.Charles Johansen. 
In 1955, he reported on a "retlculo-endothellal sarcoma 
in rabbits provoked by intravenously deposited thorium 
(Johansen, 1953«, b). Dr.0.0.Backer (1956, 1958) 
carried out extensive baeaatologlcal studies. "The 
physical and technical parts of the work", especially 
the total body radioactivity measurements, were carried 
out by Mr.(now Professor) P.G.Jensen and Dr.A.B.Ward, 
a physicist seconded fro« Harwell. He was succeeded by 
Dr.J.Rundo who correlated the total body y-ray activity 
measurements on the patients with measurements on a 
realistic phantom and calculated the radiation dose in 
rads in various tissues and organs.. Professor J.Rotblat, 
Dr.G.B.Vard and Dr.G.HJort studied autoradiography. 
Great attention was paid to the problems of evaluation 
of tissue dose in individual patients. He shall hear 
to-day about the recent developments in this field. 
In the last 20 years, a number of other surveys and 
epidemiological studies of Thorotrast patients, and a 
wide range of experimental investigations have been 
carried out throughout the world. May I emphasise the 
value of collaboration between groups in this type of 
work. This meeting provides a great opportunity both 
for assessing the present position and for looking to the 
future. In concluding this Introduction, may I thank 
Professor Mogens Faber on behalf of all of us for 
arranging this conference. 
12 
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Tissue Distribution and Steady State Activity Ratios of 
Til and Daughters In Man following intravascular 
Injection of Thorotraat* 
by 
A. Kaul 
Klinik fttr Radiologio und Nuklearned!sin 
- Nuklearaed. Physik und Strahlenschutx (Biophyaik) -
Klinikum Steglitz dar Praian Universitet Barlin 
Abstract 
Publlshad data and rasults of own investigations on tissue 
232 distribution and steady stata activity ratios of Th and 
daughters in n n ware compiled in order to get "best estimates" 
for doss rate calculations in patients with long-tarsi Thorotrast 
burdens. 
According to the results about 95 # of intravascularly in-
jected colloidal ThO_ are retained by the organs of the rati-
culo-endothelial-eystesi (RES) of the "standard Thorotrast 
patient" (liver: 59 1>\ spleeni 26,5 f.; bone »arrow* 9.3 % ) • 
Only 0.7 and 0,1 £ are distributed within the lung« and the 
232 kidneys, respectively. The fractional retention of Th in 
the marrow-free skeleton proved to be k £ on the average. 
Due to recoil at the »stent of their creation by decay 
thorium daughters are able to escape from the ThO. aggregates 
in order to be translocated to other organs or to be excreted 
fro* the body. Consequently the activity ratios between daugh-
* Dedicated with Gratitude to Prof. Dr. B. Rajewskt on his 
60th Birthday 
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tors and Tb "* in tissues of Thorotreat pat!onto aro quit* dif-
forant from tho«« in a««lod Thorotraat ampoules of tho same 
ago. Thus, in ca««o of long-term Thorotrast burdens, Ra io 
only up to kO % in equilibrium with it« paront Th " in organs 
232 
of tho RES, ond in txcais to Th ' in narrow-fro« bona in tha 
ord or of 20 £. Tho same proves trua for Ra , which io elimi-
natod fro« the Thorotraat daposito of tha RES and partly trana-
locatad to tho marrow-free okoloton. Tha corresponding activity 
ratio« between Ra224 and Th232 yialdod 0,25 - 0,36 for tho 
liver, spleen and bono narrow, and proved to ba almost 2 for 
2 12 tho narrow-froo skeleton. In tho lung« Pb io assumed to bo 
224 in excess to it« paront Ra by a factor of noarly 20, duo to 
212 Pb bound to th« collular fraction of blood, and duo to dacay 
220 
of Rn having boon escaped from tha RES into tho gonoral cir-
culation. 
232 Tho avorago steady atat« activity ratio« of Th J within tha 
RES of the "standard Thorotrast patient* proved to ba quite 
comparable to those observed in animal experiments, indicating 
232 
tho elimination of Th decay product« in vivo fro* ThO. ag-
gregates to be a property of Thorotrast itself rather than of 
tho animal. 
Introduction 
Patienta with Thorotrast body burden« conatituta a signifi-
cant population for epidemiological atudias on the effects of 
chronic internal irradiation. However, in addition to clinical 
examinations, information on the asaociated radiation energy 
absorbed is necessary if these studies are to yield results 
of general usefulness. 
Unfortunately, Thorotrast radiation dosimetry is a problem 
of great complexity. This is, in part, due to the colloidal 
nature of Th 3 0-, and the large number of differaat radio-
232 
nuclides which constitute the Th d>c«v series, and will 
exhibit its own characteristic metabolic behaviour within the 
232 body. Because of this different movement of Th and its 
daughters aa well as their inhonwgeneou* distribution in seve-
ral different physical phases of tha injection material radio-
active equilibrium will not »1st within the body tissues. 
Morsover, non-uniform distribution of ths thorium colloid in 
16 
tissues as vol! aa self-absorption of emitted radiation duo to 
aggregation of tho ThO_ particles within the living tiasuss 
also sorv« to complicate doso calculations. 
During tho past years varioua investigators have coneamad 
with extensive inveatigationa on the diatrlbutlon and metabolic 
pathways of Th and ita longer livad daughters In Thorotraat 
patlsnts as wall aa in animals, as a basis for estimating ab-
sorbsd dosss (ROTBLAD st si., 1953; RONDO. 1956; 1957; 1958; 
i960; HVRSH st si., 1957; HURSH, 1965; REYNOLDS at al., 1957; 
MARINELLI st al., 1962; 1963; HEYDER, 1968; KAUL, 1964; 1965si 
1965b; 1965c; 1969; 1971; U H st al., 1969; 1970; HUTN at al., 
1962; OBERHAUSEN at al., 1964). Ths amtabolic pattarn of be-
220 haviour of tha ahort-livsd thorium daughter Rn waa exten-
sivsly studiad in aan particularly by RONDO at al. (1958). 
RRILLMAIER (196«), GRILLMATER at al. (196«), KAUL (1964), and 
HURSH (1965; 1966). 
On th« basis of publishsd data and thoaa of own investiga-
tions PARR and co-workers (1969) suaawrlzed eome of tha cur-
rently accepted data on Thorotraat metabolism with particular 
21Z 
coneideration of the metabolism of tho shorter-lived Th 
.. _^. j « . 228 __22* -.212 . -.212 daughter products Ac , Ra , Pb , and Bl 
Similarly to theae authoro it is tha aim of the preaeut 
atudy to derive from published data and thoae of own investiga-
tions present "best estimates* on tissue distribution and 
232 
steady state activity ratios of Th * snd daughters in nan, and 
to coapare the results with those of own anlaal experimenta 
and those of others. 
Rssults 
232 In table 1 average concentrations of Th "^  in various organa 
of Thorotrast patients are suswjarised frosi resulta of tissue 
analyses of 30 patients publishsd up to now. According to PARR 
et si. (1969) the concentrations of Th ' in ths tissues have 
232 been normalized with respect to the Th content of the liver, 
Tor being sble to extrapolate the average tiasus distributions 
to the whole body under constant conditions. The reaults indi-
232 
cate the average Th concentration in the spleen of Thoro-
trast pstisnts to be approximately 500 < of that in the liver. 
17 
taining sorrow proved to bo 18 % on the average while that in 
marrow-free bone, the kidneyP, and the lungs yielded 1 to 2 i 
232 
of that in the liver. Published data on Th concentrations in 
kidney samples of petients with retrograde Thorotrast pyelogra-
phy and those in perivascular depoaits were not compiled, be-
cause the injection conditions are hardly to be compared to 
those of usual intravascular applications of colloidal ThO«. 
In order to get present "best estimates" of the organ dis-
212 tribution of Th in a "standard Thorotrast patient" after 
intravaacular injection of Thorotrast, extrapolations fro* the 
2*12 
average data on Th tissue diatribution of table 1 for man 
to the whole body had been made for the Standard Man. The re-
sults are summarized in table 2, indicating: a fractional reten-
tion of Th ' in the liver of about 60 %. The average Th ^ 
content of the spleen proved to be 25 £• and that of the red 
bone marrow about 9 £, relative to the asmunt within the whole 
body. In the total narrow-free skeleton less than 4 £ of whole 
212 body Th J are retained, while the corresponding distribution 
in the lungs and kidneys is below 1 £• A«wunts of Thorotrast 
contained in other organs are assumed to be negligible. As rele-
232 
vant data on the fractional retention of Th in lymph nodes 
are lacking- no estimate of the amount of Thorotrast in the whole 
lymphatic system has been done. 
In table 3 the calculated average organ distribution of 
232 Th in sian is compared to results of foraer own estimates or 
those published by others. Generally, the data are in rather 
good agreement , indicating; about 95 £ of whole body Th to 
be retained by the RES in cases of intravascularly injected Tho-
rotrast into patients. 
According to the above remarks further presupposition for 
estimating dose rates in organs of Thorotrast patients is the 
knowledge of the stady state activity ratios between thorium 
232 daughters and Th in tissues of men. 
Concerning the activity ratios bstween the longer-lived 
thorium decay products, i.e, Ra228/Th223, Th228/Ra228, and 
18 
2»k 228 
Ra /Th , in tissues belonging to the RES, quite relevant 
data fron a larger nuaber of carefully analyzed Thorotrast 
cases are available fron literature. Equilibrium activity 
212 
ratios of Th J daughters in liver, spleen, and bone marrow 
including bone containing narrow, as well as in narrow-free 
bone have been compiled from literature or calculated from pub-
lished activity data for long-term Thorotraat burdens, and sum-
marized in tables h - 7. Average values of the activity ratios 
of tissue samples of 10 - 27 individual cases are included in 
the tables in a qualified sense that those ratios which were 
felt to be obviously consistent with the majority of published 
data were not taken into consideration. 
212 
Concerning the equilibrium activity ratio between Pb and 
22** Ra only few data are available for nan, particularly for 
bone marrow and narrow-free bones. This proves true above all 
212 212 for the ratio Bi /Pb which was determined in only 2 human 
samples of spleen tissue. 
For the lungs and kidneys of patients with intravascularly 
administered Thorotrast data on steady state activity ratioa 
232 between thorium daughters and Th are only known at present 
from investigations of PARR and co-workers (1969) in 4 patients 
with Thorotrast burdens between 26 days and 26 years. Though 
these data may hardly be assumed to be of general relevance, 
average values have been estimated from the different activity 
ratios, being summarized in tables 8 and 9. 
Similarly to the above procedure of calculating present 
232 
"best estimates" of the tissue distribution of Th in the 
body of a "standard Thorotrast patient" present "best estimates'1 
of steady state activity ratios in patients with long-term 
Thorotrast burdens after intravascular injection of the ThO_ 
colloid were performed as was done earlier by PARR and co-wor-
kers in 1969. The results having been summarized in table 10, 
212 212 
again elucidate the absence of relevant data on Bi /Pb 
activity ratios in most tissues of man* 
Within organs belonging to the RES, i.e. the liver, spleen, 
and bone marrow, distinct radioactive disequilibrium excists 
between Ra and its parent Th J , according to a continuous 
wash-out of the long-lived radium isotope which proved to be 
60 $> according to own animal experiments with rabbits (KAUL, 
19 
. 22å 
1969; KAUL et al., 1969). The same proves true for R* which 
is obviously eliminated from Thorotrast deposits within the 
liver, apleen and bone marrow to a less extent compared to 
Ra , as can be seen from the corresponding activity ratios 
Z2h 228 Ra /Th . Again from animal experiments we know that only 
00(1 228 
35 £ of Ra being created by decay of Th is released from 
ThO. deposits within the liver and spleen (KAUL, 1969: KAUL et 
224 
al.t 1969)> This reduced elimination of Ra is more likely 
ZZk 
due to the higher recoil energy of 97 keV of Ra at the mo-
ment of its creation (by d-decay of Th ) compared to that 01 
Ra (70 keV), and in pursuance of which, due to a higher 
probability of being retrapped by surrounding ThO- particles 
22* 
of the aggregates. The shorter half-life of Ra is probably 
of less importance, as we know from animal experiments, that 
the biological half-life of radium in ionic form within the 
liver and spleen of rabbits is only about 6 hours (KAUL, 1969)* 
228 224 In marrow-free bone Ra and Ra have been found to be 
in excess to their parents due to translocation, in part, of 
both radium isotopes, mainly from the liver and apleen to bone. 
This process, first carefully studied in 1957 by REYNOLDS and 
co-workers, had been investigated in Thorotrast rabbits, and 
formally described by means of a compartment model, revealing 
- 22k 
15 % of Ra , being eliminated from the RES, to be transloca-
ted to the entire skeleton of the animals (KAUL, 1969; 1971; 
219 22ii 
KAUL et al., 1970). The excess of Pb compared to Ra by a 
factor of approximately 18, as published by PARR et al. (1969) 
212 for only one sample of lung tissue, is due to Pb bound to 
220 the cellular fraction of the blood, and due to decay of Rn , 
having been escaped from the RES into the general circulation 
in the order of 16 or 20 %f according to HURSh (1965) and 
GRILLMAIER st al. (1964), respectively. 
232 The average steady state activity ratios of Th daughters 
within ths RES of the "standard Thorotrast patient" of table 
10 prove to be quite comparable to those observed in own ani-
mal experiments (HEYDER, 1968; KAUL, 1969) and those published 
by PARR st al. (1969), indicating the mechanism of elimination 
232 
of Th •* decay products in vivo from ThO, aggregates to be a 
property ot Thorotrast itself rather than of the animal (see 
table 11). The corresponding mechanism, having been shown to be 
20 
most adequate to predict elimination of thorium daughters from 
ThO. particles in vitro as well as in vivo is that of escape 
of thorium decay products by recoil at the moment of their 
creation. This recoil model had been developed by PARR {l965)t 
and was applied later to interpretations of results of own in-
vestigations (K\UL, 1969; HEYDER et al., 1971). 
For the whole body, estimates of the steady state activity 
ratios have also been done on the basis of average tissue 
equilibrium activity ratios of table 10, by attaching weighting 
232 factors according to the organ distribution of Th as derived 
above (see table 2 ) . The results of these calculations, summa-
rized in table 12, prove to be quite comparable to those 
estimated from excretion analyses, as obtained by different 
authors (HURSH et al., 1957: RUNDO et al., 1958; MUTH et al., 
1962; KAUL, 196**; GRTLLMAIER, 1964; HURSH, 1965). 
Discussion of the results 
Dose rate calculations in patients with long-term Thorotrast 
232 
burdens presume knowledge of organ distribution of Th and 
232 
activity ratios between Th and its daughters. For that pur-
pose data of others and those of own investigations were com-
piled from literature as basis for calculating present "best 
estimates'*. All data only refer to the less complicated case 
of purely intravascular injection of Thorotrast, and may not 
be applied without precautions to cases of retrograde Thoro-
trast pyelography, or patients with important perivascular 
Thorotrast deposits. 
Considerable caution is also called when using the results 
232 
of the average Th organ distribution to predict whole body 
and organ Thorotrast burden from tissue analyses of any one 
Thorotrast patient , or to estimate Individual organ distri-
232 button of Th ' and its daughters from results of whole-body 
counting. To the same extent all calculated steady state acti-
vity ratios as given above may only be considered as coeffi-
cients for dose rate estimates in typical cases of long-term 
Thorotrast burdens. 
The limited relevance of these data, though nevertheless to 
be necessary at least for estimating mean organ doses, and un-
likely to undergo major revision in future, is mainly due to 
the fact, that in most cases results of tissue samples had to 
21 
be extrapolated to whole organs, and different pathological 
conditions fro« which these patienta suffered war* not able to 
be considered with regard to distribution of Th and daugh-
ters within the organism. 
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Radiation Dose in Lunsa 
R. Grlllmaier and H. Muth 
Institut ffttr Biophysik - Boris Rajevslcy-Institut -
Universitet des Saarlandes 
Romburg (Saar) 
Abstract 
'Die fundamentals for calculating radiation doses in the dif-
ferent parts of the lungs of thorotrast patients are descri-
bed and doses and dose-rates depending on time after injec-
tion of the contrast medium and on the injected amount are 
given. 
Key vordss Ihorotrast 
Ihoron 
Lung-burden 
Die calculations of the radiation dosas in the different re-
gions of the lungs of Ihorotrast patients are based on the 
following fundamentals (Grillmaler and Muth). ' : 
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1. On the results of measurements of the thoron concentration 
in the exhaled air. Measurements of the first 46 patients 
at the beginning of the Thor o t rast research program had 
shown that in good agreement vith other series of Investi-
ng 
gations (Rundo) ' patients with only RES-depcsits (without 
paravascular infiltrates) on the average exhale (8 + 3) # 
of thoron. More recent measurements of thoron concentra-
tion in the exhaled air of further 6l patients have con-
firmed this value again. 
2. The geometrical data as length, diameter, volume, and num-
ber of the different parts of the bronchial tree and al-
voeli, which are necessary for the calculations, we have 
taken from the anatomic lung model of Landahl. This model 
is shown in table 1. It also includes the ciliary trans-
port velocities. 
Table 1 
Region 
Trachea 
Main Br 
Lobar Br 
Seam Br. 
SubsegBr 
Terminal Br 
Resp. Br 
Alveol duct. 
Alveol sacc 
Anatomic model of humon kino. 
Umber 
1 
2 
12 
100 
BOO 
6 »10* 
2« I 0 5 
5»I06 
5»o' 
Diameter 
(cm) 
1.6 
1.0 
0.4 
0 2 
0.15 
0.06 
0.05 
0 0 4 
Length 
(cm) 
12 
6 
3 
IS 
0.5 
0 3 
0.15 
0 0 5 
0.04 
Total 
surface 
area 
(cm') 
60 
4 0 
45 
100 
200 
3 4 0 0 
4 7 0 0 
30,000 
250.000 
Total 
volume 
(cm') 
24 
10 
5 
5 
10 
50 
60 
300 
2500 
Ciliary 
transport 
velocity 
(cm/mm) 
15 
0 8 
0 3 
0.1 
0 0 2 
0 0 0 4 
-
-
-
3. For the calculations the following physiological mean va-
lues are assumedi 
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a) Breathing rate is taken as 7 l/min. This value is in 
agreement with the mean, value ve have found for thoro-
trast patients. 
b) The breathing volume is taken as 0.5 1. 
c) The volume of the lungs is taken as 3.25 1. 
d) The total mass of the respiratory zone (resp.br., 
alveol.duct*, alveol.sacc.) is taken as 800 g. Density 
of lung mass is 1 g/cm . 
4. The penetration depth of the n -particles Is assumed to be 
about 50 11. From this value and unit density the mass of 
the irradiated lung tissue in the bronchial tree (exclu-
ding the resp. zone) is calculated. 
5. Only the K-particle radiation doses as the most important 
factor are calculated. 
For computing the radiation dose at a certain time after 
injection the time dependend behaviour of the dose rate has 
to be known. The dose rate however is depending on the 
activity ratios of the thorium-232 daughters in the or-
ganism* 
The following assumptions confirmed by special investiga-
tions have been made: 
a) At the time of injection the thorotrast does not con-
tain radium 228 (Rundo,3' Haul,4' Rotblad and Ward,5') 
but the equilibrium amount of thorium 228 (Kaul. ' 
Parr6*). 
b) After injection 50 $ of the radium 228 which grows in 
vivo from thorium 232 is excreted. It is assumed that 
no appreciable amounts of other daughters are excre-
ted. From these assumptions the time dependence of the 
thoron proauction is evaluated. 
To receive the doss rates or doses the knowledge of the 
activity ratios of thoron and its daughters in the lungs 
and on ths lung epithelium Is also necessary* For Invest!* 
3U 
gating these activity ratios the following factors are taken 
into a account: 
a) The deposition of thoron daughters built/In the breathing 
air on the lung epithelium. 
b) The attachment of thoron daughters to aerosol particles in 
the air which possibly leads to a decrease in the deposi-
tion on the lung tissue, 
c) The transfer for thoxon daughter particles deposited on the 
mucus layer of the lung epithelium or still in the air out 
of the lungs. 
The results of the computations establish that in the respi-
rative zone practically all polonium-216 and lead-212 atoms 
are deposited on the walls of the respirative bronchi and al-
veoli before decaying ore before attachment to aerosol par-
ticles is possible. It was assumed, that the particles remain 
at the site of deposition so that in the respirative zone ra-
dioactive equilibrium between thoron, polonium-216, lead-212 
and the other thoron daughters exist. 
In the broncb&yl tree including the bronchi up to the trachea 
the mean residence time of the air in comparison to the half 
life of polonium-216 is so long, that the radioactive equili-
brium between thoron and polonium-216 practically exists at 
once, whereas the half life of lead-212 is much too long so 
that no lead-212 activity can grow up in the air. In addition 
to these facts it was established, that even in the case of 
complete deposition of polonlum-2l6 on the mucus layer of the 
epithelium and even in the region of the highest ciliary 
transport velocity the radioactive equilibrium between thoron 
and polonium-216 is not disturbed. 
In comparison even in the region of lowest velocity of ciliary 
transport no appreciable amount of lead-212 activity is built 
up by decay of deposited polonium-216. 
Therefore the computations of the radiation doses in the dif-
ferent parts of the bronchial tree concerning the activity 
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ratios of thoron and its daughters are based on the following 
assumptionst 
During exhalation air vith thoron but free of polonium-2i6 
and lead-212 is introduced from the alveolar region in the 
upper airways. Vithin a very short time polonium-216 is in 
radioactive equilibrium vith thoron independent of the fact, 
that it may be deposited on the mucus layer or not. 
Lead-212 however cannot build up an appreciable amount of 
activity neither in the air nor on the epithelium. 
During the inhalation period and the period of air retention 
in the lungs the thoron containing air is drawn into the 
respirative zone. The bronchial tree is filled vith fresh 
thoron free air. 
Polonium-2l6 particles which perhaps are deposited on the 
epithelium decay at once. No irradiation occurs during this 
period. Only in the terminal bronchi it is assumed, that the 
inhaled air is mixed uniformly with the thoron containing air 
of the respirative zone. 
The time dependent relationship of the dose-rates and doses 
in the different parts of the lungs during the period of 15 
to 30 years after injection of 20 ml thorotrast is shown in 
figure 1. 
The increase of the dose rates is caused by the increase of 
the radium-228 activity which grows up In vivo. 
Table 2 contains the alpha-ray doses 30 years after the in-
jection of different amounts of thorotrast in the different 
parts of the lungs. It can be seen, that the doses vary 
markedly in the different regions« If one take* into conside-
ration the biological effectivness of alpha-rays the equiva-
lent doses exceed the maximum permissible doses partially by 
a high factor. 
It must be mentioned that the absorption of alpha-ray ener-
gies in the air and in the mucus layer have not been taken 
Figur« I 
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Dos* retp. do*« rat« after injact ion of 2Oml(0.«5rCi23aTli>ThofOtra»t 
into account, Therefore the radiation doses in the upper air-
ways especially in the trachea are a little too high. Hie 
real values may be 20 to 30 £ lower. 
A further comment is to make! Many of the patients ve have 
evaluated have additional large paravascular infiltrates fil-
led with thorotrast. As recent measurements have established. 
practically no thoron is released out of these infiltrates. 
But because these patients have in a first approximation an 
equal amount of thorotrast in the organs of the RES. for cal-
culating the lung doses we take an exhalation rate of {k J l) •« 
relating to the whole body burden measured. Ibis is a mean 
value ve have obtained by measuring thorotrast patients with 
both. RES-deposits and paravascular infiltrates* 
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Table 2 
INJECTED 
THOROTRAST (ML) « 5 12 20 l»5 
RESP. ZONE 
TERN. BR. 
SVBSEGM. BR. 
SEGM. BR. 
LOBAR BR. 
MAIN BR. 
TRACHEA 
18 
9 
11 
15 
30 
77 
122 
1*1. 
22 
27 
36 
73 
184 
293 
73 
36 
*5 
60 
122 
306 
488 
165 
82 
102 
136 
27k 
689 
1100 
DOSE (RAD) 
Concluding the considerations one has to take into account 
the possibility of additional irradiations of the lungs by 
primary thorotrast depositions in this organ or respectively 
in the lymph nodes placed in the lungs. 
Table 3 contains the results of investigation* concerning 
this point. The mean thorotrast content in lung tissue is 
0.7 % of the whole body burden. Ihis amount would cause a 
alpha-ray dose rate of 3 jf in the trachea to 33 1> in the ter-
minal bronchi of that applicated by thoron and its daughters 
in these parts of the lungs 30 years after injection ot thoro-
trast. Calculating the dose rate by primary thorotrast depo-
sits in the lungs a uniform distribution of ThO, was assumed. 
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Table 3 
RADIATION DOSE DISTRIBUTION IN LUNGS OF THOROTRAST PATIENTS 
Tablt 2. »TlwMlRi rflmgs (Whali organ nlatat to mtstr bait brnJui) 
Author 
HuRSHff di 
KAOL 
DUDLEY 
PAW 
Sum 
Average 
Number of 
cases 
4 
1 
1 
5 
11 
Duration of 
body burden 
17d»yi-19yr 
long term 
~25yr 
26da.ys-26yr 
Th-eontent 
1.4 
ao5« 
0.14« 
0.3 
1.4 X4 
0.05 x 1 
0.14 x 1 
0.3 x 5 
7.29 
7.29:11 =0.66% 
* Calculated from measured Th-content, assuming that the activity ratios of 
°*Th and its followers in the lung arc the same as in the organs of the RES. 
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Abstract 
Estimates of mean organ dose rates for patients with long-
term burdens of intravascularly injected Thorotrast (^0, 30 
and 50 ml) were performed based upon present "best estimates*' 
on tissue distribution and steady state activity ratios of 
232 
Th and daughters. Self-absorption of emitted radiation due 
to aggregation of the ThOg particles within the living tissues 
was considered by application of conventional methods of empi-
rical origin. In addition, long-term (0,125-392 days) animal 
experiments were done with rabbits, considering the size of the 
Th02 aggregates in vivo, and their variation with time in tis-
sues of the reticuloendothelial system, by analyses of histo-
logical sections using a picture analyzing computer ("flying 
spot analysis"). 
* Dedicated with Gratitude to Prof. Dr. B. Rajewsky on his 
HOth. Rirthday. 
•u 
For an intravascular injection of 50 ml Thorotrast the mean 
ot -ray dose rate in the liver, spleen, and bone •arrow proved 
to be about UO, 120 and 23 rd/year, respectively. The corre-
sponding self-absorption correction factors foroC-particles 
yielded 0,52, 0,29 and 0,87, respectively, if calculated 
according to conventional methods. By computerized picture 
analyses of rabbit tissue samples (liver and spleen) containing 
232 Th at comparable concentrations self-absorption correction 
factors have been calculated which proved to be approximately 
0,6 and 0,**5» respectively. 
Moreover, the results of the animal experiments have indi-
cated the process of aggregation of ThO- particles within the 
liver tissue to be continuing for times of more than 400 days 
after Thorotrast injection. In the spleen, however, the aggre-
gates size distribution remained nearly constant at times of 
more than about 150 days after Thorotrast application. 
Introduction 
Thorotrast dosimetry is a problem of great complexity due 
to incomplete knowledge of purely physical, physicochemical, 
and biological factors, affecting radiation dose to organs of 
Thorotrast patients. Nevertheless, as Thorotrast patients pos-
sibly constitute an important and unique population for the 
study of low-level and long-term irradation effects in man, 
calculations of mean dose rates delivered to the tissues of 
Thorotrast patients need to be done. For that reason according 
to previous investigators (RUND0, 1958; 1960; HURSH et al., 
1957; HURSH, 1965; KAUL, 1964; 1965a,b,c; MARINELLI, 1965; 
DUDLEY, 1966; PARR et al., 1969) the present study is concerned 
with the evaluation of dose rates, as to derive the current 
"best estimates" based on average data on organ distribution 
232 232 
of Th , and on steady state activity ratios between Th 
and its daughters, as had been compiled on the occasion of the 
present meeting (KAUL, 1973). 
Tn addition, self-absorption of emitted radiation due to 
aggregation of colloidal thorium dioxide in tissues of the 
RES will be dealt quantitatively based on recent results ot 
animal experiments with rabbits. 
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Results 
1 Calculation of mean dose rates 
As a presupposition for dose rate calculations, the average 
232 
organ distribution of Th has been calculated as present 
"best estimate" applied to a "standard Thorotrast patient" 
after intravascular injection of Thorotrast (KAUL, 1973). The 
results once more summarized in table 1, indicate an average 
212 fractional retention of Th in the liver and spleen of 60 and 
26 #, respectively. The corresponding value for the red bone 
marrow proved to be about 9 $>, that for the total skeleton was 
less than h £. Within the lungs and kidneys less than 1 *% of 
232 
whole body Th were etimated to be retained. 
As even in long-term cases of Thorotrast burdens thorium 
232 daughters will never reach radioactive equilibrium with Th 
due to continuous translocation within the body and excretion 
from the body, dose rate calculations presuppose additional 
232 information on the steady state activity ratios between Th 
and its radioactive decay products. The corresponding data 
have been derived for various tissues of human Thorotrast cases 
from publiahed equilibrium activity ratios between the different 
2 32 2 T2 
Th daughters, and (normalized to unity for Th ) presented 
as current "best estimates" in table 2. 
From the purely physical point of view these data, completed 
by data on radiation type and average energy per desintegration 
of each radionuclide, are sufficient for dose rate calculations. 
However, from the early investigations by BERENBAUM et al.(l953) 
colloidal ThO_ proved to be deposited within the living tissues 
in aggregates or granules up to 100yum across, giving rise to 
substantial self-absorption of oC-particles. By combination of 
autoradiography und light microscopy ROTBLAD et al, (1953) were 
able to estimate the fraction F of eC -ray energy being dissi-
pated outside the ThO_ aggregates, from observed track concen-
trations and lengths in the nuclear track emulsions. Further 
investigations by WARD (1955), GUIMARAES et al. (1956), and 
BUN DO (1958) yielded the degree of self-absorption to be depen-
232 
dent on the concentration of Th in the tissue, and on the 
period of deposition. 
According to the results of these authors, the average 
fraction f of the oC-ray energy being dissipated outside the 
*3 
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ThO. aggregates in tissues of long-tern Thorotraat body burdens 
232 
can be represented empirically as a function of mean Th 
tissue concentration as follows: 
f = 0,645 exp(-1,50A) + 0.355 exp(-0,0*»7A) 
where A is the concentration of Th expressed as dpm/swr . 
Based upon this conventional concept of calculating self-
absorption, and considering both the above mentioned organ 
2 32 distribution of Th and equilibrium activity ratios mean 
organ oC-dose rates D*(rd/year) have been estimated for 10, 30 
and 50 ml Thorotrast intravascularly injected 20-25 years pre-
viously. The results of the estimations are summarized in 
table 3 together with the corresponding self-absorption correc-
tion factors for oC-particles. For example in case of 50 nil 
Thorotrast application the mean oC-ray doae rate for the liver 
is only about 50 <ft of that if self-absorption by aggregation of 
232 
ThO were not to be considered. Due to the high Th concen-
tration of the spleen which proved to be approximately 500 $ 
of that of the liver (KAUL, 1973), self-absorption amounts to 
70 # so that the mean ot-ray doae rate of the spleen is only 3 
times thai- of the liver. According to the less concentration of 
212 Th in other tissues, self-absorption of«c-particle energy is 
only 13 <i in red bone marrow and may be neglected for marrow-
free skeleton, lungs and kidneys. 
During the past, aome others have also estimated dose rates 
to different organs of Thorotrast patients which were, in part, 
normalized to an injected amount of 50 ml Thorotrast for reaaona 
of comparison as has been done previously by PARR et al. in 1969* 
The results are contained in table k and prove to be in rather 
good agreement with the above "best estimates". This ia partly 
due to the fact that the present authors' calculations have 
also relied on data of previous publications in this field. It 
should be pointed out, however, that some data which had to be 
normalized to 50 ml Thorotrast had been calculated on the as-
sumption of proportionality between dose rates and volume of 
administered Thorotrast, negelcting differences in self-
absorption of radiation. Dose rates to the lungs have to be 
regarded only as rough estimates as they do not take into 
account differences in the various regions of the lungs aa has 
been recently shown by GRTLLMATER et al (1971). Moreover It 
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4b 
should be pointed out, that for the purpose of the present dose 
estimates only ot-ray dose rates are considered as the (S - and 
^f-ray dose rates are comparably low (less than 10 4>). 
2 Estimation of self-absorption 
It follows from what has already been said that radiation 
doses in tissues of Thorotrast patients are reduced to a con-
siderable extend by self-absorpcion of radiation emitted from 
ThO„ aggregates. The magnitude of this effect and the variation 
of self-absorption with time of Thorotrast tissue burden are 
not well established p** the concept of estimating the average 
fraction for the ot-ray energy being dissipated outside the 
ThO„ aggregates in tissue is based upon autoradiography, and 
does not take account of the wash-out of the short-lived thorium 
daughters in vivo. 
For that reason animal experiments were done in rabbits con-
sidering the size ami variation with time of ThO_ aggregates in 
organs of the RES. Each animal was injected in the ear vein with 
2 ml of Thorotrast supplied by Testagar Fellows (Detroit, Mich., 
USA), corresponding to an average injected amount of 50 ml in 
man. The time of Thorotrast burden varied between 0,125 and 
530 days. 
At different times after administration of Thorotrast animals 
were sacrificed, and dark-field microphotographies of unstained 
histological sections of the liver and spleen were made (see 
fig. l). The films were evaluated for particle size distribution 
of ThO_ aggregates using a picture analyzing computer ("flying 
spot analysis"). By this method as described earlier by ABMAYR 
et al« (1970) and HINDRINGER et al. (1972) sections of the 
pictures, each of 0,^62 mm area (corresponding to 240x2*(0 bits), 
were stored on-line with a local resolution of 1 bit(correspon-
2 /u 
Considering both the measured equilibrium activity ratios 
232 between Th and its daughters in tissue samples of the liver 
and spleen, and the ranges of the emitted oC-particles in ThO_, 
the fraction Pfec'/N* o f ot-particles emitted from ThO„ aggre-
gates were calculated as function of th* area of cross sections 
of ThO, aKSr*gatec, having been assumed to be of spherical shape. 
The results of these estimates are presented in figure 2 for steadv 
i»7 
Fig.): Dark-field •icrophotographiea of 
splean tiaaue aectiona 1 day (left) 
and 392 daya after intravaacular 
injection of 2 ml Thorotraat into 
a rabbit (Magnification factor 
about 120) 
AREA OF THE SPHERICAL CROSS-SECTIONS ll^m'l 
F i g . 2 : Fraction NK~/NK of a l - p a r t i c l e s 
• n i t t a d fron ThOg aggregate« a* 
funct ion of tha area ot apharical 
croaa aactiona 
**e 
state conditions, indicating 100 % emission of ot-particles 
from spherical ThO? aggregates up to croaa sections of about 
2 50 .un area. 
From these results corresponding area classes war* calculated 
for decreasing oc-particles emission probabilities in steps 
of 5 £ between 1 and 0,2, in order to classify by computer the 
number of ThO- aggregates of each tissue section for different 
times of Thorotrast burden. As an example, results are shown 
in figure 3 for tissue samples of the liver and spleen 1 and 
392 days after intravascular injection of Thorotrast into rab-
bits. According to these results about 90 £ of Th0_ aggregates 
of the spleen had diameters between k and 17<um 1 day after 
Thorotrast application, while 392 days thereafter the correspon-
ding fraction had decreased to about 50 %, At that time the 
maximum particle diameter proved to be 70 ,um compared to the 
liver for which maximum particle diameters of 37/um were ob-
served. 
As the average rate of ot -particles created by decay of 
232 
Th and its at -instable daughter products is proportional to 
the mean volumes of ThO. aggregates in the tissues, the fraction 
of oi-particles emitted from the aggregates had been possible 
to calculate from the actual ThO„ particles size distribution 
for various times of Thorotrast burden. In figure 4 the results 
of these investigations are shown for the liver and spleen, 
indicating the process of aggregation of ThO_ particles within 
liver tissue to be continuing for times of more than 400 days 
after Thorotrast application. In the spleen, however, the aggre-
gates size distribution remained nearly constant at times of 
more than about 150 days after Thorotrast injection* The cor-
responding s*lf-absorption correction factors for the liver and 
spleen expressed by the numbers of ot-particles emitted from 
ThO^ aggregates (>V") relsted to those created by decay of Th 
and its oC-instable daughters (N^ ) proved to be about 0,6$ and 
0,45, respectively, for a 50 ml equivalent Thorotrast burden 
of 400 days. 
Though the presented results did not yet take into account 
the energy spectrum of the ot -particles being emitted from ThO-
aggregates, the actual fraction of the oC-ray energy being dis-
sipated outside the aggregates should not be too different from 
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gragatae aa function of araa clasa 
in tissue saaplos of liver and 
spleen for Thorotrast burdans of 
1 and 392 days 
?* 
?« 
TWE OF rMMønuST AMEN Ml 
\ at 
mt v TMMonusr a 
Fig.it . Fraction of o t - p a r t i c l e s enltted 
froai Th<>2 aggregates as function 
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the above estimates if one considered the very simplified as-
sumptions on both the shape and the correlation between volume 
and microscopically determined area of the aggregates. Finally 
we can conclude from the agreement of the data on self-absorp-
tion estimated according to the conventional concept and those 
obtained by computerized picture analyses of animal tissue 
samples (0,56:0,65 for the liver; 0,35:0,^5 for the spleen) 
that the prevailing method of calculating the amount of dose 
rate reduction is quite sufficient for the purpose of Thorotrast 
dosimetry. 
Discussion of the results 
Dose rate calculations have been done for long-term Thoro-
trast burdeno after injection of 10-50 ml colloidal thorium-
dioxide to patients. As the presented data only refer to the 
less complicated case of purely intravascular injection of 
Thorotrast the results may not be applied without precautions 
to cases of retrograde Thorotrast pyelography, or patients 
with important perivascular Thorotrast deposits at the site of 
former injection. 
Moreover the published data are to be considered as current 
"best estimates" of mean tissue dose rates as they are based 
232 
upon average tissue distribution of Th and steady state 
232 
activity ratios between Th and its daughters which can be 
submitted to wide variations from patient to patient• In addi-
tion, the calculations did not allow for the hitherto quanti-
tatively unknown process of continual redistribution of Thoro-
trast aggregates within the organs of the RES, as well as for 
inhomogeneities in micro-distribution of thorium aggregates 
which can give rise to local dose rates up to at least one 
order of magnitude. 
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assessment of Organ Distribution of Thorium 
by Neutron-Activatlon-Analysl3 
by 
H. Wesch, H. Kampmann and K. Wegener1" 
Institute for Nuclear Medicine , German-Cancer-Research-
Center, Heidelberg 
institute for Pathology, University Heidelberg 
Abstract 
The thorium content of 2500 specimens was determined by 
means of neutron activation analysis. The samples were taken 
out of the different regions of the body from 17 Thorotrast-
patients after death. The highest concentrations were found in 
the main organs of the RES (up to 90 mg Th/g). The least con-
centration was found In the brain (0.05 jag/g). The variations 
cf thorium within the organs were remarkable. Xn the liver of 
one and the same patient the variation could be up to a factor 
of 50, in the bone marrow up to 100 and in the lymphatic nodes 
up to 1000. 
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Introduction 
In the last three years we had the opportunity to study, 
in detail, specimens taken from 17 different Thorotrast-patients 
after death. There were three women and 14 men who were between 
46 and 72 years old. They had received Thorotrast in unknown 
amounts 25, to 32 years before they died. 
In total we investigated 2500 samples out of the different 
regions of the body. The samples were examined by histology and 
autoradiography. Furthermore the content of thorium was deter-
mined quantitatively. I will speak about the quantitative re* 
suits. Mr. Wegener will report on the pathological-morphologi-
cal findings. 
Method 
The content of thorium was determined by means of neutron 
activation analysis. The material obtained from the autopsy was 
devided into parts weighing about 1 to 2 grammes. After freeze-
drying the samples were put into a polystyrene container. Then 
32 samples, together with 8 standards, which contained diffe-
rent but known concentration of thorium, were irradiated in the 
rotating position of the research reactor Triga Hark I of the 
German-Cancer-Research-Center. The flux during the irradiation 
was 2.10l2n-s~1cm~2. The irradiation time lasted about 8 hours. 
The nuclear reaction equation for the irradiation and the decay 
of the thorium is as follows: 
'"ThCn,,, 2 3 ^ 4 s » 2 3 3 p a 4 ^ *"» 
The neutron capture of thorium 232 causes the conversion 
to thorium 233, which decays with a half-life of 22 minutes to 
protactinuum 233. This decays with a half-life of 27 days to 
uranium 233. This long half-life permits the activities of ele-
ments like sodium, bromine, chlorine etc. to decay. They were 
also produced by neutron Irradiation and disturbed the detec-
5ti 
tior. of thorium. The rule is, that the quantitative measure-
ments were done 14 days after the end of the irradiation. For 
this purpose the V-rays, which resulted in the decay of pro-
tact inum, were measured. 
By integration of the photopeak of the sample, and by 
comparing it with the photopeak of the standard, it is possible 
to determine the content of thorium in the sample. The measure-
ments were done by a Germanium Lithium drifted detector or a 
5" x 5" Na-J well type detector, depending on the content of 
thorium in the sample. 
The limit of detection without chemical seperation amounts 
to about 0.1 to 0.05 pg,depending on the phosphorus content in 
the sample. The margin error for this method is about 5%. 
Results 
Table I shows the minimal and maximal values of thorium 
content in the main organs. The large variation within the 
organs results from the different amounts of Thorotrast, which 
was given to the various patients, and the method by which it 
was stored within each patient. Due to the different concentra-
tions even in the organs of one and the same patient, we did 
not calculate the mean values. In spite of these large varia-
tions it is possible to see regularities of the distribution 
of thorium. It is well known, that the main organs of the RES 
possess the highest concentration. 
The second group contains the lungs, the pancreas, the 
adrenal gland, the gastro-intestinal tract and the bones. Thi« 
group had an intermediate amount of thorium. 
The third group, which stores very little amounts of 
thorium, contains the kidneys and the organs of the circulatory 
system. In all cases the brain shows the least concentration. 
The values of four cases were under the detection limit. 
SS 
TABLE ' I 
Thorium Cam»ntrafan in DHfVMt Tesus 
TiMUt 
SptNn 
Lymphatic nodes 
Livtr 
BMMt morrow 
Adrenal gland 
Lung 
fetti* 
Gartnmtettinil tract 
BDMT ittntpocio) 
Khjrwy 
Pmtot* 
CnuWiBfy syslMn 
Brain 
»»Til r « / » l 
5000 - 8DQ00 
60-90000 
670-13500 
130 - 2B0 
22- no 
1 0 - 120 
• - SO 
S - 21 
4 - 21 
5 - 16 
i - 13 
1 - 0 
qgs- 2,6 
Because of the large variations within an organ we have 
tried to see whether a single detection could be representative 
of the content of thorium in the organ. For this purpose we 
have taken 10 random samples from 10 different livers. Each 
•ample weighed about 1.5 grammes, and from each the concentra-
tion of thorium was determined. The results are shown in table 
II. 
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TABLE I I 
Thorium Concentration in Ifew 
Coses 
V69/13 
V 69 /29 
V S 9 / 1 
V 6 9 / 3 
VS9/Z5 
V 69/16 
VS9/6 
V69/19 
V69/17 
V69/23 
»»Th [jug/gl 
100-3(300 
1700-29000 
2300-3(001 
1600-20000 
2000-15000 
310- 3000 
1200- 7500 
3 ( 0 - 2300 
1000- 2900 
900- 2300 
Factors 
a 
17 
15 
13 
• 
• 
E 
5 
3 
3 
Here you see the range of variation of 10 samples for each 
case. The last column shows the quotient of the maximal and the-
minimal value. After these results we found it interesting to 
study the distribution of thorium in a complete liver. We wan-
ted to see whether there was sane regularity in the storing of 
Thorotrast. The liver which we chose, had a malignant hemangio-
endothelium. The liver was devlded into 952 parts in the 
following manner. 
First it was cut into halves along the longitudinal line 
and then sliced into 20 sections in the vertical direction. The 
slices which we got in this manner were again devlded into 7 
5? 
horizontal sections and 14 vertical sections, where width and 
height allowed, From these divisions resulted 952 cubes with a 
side of 1.3 cm in length. 
Fig. 1 shows the distribution of thorium in the horisontal 
section 3. 
Fig. 1. Distribution of thorium 232 in the hori-
zontal section 3 
The right lobe of the liver shows a large area of low con-
centration. In this region the malignant tuaour was located. In 
the area surrounding the tuaour unhomogeneous deposits of thori-
ust could be seen. In the left, tumour-free lobe the storing of 
thoriuB is irregular and unhoaogeneous. Areas of very high con-
centration are found in the parenchyma of the liver as well aa 
sporadically In the region of the capsule. A similar picture 
shows the other horizontal sections. 


59 
the skeleton and in bone narrow. 
The results (table IV) show, as in the other two investi-
gated organs, that there are considerable variations within the 
same portion of the skeleton, as well as between different por-
tions. The highest concentration of thorium is found in the ver-
tebral bodies, which contain a big part of the erytropoietic 
sys tea. The measurements on the eoapacta of long bones show the 
least concentration of thorium. 
It's surprising that the pure, red bone marrow of the 
femur has a lower concentration than the vertebral bodies. In 
the bone marrow we thus see considerable variations, which can 
be up to a factor of a hundred. 
TABLE IV 
ThwMffi Cnccntraim in Bones 
Boms 
Bee 
(compocto) 
00M PWTOW 
(»*) 
fjMow) 
Wi f i l ia l baOias 
(omiL,dM%,tun«L) 
Stamum 
Collot. 
Ftmur (caput) 
Rita 
» T h l > g / g l 
t - 21 
3 5 0 - 150 
1 5 - »30 
530- 2320 
130- WOO 
3 1 - 2UI 
H - 1290 
4- »20 
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Conclusions 
The results which were presented in this report give the 
state of the distribution of thorium 20 to 30 years after in-
jection of Thorotrast. 
The unhomogeneous storing could be found in all organs. 
The variations in the liver, the lymphatic nodes and the bone 
narrow are considerable. From this we can draw the following 
conclusions: 
1. The radiation injury is not only different between the 
different organs but also within one organ. 
2. A calculation of the radiation dose of the total organ 
is difficult. 
3. The concentration of thorium in a sample, which is ob-
tained by needle biopsy, gives no clue of the weight of the 
Thorotrastose. 
4. Conclusions about the development of the tumour in the 
liver of a Thorotrast-patient are not possible only on the ba-
sis of the quantitative determinations of the thorium. 
Mr. Wegener will report, and discuss in detail the morpho-
logical findings of the examined samples during this meeting. 
This study was supported by the Bundesministerium fur 
Forschung und Technologie. 
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The Retention o* *h» n»"ghters of Thorium 232 
In the Soft Tissu« <" >»^m»i« 
by 
Carsten Trolle 
The Pinsen laboratory 
The Pinsen Institute, 
Copenhagen, Denmark. 
It is shown that 10$ of an amount of Ra 228 injected i.v. is de-
posited in the bones in equilibrium with all of its daughters, 
and that no Ha 228 is found in the soft tissue. About 30 to 40$ 
of an amount of Th 228 injected in animals will be deposited in 
the soft tissue. Of the daughters formed by Th 228 about 40$ is 
found in the body of a sacrificed animal. Of this 40$, 15-20$ 
has arisen from tboron which have diffused to the blood but have 
decayed before the blood has arlved to the lungs. Of the 60$ of 
the Th 228 daughters which have left the living animal, about 
15-20$ has been exhaled ae Rn 220, about 40$ has been excreted 
as Ra 224 and about 5$ has been excreted as Pb 212. 
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In the evaluation of the radiation dose to a tissue in 
which Thorotrast is deposited it is necessary to know to which 
extend the thorium-daughters will move away from the site where 
they have been formed. 
The literature shows that a number of studies of the me-
tabolism of the thorium-daughters have been performed in the 
Thorotrastpatients as well as in animals injected with Thoro-
trast, and we have learned that much information have been col-
lected. But in order to get an even clearer picture of the fate 
of the single thorium-daughter I have thought it of interest to 
study their behaviour without the presence of the parent from 
which they will be continously formed. 
My attention has of course been drawn to the daughter-
products living long enough to move from one tissue to another 
or to be excreted or exhaled. I have therefore concentrated my 
interest around the - from a biological point of view - long li-
ving nuclids i.e. the radiumisotopes 228 and 224, the thorium-
isotope 228 Bnd the leadisotope 212. Further thoron, the radon-
isotope 220 is of interest - in spite of the short half life -
as it as an inert gas rapidly will diffuse to the blood and part-
ly will be exhaled in the lungs. 
Experimental procedure. 
The experimental animals were rabbits and all injections 
were given intravenously in an ear vein. The measurements of the 
amounts of the different nuclide were performed by repeated 
countings of the very high energetic ^-activity of thallium 206 
and by the knowledge of the physical halflives of the nuclide. 
S3 
Analysis of the radioactivity were performed both on li-
ving and on dead animals and on single organs. During the measu-
rements the rabbits were held tight in a box, and in consecutive 
examinations the variation in the number of counts per unit time 
was within the statistical variability for successive countings. 
The dead animals and the single organs were kept at -20°C be-
tween the examinations. 
In most of the experiments the daughters of thorium 232 
were injected in equilibrium with each other in amounts which 
for thorium 228 were about 10"" g/kg. The solution in which the 
thorium-daughters was injected was physiological saline. I want 
to emphasis this, as it may be of importance to know that no 
possibility existed for the nuclids to form complexes with any 
oxyacid e.g. citric acid, in the solution used for the injecti-
ons. 
In supplementary experiments either radon 220 was inhaled 
or lead 212 was injected. 
Results. 
From fig. 1 it will appear that after an initial period 
of about a month curves drawn for the numerical value of the 
y-qctivity from thallium 208 decreases to about half the values 
after a period of little less than 2 years. In the figure curves 
are shown both from an animal killed after having been injected 
witn the daughters of thorium 232 in equilibrium, and from an 
animal still alive. As the curves from this two animals decreases 
in an almost identical way, the curves tell that almost all of 
the radium 228 injected will be excreted soon after tLa injecti-
on. Along with radium 228 also radium 224 must be supposed to be 
s« 
excreted. 
Further the curves will show that the amount of thori-
um 228 which is not excreted during the first short period after 
the injection will stay in the tissue almost without any excre-
tion. It must be kept in remenberance that thorium 228 will 
reach very near to equilibrium with its daughters in 20 days 
and that the measured activity of thallium 208 produced all the 
time therefore directly will give the amount of thorium 228 - at 
least in the dead animal. 
Of the injected amounts of thorium 228 about 60 to 70?S 
will be excreted in the first days after the injection, the rest 
30-4038 will, almost without excretion, be deposited in the ani-
mal. 
In order to determine the distribution of the thorium 228 
which is retained I have studied the -y-actlvity (from thalli-
um 208) from different organs and at different times after an 
aniaal has been killed. The organ especially studied was the li-
ver, as this organ because of its size was the easiest organ to 
handle in the measuring system at my disposal. The spleen showed 
a higher weight per cent for deposited thorium 228 but there 
were no distinct difference in the ways in which these two or-
gans - as well as the lungs and the blood marrow retained the in-
jected thorium-daughters, as time, after the injections had been 
given, grew on. The way in which thorium 228 is handled in these 
organs and up to a certain degree also how its daughters are 
handled will appear from fig. 2. 
But before I go into details with the curves shown in the 
figure it may be worth mentioning that a part of the thorium 228 
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injected will be retained in the bones. In this case it will be 
deposited almost in equilibrium both with radium 228 from which 
it originates and with all of its daughters. The amount of tho-
rium 228 in the bones will be about 10$ of the amount deposited 
in the body. This amount of radium 228 with all the daughters 
almost in equilibrium with each other will stay in an almost 
constant amount in solid bone for a period of at least 2 years. 
In the fig. 2 the curves are arranged in such a way that 
all of them are coins through the sane point 20 days after the 
sacrifice of the animals. 
It will be seen that in relation to the amounts of the 
other thorium-daughters taken up in the first days after the in-
jection a relatively large amount of lead 212 is taken up in the 
liver, as it is shown in curve 1 and 2. 
Curve 3 gives the distribution of the daughters 3 weetfs 
after the injection. Here the picture is dominated of an amount 
of thorium 228, almost no radium 224 and a small amount of 
lead 212. After the animal was killed the daughters grew up and 
we have the typical curve for the growth of the thorlu.ii 228 
daughters measured by the amounts of the thallium-daughter. 
Tor animal killed 7 and 28 weeks after the injection it 
seems that a part of the daughterproduct radium 224 and nay be 
also parts of radon 220 and lead 212 produced in the liver by 
the disintegration will stay in this organ together with the 
mother. To my opinion this may indicate that a part of the tho-
rium 228 had moved inside the cells. From the interior of a cell 
the passage of radium 224 to the blood may be more difficult 
than from the extracellular space. 
S6 
Having thus seen a qualitative picture of the distributi-
on of the daughters in the liver it vill be of soae interest to 
show the quantitative. 
Table I. 
Time after injection 
1 d 
1 week 
5 d 
3 veeks 
7 weeks 
28 weeks 
74 weeks 
per cent of Th 228 deposited in 
the liver of the amount injected 
1* 
IS« 
30!« 
203« 
83« 
43« 
It will be seen that during the first week only small 
amounts of the injected thorium 228 were found in the liver. In 
the third week the highest concentration was found and it will 
appear that this concentration will be reduced with time. This 
is found in the liver as well as in the spleen, the bone marrow 
and the lung. 
Also in an other way it is possible to show that thori-
um 228 with time will have a more diffuse distribution. Animals 
were aeasured alive and again just after they had been sacrified 
and exviscerated. In an animal which had lived for 3 weeks after 
the injection the number of counts decreased to half after the 
exvisceration while in an animal which had lived for 74 weeks 
after the injection a decrease of only one tenth was observed. 
(In this connection it must be kept in remenberance that ait ani-
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mal killed 3 weeks after the injection and not exviscerated -
fig. 1 - Hill show an increase of 2 1/2 times in the number of 
counts). 
Up to now - after having shown that radium 228 is not de-
posited in the soft tissue - I have talked almost exclusively 
about thorium 228. However, the younger daughters are also of 
interest as there among them are four a-emitters. An increase in 
the number of counts arising from the y-aetivity of thallium 228 
after the animal was killed (as it is demonstrated in fig. I) 
shows that a part of daughters build up in the dead animal from 
the thoriumisotope. In the living anlma] they must have been ex-
creted or exhaled. 
I have tried to study the problem a little more thorough-
ly by indirect ways. First I have examined rabbits with thori-
um 228 and compared them with rabbits which had inspired air 
with radon 220 in it. The results are given in 
Table II 
y-activity 
blood 
fat tissue 
muscle 
fat tissue 
Hn 220 rabbits 
1 
1 5 
Th 228 rabbits 
100 
1 
16 
It will be seen that - in the thorium 228-animals - al-
most no activity exists in the fat tissue; the tissue in which 
the solubility for thoron is 7-8 times higher as in other tis-
sues. It can therefore be concluded that no thoron will be pre-
sent in the blood of the thorium 228-animals after the blood has 
es 
passed the lungs. This would of course have had to be expected 
hut it had to be proved. 
A more interesting point is the behaviour of lead 212 the 
relatively long living daughter product of radon 220. Intrave-
nously injected without its parents it will distribute in the 
following way: 
Table III 
Amounts of lead 212 in organs in relation to the amount adhering 
to erythrocytes. 
Time between 
injection and 
analysis 
10 min. 
1 h. 
24 h. 
erythrocytes 
1 
1 
1 
per g. 
kidney 
2 
2 
1/2 
liver 
1 
1 
1 
spleen 
1/5 
1/5 
1/5 
lung 
1/5 
1/5 
1/5 
1/5 of injected amount of lead 212 was excreted during 
24 hours. 
Prom the table it will be seen that lead 212 produced in 
the blood by the disintegration from thoron will adhere to seve-
ral organs almost in the same amount as Bevesy and his coworkers 
has found it to adhere to the erythrocytes. Only a small part of 
the continously formed leadisotope will be excreted. 
In animals which had lived for differed periods from 3 
weeks to 6-7 weeks after the injection of the daughters of tho-
rium 232 I have found that about 5* of the total amount of the 
y-energy from thallium 208, which the dead animal after equili-
brium was found to possess, originated from lead 212 in the 
ts 
blood. If v* take the observations given in table III into con-
sideration we hare to Multiply the aaount of lead 212 found in 
the blood and hawing arlsrd fro« decaying thoron in the blood 
by a factor of 3 to 4, to have the total aaount of thoron which 
have decayed in the blood. Proa this observation and fron a »ore 
detailed analysis of the figures for the increase in the y-actl-
vity in the period after the sacrifice of the rabbits. I have 
arrived at the results given in table IT. 
Cable IV. 
II percentage of nuclide found || in the living aniaal in || "Th 228 steady state" 
Ih 228 
Ba 224 
Bn 220 
Pb 212 
11 208 
about 100* 
about 60* 
about 40-45* 
about 40* 
of which alaost the 
half originate fron 
Bn 220 decaying in the blood 
about 40* 
percentage of nuclide 
excreted or exhaled 
about 0* 
about 40* 
about 15-20* 
about 5* 
about 0* 
This table suaaarise the results of ny study. 
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SNUBUl 
Thorotrast was intravenously injected into 80 SM mice. The volume admi-
nistered per animal was 0.1 cc for one half of the samples and 0.5 cc for 
the remaining half* Twenty of the animals given 0.1 cc and an equal number 
of those given 0.5 cc were sacrl f ied three months after inject ion , and the 
gamma-ray a c t i v i t y in the ir organs was measured for the ensuing 30-day 
period under ident ica l conditions for a l l samples. The rest of the samples 
were l ikewise sacr i f iced and examined f ive months after in jec t ion . 
The build-up curves« plotted for each organ on the basis of these measure-
ments. Indicated that 19.9% of injected ThO, had been excreted and that 
861 od the ThO, retained in the body hed deposited in the l i v e r , spleen 
and bone at the ra t io of 67:22:11, respect ive ly . The rate of thorium 
daughters excretion by these organs was measured at 761 for the l i v e r , 
79X for the spleen and 130% for the bone. 
The absorbed dose of internal irradiat ion, estimated from the foregoing 
r e s u l t s , was much smaller than the values reported in the past . Inciden-
t a l l y , no s ign i f i cant difference of measurement resul ts was noted between 
the animals given 0.1 cc of Thorotrast and those given 0*5 c c . 
MTtODflCTIOM 
I t i s wel l known that radioactive Thorotrast, once intravenously injected 
as a radiological contrast medium, remains in the body semi-permanently as 
deposits in the l i v e r , spleen, bone and other organs belonging to the re t i cu lo -
endothel ial system, the rate of i t s excretion by these orgsns being ex-
tremely low. The potent ia l r isk due to the resultant chronic internal 
irradiat ion I s quite ser ious , to evaluate which i t i s necessary to 
7U 
accurately estimate the dose of internal irradiation emitted by Thoro-
trast deposits in the organs, and this in turn makes it desirable that 
the distribution of the Thorotrast and i ts daughter products in the body 
be clarified. 
For these purposes, the following experiments were undertaken. 
1. Distribution of ThO : 
Eighty SM mice were Intravenously injected with 0.1 cc and 0.5 cc of 
Thoxotrast each in equal numbers. Three months after Injection, 20 of the 
mice given 0.1 cc and another 20 of those given 0.5 cc were sacrificed for 
immediate removal of their organs. The remaining 40 samples were likewise 
sacrificed five months after injection. In each case, the gamma-ray acti-
vity in the removed organs was measured by use of a scintillation counter 
over a period of 30 days subsequent to the organ removal. The gamma-ray 
activity levels of the organs, measured at the end of the 30-day period, 
were compared with the corresponding values for the controls to determine 
the amount of ThO, present in each of the organs* 
As a result of this experiment, i t was found that five months after injec-
tion, 19.9% of the Th02 had been excreted, and that 361 of the ThO. retained 
in the body had deposited in the liver, spleen and bone at the ratio of 
67:22:11. 
2. Distribution of daughter products! 
In this experiment, the gamma-ray activity in the specimen organs was 
measured at 24-hour intervals during the 30-day period, and build-up curves 
were plotted from the measured values. Particular attention was paid to 
TS 
ensure this and other experiments wan conducted under Identical condi-
tions with respect to measuring methods and instruments. 
a) Build-up curves of the liver and spleen: 
In all of *-he specimen organst the total gamma-ray activity level 
changed rapidly with the lapse of time. The gamma-ray activity in 
the organs immediately following removal was always lower than that 
in the same organs in a state of equilibrium. Also* the longer the 
duration from injection to sacrifice, the steeper became the build-up 
curves. These observations seemed to imply that the translocation 
of thorium daughter products from the liver and spleen increases with 
the length of time between injection and sacrifice. 
b) Build-up curve of the bone: 
For about three days after sacrifice, the total gamma-ray activity in 
the bone increased rapidly and then turned downward, thereafter conti-
nuing to decrease t i l l i t reached an equilibrium in about 30 days. 
This appears to suggest that the presence of larger amounts of thorium 
daughters in the bone than are produced there i s due to the translo-
cation of some daughter nuclides from the liver and spleen to the bone. 
Also, from the fact that the gaaoa-Tay activity In the bone registered 
a sharp increase during the first three days following sacrifice, i t i s 
presumed that the decay products of Ra include one particular nuclide 
that is translocated to other organs than the hone in large quantities. 
Judging by i t s half-life and by the build-up curve of the bona, this 
212 daughter nuclide i s thought to be Pb. 
c) Distribution of daughter nuclidesi 
Based on an analysis of the build-up curves, the respective quantities 
of 22*Ra and i t s daughter nuclides in the organs were wml#njl«WA t y 
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using the formula: (Total gamma-ray a c t i v i t y in the organ at v i v i -
section minus Total gamma-ray a c t i v i t y of Th / Total gamma-ray a c t i -
v i t y In the same organ 30 days af ter v i v i s e c t i o n minus Total gamma* 
ray act iv i ty of Th) x 100. 
As a resul t , i t was found that on the average 24% of Th daughter 
products was retained in the l i v e r and 211 in the spleen f ive months 
af ter inje t i on . Meanwhile, the amount of daughter nuclides in the 
bone was shown to have increased to approximately 130%, presumably 
owing to the redeposition of nuclides excreted from other organs. 
Since Ra and Ra, being i so trop ic , are considered to exhibi t 
ident ical behaviors in l iv ing organisms, i t i s thought that about 
22% of T h decay products, i . e . Ra, Ac and T h , and about 
224 5%
 0 f Th daughters were retained in the l i v e r . The corresponding 
figures were 21% and 4% for the spleen, and 119% and 144% for the 
bone. 
In the case of daughter nuclides descending from Th, the reten-
tion rate was calculated at 22% for the liver, 21% for the spleen 
and 119% for the bone. 
3. Estimation of Absorbed dose in human organs: 
In order to estimate absorbed dose in human organs, calculations 
were based on the following assumptions: 
Approximately 20% of intravenously administered Thorotrast is excreted 
from the toAy immediately following administration, but excretion 
thereafter falls to a negligible level. About 90% of Thorotrast re-
tained in the body is deposited in the liver,-spleen and bone, the 
distribution ratio among these three organs being approximately 70i20il0. 
232 228 
At the time of administration, Thorotrast contains Th and Th in 
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a stake of equilibrium; other than the thorium series i t docs not contain 
radioactive substance. Out of the daughter nuclides produced from ThO 
232 deposited in the liver and spleen following injection, 70% of Th 
daughters, i . e . S a , Ac and 2 8Th, and ° l t of 224Ra and its daughters 
228 are excreted. Further, 70X of daughter nuclides from Th i s also 
excreted. On the other hand, a total of 120X is deposited in the bone 
because of translocation from other organs. 
In the liver, spleen and bone, the self-absorption rate of alpha-emission 
i s 501, 751 and 75%, respectively (ref. Rotbiat, J . ) , but self-absorption 
o£ beta-emission in these organs is negligible. The alpha- and beta-emission 
energies of the thorium decay series are shown in the table below; 
S ^ n K S 4 , 0 5'*2 5.6« «.2« 6.78 6.05 8^8 
h t a (N.V) 0 . 0 K 1.11 0 .33 2.25 1.79 
How, absorbed dose of internal irradiation in an organ where Thorotrast is 
deposited can be estimated by correcting with the assumptions given above 
the emission energy calculated by the usual method employed in nuclear 
tion terms, and the amount of energy E which the organ absorbs when *""Th 
disintegrates at the rate of one particle per second at t = 0 is expressed 
If, for example, 10 cc of Thorotrast was intravenously administered to an 
average Japanese male {with a liver weighing 1,200 grams and a spleen weigh-
ing 100 grams), the Internal irradiation dose absorbed in his liver during 
the first 10 years would be 81 rads of alpha-rays and 2 rads of beta-rays, 
while the corresponding figures for his spleen would be 138 rads (alpha) 
and S rads (beta), respectively« In bis bone, meanwhile, the dose absorbed 
during the same period of time would be 33 x 10 MeV • / alpha-rays and 
78 
1 x 10 HeV of beta-rays. 
These values are much smaller than the values thus far reported. 
DISCUSSION 
Various hazards to the v i t a l organs due to the deposit ion of Thorotrast in 
the t i ssues have been reported to date. In studying the e f f e c t s of internal 
irradiation by Thorotrast, the absorbed irradiat ion dose must be determined 
as accurately as poss ib le , and the determination of the absorbed dose requires, 
among other things, c l ar i f i ca t ion of the metabolic processes involving Th0? 
and i t s decay products. Although many studies have been published by 
researchers in t h i s area, there have been few reports to date that deal 
spec i f i ca l ly with such metabolic processes in the bone. In th i s sense, i t 
i s f e l t that some meaningful resu l t s have been obtained in the present study. 
The absorbed dose reported in th is paper i s much smaller than the values 
reported in other s tudies . However, considering the very short track (20 
to 30 microns) of alpha-rays emitted by nuclides within t i s s u e s , i t i s pre-
sumed that the absorbed dose in the immediate v i c i n i t y of the s i t e s of 
Thorotrast deposition can be quite large. 
* * * * 
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J h o r i i i Serie« Radionuclides i n Compact Bone of Tho rot rast 
Cases - Results of Measurements at IAEA 
by 
Robert A. Dudley 
Dept. of Research and Isotopes 
IAEA, Vienna 
The a c t i v i t y of thorium-series radionuclides in conpact bone of Thoro-
t r a s t cases i s of in t eres t because of the p o s s i b i l i t y of extract ing skeleta l 
dose-ef fect re lat ionships i n t h i s population for comparison against s imilar 
data fro« populations containing Ra, Ra, or Ra. Estimates of 
a c t i v i t y l e v e l s i n compact bone can be obtained d irec t ly from measurements 
on such t i s s u e co l l ec ted at autopsy, or ind irec t ly from measurements on the 
re lease of radium isotopes from the primary Thorotrast deposits in other 
t i s a n e s combined with ca lcu lat ions of ske l e ta l deposition based on the new 
ICRP model of a lkal ine earth metabolism in adult humans. Autopsy samples 
from 5 Thorotrast cases have been measured in the laboratory of the IAEA. 
2^2 Th* r e s u l t s of these measurements suggest that : ( l ) Th concentrations 
(nCi/g wet t i s s u e ) in compact bone are about 1 % of those in l i v e r , 
(2) 2 Z 8 H . mt. 2 2 < B . translocate to compact bone in amounts about equal to 
228 
or l e s s than those predicted by the ICRP model, and (3) Tfc translocates 
to compact bone at- dos imetr ical ly ineonse'quential l e v e l s . The measured 
compact bone a c t i v i t i e s res ide near the low end of the spectrum of pre-
v ious ly reported r e s u l t s . 
Key words 
Iborotrast dose 
2 2 s . ton* 
62 
I« Introduction 
A very small part of the Thorotrast injected into the blood of a 
person i s presumably deposited i n the marrow-free skeleton, and BOB* of the 
radionuclides descended from thorium are deposited in the skeleton fo l low-
ing their escape from the primary Thorotrast depos i t s elsewhere in the 
body. Attention has been drawn, part icularly by Marinelli ( e . g . , Xarinel l i 
and Lucas, 19&2)r to the poss ib le tox ico log ic*! consequences of the r e s u l t -
ant skeletal i rradiat ion . Thus, i t has been suggested that the average 
skeletal dose rates in ThorotraBt cases may be a substantial fract ion of the 
average skeletal dose rate associated with a Ra deposit of 0 .1 |iCi t the 
long-standing maximum permissible burden of t h i s reference radionuclide. 
If so, i t has been further suggested that bone cancer incidence rates in the 
world's population of Thorotrast cases might help to confirm or to disprove 
that such ske le ta l di.se rates are innocuous. 
The then avai lable data on ske le ta l dose ra te s in Thorotrast cases 
were summarized by Karinel l i at the 1965 IAEA-WH0 meeting on The Dosimetry 
and Toxicity of Thorotrast ( s ee Harinel l i (1968) or Dudley (1967)) . Since 
then, new data on ske le ta l radioact iv i ty in Thorotrast cases continues to 
be co l lec ted , the means of interpret ing such data have been great ly ad-
vanced by publication of the ICRP's new and deta i led model of a lkal ine 
earth metabolism in adult man (Marshall et a l . , 1973), and in teres t in the 
subject has been heightened by the appearance of dosimetric and epideaio-
logical data on persons injected with Ra (Sp ie s* and Kays, 1970) . 
The purpose of t h i s paper i s to add to the e x i s t i n g l i t e ra ture the 
observations made at our laboratory on radionuclide concentrations i n 
compact bone of Tho rot rast cases , and to compare them with predict ions of 
the ICRP model. 
I I . Measurements and analys is of measured data 
A. Autopsy samples 
The work performed at our laboratory relevant to a c t i v i t y in compact 
bone cons is ts primarily of measurements on autopsy samples from 5 Thoro-
tras t cases . For only 3 of these were measurements performed on the bones 
themselves, but useful data on the escape of the bone-seeking thorium 
descendants from l i v e r and spleen were obtained from a l l 5 oases. 
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Autopsy samples hav* reached th* laboratory anyNbara froa hoars to 
days aftsr d*ath of th* subject. Bon*s war* usually earned longitudinally 
with a hacksaw, scraped free of narrow and trabecules, and cleaned with a 
water jet. Other tissues war* processed only to the extent of dividing 
them with a knife so as to f i t than into containers. All saaplaa whose 
measurawnts ax* reported here war* weighed in th* wet stat* and packed into 
tin cans (9 cat (7 x 12 cm). Paper stuffing was added i f necessary to 
immobilise th« saaples in the cans, and th* cans war* than staled. Tmey 
were kept thereafter in a deep frees* unit except during counting.. 
The activity in the canned saaples was aeasured with a Vat(ll) 
detector (20 en ^ x 10 est) coupled to a multichannel analyser. Qeometry of 
measurement was individually selected with priorities in th« following 
order when compromises were necessary: ( l ) reproducible conditions, 
(2) statistically adequate counting rates, and (3) minimum geo—trical 
ambiguity in coaparing samples against standardised reference sources to 
establish absolute activit ies. Cans containing bone saaples, whose activity 
was always Marginalr were usually positioned directly on the crystal face, 
while those containing l iver or spleen samples ware counted at a distance 
of about 35 c» froa the crystal face. 
Reference standards consisted of aged (1906) thorium having an equi-
librated decay chain, and in plus descendants. Two aged thorium 
standards were used, the first a thin layer and the second a slender 
cylinder. The 1% standards were the residue of evaporated droplets of 
Hi solution heat-sealed between thin sheets of plastic. 
taring neasureaent these refsrenos standards were variously positioned 
in cans partially or completely fi l led with sugar to simulate the sample 
mass, or in Presdwood phantoas. Differences between samples and standard 
with respect to geometry and absorption were sufficient to give appreciable 
errors in absolute activity estimates for samples such as bone that ware 
positioned on the crystal face. However, they ware not so large as to 
cause important errors in estimates of parent-daughter activity ratios, and 
i t i s these ratios that are of predominant interest. 
Deduction of the absolute activities and the activity ratios (at 
death) of the thorium series radionuclides in each sample was based on 
analysis of the spectral peak at 0.93 tfe7 attributable to the 0.90 and O.96 
We? y rays of 228Ac( and the peak of the 2.62 Ms? y ray of Tl. The con-
tribution of the 2.62 Ke? v rays to the counts at O.93 Ma? was stripped out 
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by reference to the spectrin* of the Th standard (containing no Ac). 
The absolute activity of At was determined by comparison of the net 
0.93 KeV counts of sample and analogously positioned standard within days or 
weeks of death. The activity ratio R»/ Th was calculated fro* the 
growth of Ra during subsequent years, The activity ratio Th/ Ra 
was established by comparison of the relative abundance of counts fros 
-0-93 KeV" and 2.62 KeV Y **ys »t about 1 month after death. The activity 
ratios 22*Ra/2 Th and 212Pb/224Ra were computed fro* the changes in the 
relative abundance of counts from "0*9) NeV*1 and 2.62 MeV y rays during the 
f irst month after death, using the Batsman equations« In most cases the 
212 
samples were obtained more than a day after death, so that assay of Fb 
was impossible. 
A primary issue i s the assignment of realistic estimates of standard 
deviations, allowing; for errors of al l origins, to the quantities deduced 
from the measurements• Both absolute activities ?.nd ant*vity ration are 
given in the subsequently tabulated results in order that their respective 
errors may be separately displayed* The error in absolute activity i s 
generally proportionately larger since i t includes a contribution from 
geometrical ambiguities in comparison with the standards, while the errors 
in the ratios are substantially or entirely free of such contributions. 
Inevitably the error estimates contain an appreciable element of subjective 
judgement to allow for the numerous uncertainties beyond counting sta-
t i s t ics : weighting of discrepant results, allowance for shifts of back-
ground, allowance for differences between Mandards and samples, etc. It 
i s likely that the data collected in further measurements on these and other 
samples, and the insight they give into errors, will lead us to adjust both 
the results and the error estimates in our next compilation. However, i t i s 
not likely that these adjustments will be so large as to give conclusions 
differing significantly from those drawn in this paper. 
B. Living subjects 
On about 75 living Tnorotrast oases we have measured the total body 
burden of Ra (via the 0.90 and 0,96 MeV Ac Y rays) and ^ ^ i (via the 
2.62 MeV Tl y r»y)f and the profile of a *Bi activity along the length 
of the body. The total body activity measurements were performed in the 
IAEA whole-body counter, with a 20 cm $ % 10 cm Nal(Tl) detector scanned 
along ths length of the subject reclining first prone and then supine 
BS 
(Itadley and ban Haim, 1968). "Hie profile scan was performed with the same 
instrument using a s l i t collimator over the detector face (Parr et a l . , 
1972)* while in general these results are of only peripheral relevance to 
skeletal activity, the measurements we were able to nake on 4 of the 5 cases 
who subsequently case to autopsy have helped to round out the picture de-
duced fro« the fragmentary sets of autopsy samples obtained. 
III. Results 
Case history data on the subjects who came to autopsy are given in 
Table 1, activity concentrations as of death in the autopsy samples rele-
vant to skeletal activities are given in Table 2, and activity data for the 
whole organs and for the living bodies are given in Table 3* In Table 2 
each column labeled "R" gives the ratio of the activity of the descendant 
nuclide on the right to that of the predecessor on the left , as of the time 
of the subject*s death. Liver samples A, B, C, etc. refer to separate sub-
divisions of the liver as contained in individual cans. As yet insufficient 
212 time has elapsed sines death of case Z to allow an assessment of the Th 
212_ 
activity, lit Table 3 the data for the Tii activity in the body regions 
"upper abdomen" and "injection site" are taken from the profile scan. They 
represent the activity in a volume including the full width and depth of 
the subject and about 37 cm of his length at the regions in question; they 
thus include respectively the liver-plus-spleen and the Thorotrastoma ( i f 
any), and in addition neighboring tissues. All errors quoted are standard 
deviations representing the author's best estimate of composite errors 
derived from all sources. 
IV. Deductions 
A. Measurements on bone 
The data directly relevant to activities in compact bone free of red 
marrow are the results given in Table 2 for the 6 such samples (one from S, 
2 from B, and 3 from Z), and the related values in Table 3 for activity in 
the entire available organs or in the living bodies. (The femur head of H 
and the ribs of Z contain red marrow, and their activity patterns are 
typical of those expected from Thorotrast itself in the marrow.) 
It is apparent that all radionuclides are found in essentially all of 
these sample« (although in many oases near the lower limit of sensitivity of 
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the assay method used) at a concentration of the order of 0.5 % - 5 % ot 
that in liver* Beyond the absolute activities, the ratios of activities 
should also be important in that they may reveal the median, em by which the 
respective radionuclides come to be deposited in bone, hence in Which of its 
component structures they are located, hence how toxic they are likely to 
be. There are probably no data available on the fractional retention, at 
the sites of Hi localisation in bone, of the Ra b o m therein* This 
^ Th may well be in the form of Thorotrast particles, in which case the 
Ra retention probably would resemble that observed in Thorotraet de-
posits in soft tissue. For present purposes this fraction is taken as 
0.4 1 0.1, a range encompassing all the values in Table 2 for Thorotrast in 
soft tissue. One may probably assume without great error a fractional 
retention of unity for each subsequent radionuclide b o m in bone from 
chronic depositions of the parents, although this would be less nearly true 
if a substantial fraction of the activity were in Thorotrast particles. 
Upon adoption of these assumptions, it is possible to calculate for 
the compact bone samples in Table 2 the concentrations of the radionuclides 
in excess of those expected to result from the concentrations of their pre-
decessors. These excess concentrations are attributable to escape of the 
respective radionuclides from the primary Thorotrast deposits and their 
redeposition from the blood into the skeleton. The inferred excess con-
centrations are shown in Table 4, under the column heading "observed'*. 
(The standard deviations attached to these inferred excess activity con-
centrations have been propagated from those recorded in Table 2 under recog-
nition that part of the error in parent and daughter activities is correlat-
ed, reflecting uncertainties in the absolute activity of the chain, and 
that this component should hot be included twice.) 
From Table 4 it appears that Ra and do Bhow excess activity 
concentrations above those of their predecessors, but the amounts are so low 
that they are not always distinguishable from zero. Th, however, shows 
no excess activity, and the limits are sufficiently small that the toxic 
effect of migrated Th in the compact bone of these oases could presum-
ably be ignored in comparison with the effects of other radionuclides. 
B. Measurements on primary deposits of Thorotraet 
From measurements on the primary deposits of Thorotrast In these cases 
the amounts of Ra, Th, and R» continually infusing ttaa than 
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deposits into the blood can he deduced, and predictions can he aede (chiefly 
via the TCRP model of alkaline earth metabolism) for the amounts of these 
radionuclides deposited in compact hone. 
Predictions for two (H and Z) of the three cases from whoa hens 
samples were obtained axe complicated by the presence of substantial para-
vascular deposits at the sit« of injection, and these apparently relees* 
at least, to a lower extent than does liver. 11M fraction of Thoro-
traat at the sites of injection i s not well known, and th* collection of 
other tissues (liver for Z, red narrow for both) i s incomplete so as to 
prevent estimation of the Magnitude of th« deposit by the difference be-
tween whole-body activity and the activity in all other deposits, never-
theless, reasonably good estimates of the total amounts of 
infusing into the blood of the 3 cases can be made as follows. ^ t a : 
cases S and H - whole body 3a activity taken from measurements on the 
232 living subjects, whole body Th activity estimated by assuming R for 
Ra/ Th in the whole body equals that measured in liver; case 2 -
ditto, using R from case H. Ra: case S (negligible deposit at injection 
site) - whole body 22flTh equals whole body 228Ba, fraction of 22SRa at 
injection site estimated from profile scan, R for injection site equals 
0.91 (as in H Thorotrastoma) and for rest of body equals 0.75* With these 
methods the daily rate of infusion of the radium isotopes into the blood i s 
found as in ""able 5, probably with a standard deviation of 20 % - 25 $• 
?rom these data on the radium isotopes, the ICBP model (Table 36 in 
Marshall et a l . , 1973) predicts directly the resultant concentration of 
activity in compact hone, as recorded in Table 4 under the column heading 
"ICHP prediction'*. (The standard deviations given in these columns are to 
be understood as reflecting estimated errors in the infusion rates, hut 
none of the inaccuracies inherent in the model.) 
The observations and predictions in Table 4 appear to he not grossly 
inconsistent. However, in view of the experimental errors the only con-
clusion that can he drawn with som« confidence i s that the observations are 
about the same as or smaller than the predictions. If the actual Ra and 
4Ra levels were substantially higher than predicted, they wouW be clearly 
visible above the experimental errors« 
netabolisn i s not covered by the I0HP model, oat the issue of 
i t s translocation may s t i l l be considered. In Taol« 2 the »sloes of R for 
228, 
'Th, i / ^ T i in the livers i s near 1.00, inplying my l i t t l a .aes«., but 
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values aa low as 0.90, implying 10 % escape, cannot be excluded. If indeed 
5 % escaped and 70 % of this quantity (fro« animal experiments, Stover at a l . , 
i960) were deposited on bona surfaces, than the excess Th. concentrations 
expected in Table 4 would be about 1.5 pCi/g for al l 3 subjects. Since this 
value i s much higher than that observed, i t i s probable that less than 1 % 
228 
of the Th born in Thorotrast escapes into the blood in a bone-seeking 
fora. 
V. Conclusions 
Our observations suggest that: (l) The concentrations of thorium 
series radionuclides in the compact bones of Thorotrast cases are of the 
order of 1 % of those in the liver. (?) The radium isotopes released from 
primary Thorotrast deposits (about 60 $ of the Ba and 25 % of the *Tta. 
born there) are deposited in compact bone in concentrations about equal to 
or less than predicted by the new ICRP model for metabolism of alkaline 
earths. (3) So little Th migrates from the primary Thorotrast deposits 
to the compact bone that its contribution to toxicity there can probably be 
neglected. 
It must be recognised that these conclusions rest upon only our own 
observations, which are small in number and were made near the limit of 
sensitivity of our technique. Nevertheless, they are reasonably robust as 
upper limits. It may be hoped that upon conclusion of this meeting a new 
synthesis of all existing data on skeletal activities and dose rates will 
be initiated. 
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0.33*0.01 
0.46*0,02 
0.39*0,02 
0.8*0.1 
1.16*0.15 
0.38*0.02 
0.15*0.02 
0.395*0.01 
o.)C3tiua 
O.JTJiBJI 
o.37**o.oi 
0.374*0.01 
0.3733)«« 
0.38*0,01 
19429 
» * 4 
107*3 
U5*« 
«05tJT 
2-3*B-5 
7«M 
3JO*9 
270*7 
13*4 
1.8*0.5 
S.5*0.1 
2.9*0.3 
9*0-9 
50*1.5 
102*2 
9fi» 
108*2 
7 8 « 
8Ttt 
4J«9 
17.8*0.4 
35.8*0.9 
48.5*0.9 
41.4*0.9 
ac.tto.7 
34.1*0.8 
28001100 
8.7U 
1 2.9*0.4 
, 1.620.2 
, 15*4 
».95*0.04 
9.9691.04 
1.00*0.05 
D.97I0.03 
0.97*0.04 
0.98*0.02 
D.98IO.04 
».99*0.03 
1.04*0.07 
0.91*0.0} 
D.91+Ø.08 
0.98*0.02 
0.94*0.02 
0 . 9 8 * 0 . « 
0.94*0.02 
0 , 9 9 0 . 0 2 
0.93*0.02 
0.93*D.02 
1.03±0.03 
1.0390.03 
1.04*0.03 
0.97*0.03 
0.99*0.04 
1.00*0,03 
0.91*0.03 
O.98U.O6 
0.98*0.08 
0.95*0.06 
0.94*0.08 
110*8 
58*27 
2.3*0.5 
75*4 
325»8 
288*10 
ljU 
1.8*0.5 
0.5*0.1 
2.720-3 
8*1 
48*1.3 
9812 
fHZ 
100*2 
73t2 
83t3 
9 £ 3 
m
n
 
34.2*1.3 
2500I100 
8.5*1 
2.910.4 
1.5*0.* 
13*4 
0.74SD.O3 
0.79*0.03 
i .8ta.2 
0.75*0.02 
0.82*0.03 
0.91+0.01 
0.91*0.04 
I.O5+Ø.O4 
1.8*0.3 
0.72*0.03 
0.84*0.1 
0.70*0.08 
0.98*0.01 
^ M , 
1 .15».15 
3.1*0.4 
0 . 9 1 » ^ 5 
» " i . 8 » S k 
8jl« 
480*27 
4.1*0.9 
58*4 
»WI21 
8J0+1O 
1284 
1.7*0.5 
0.9*0*2 
1.9*0.2 
7*1 
24.1*1.) 
2409*409 
».Til 
3.3t0.5 
3.1*0.9 
28*4 
0.38*0.04 
0.88*0.08 
1U>3*JBV08 
1.0*0.3 
1.00*0.04 
13M 
i 8 n m 
HOOT 
12U 
1.7*04 
i 
92 
T»bl. 3 
Activity (aCi) in Tiaaaaa (at daath) 
and in Bodiaa (living) of Sab jaets Autopaisd 
Subject 
s 
H 
P 
w 
z 
S—pie 
Autopsy sample 
Liver 
Spleen 
IhorotraetOM 
Living body 
Opper abdoaen 
Injection s i te 
Whole body 
Autopay ssaple 
Liver 
Spleen 
tnorotrsstoaa 
Living body 
Upper abdonen 
Injection s ite 
Whole body 
Jutopey saaple 
Liver 
Spleen 
Autopsy sample 
Liver 
Spleen 
Living body 
Whole body 
Autopsy saapl« 
2/3 Liver 
Spleen 
Living body 
Upper sbdoaen 
Injection site 
Whole body 
f*8» 
254tl3 
66+3 
364125 
l86iio 
37+1 
8012 
463i32 
3.8*0.4 
0.59+0.06 
197±5 
99±2 
519±36 
81+2 
78±3 
46l±34 
228_ Tn 
241+13 
63t3 
180*10 
36+1 
77i3 
183+J3 
50*3 
135*iO 
30t3 
70+3 
3.5M.4 2.5S0.3 
O.54+J0.OT <M5±0.07 
187*7 
9213 
81+3 
71i3 
57t3 
68+3 
a 2 M 
243t25 
30i9 
300+21 
220±22 
107+10 
348424 
462132 
II! 
Table 4 
Inferred Concentrations of Migrated Badionuolides in Compaot Bone 
(pCi/g n t ) 
»S. 
C M « 
s 
R 
Z 
Bone 
Femur shaft 
Femur, tibia 
mid-Bhaft 
Femur distal 
end, tibia 
both ende 
Femur head 
Femur ahaft 
Femur distal 
end 
Obaervod 
1.6+0.4 
0.5S1.3 
0.3i0.2 
<9±1 
a.gtP.A 
O.610.2 
IOHP 
Prediotion 
1.2+0.2 
1.S0.3 
1.3+0.3 
1.4i0.3 
1.4i0.3 
1.410.3 
Observed 
0.0+0.1 
-0.0210.06 
0.0210.04 
-0.1±0.2 
-0.1i0.2 
-0.1±0.1 
Observed 
1.8+0.5 
O.liO.l 
0.4i0.1 
0.2+0.4 
0.4i0.4 
1.6+0.5 
IOHP 
Prediotion 
1.3J0.3 
1.4i0.3 
1.4i0.3 
1.210.3 
1.2+0.3 
1.2+0.3 
Table 5 
Estimated Rates of Infusion of Ra and Ra into Blood 
from Thorotraet Depoøits 
SM>.1«rt 
s 
B 
Z 
ff!sa 
0.21 nCi/d 
0.23 
0.24 
fffsa 
16 nCi/d 
IS 
15 
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The Skeletal Dose from Ra Following Intravascular 
Administration of Thorotrast* 
R. E. Rowland and I. Rundo 
Center for Human Radiobiology 
Radiological and Environmental Research Division 
Argonne National Laboratory 
Argonne, Illinois 60439 
Abstract 
With the use of a set of "best estimates" of the distribution of 232Th 
and its daughters in the marrow-free skeleton following intravenous adminis-
tration of Thorotrast, the dose to bone from "translocatable" has been 
calculated. "Translocatable" 224Ra is that radium created in vivo that is 
free to translocate, i . e . , equivalent to systemically Injected radium. The 
accumulated dose to bone from this 22*Ra 25 years after injection of 25 ml of 
Thorotrast is of the order of 25 rads. A linear dose-effect relationship for 
the appearance of bone tumors in man has been postulated from the observed 
tumor incidence in the series of patients injected with 2z4Ra In Germany. 
This linear hypothesis predicts more bone tumors in Thorotrast cases than 
are observed, implying either that the relationship is not linear at low doses, 
or that at very low dose rates the effect per rad is lower than predicted. 
Key words: Thorotrast 
22«Ra 
Dose 
Dose Rate 
Bone Tumors 
Work performed under the auspices of the U. S. Atomic Energy Commission. 
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In recent years the biological consequences of the Injection of 22*Ra 
into human subjects have become apparent. Spless and Mays'') have 
documented the appearance of bone sarcomas in these cases, and from their 
calculations of average skeletal dose they have postulated that the number of 
these malignancies may be related to dose in a linear fashion. Specifically, 
they have predicted that, for adults, the cumulative Incidence of bone 
sarcoma from 224R3 injections is 
0.30% per 100 rads. 
Subsequently, following a suggestion of Muller, they re-examined 
their data to determine whether protraction of the period over which the 
short-lived 224Ra was injected would tend to increase its effectiveness per 
rad. They found(2) that the effect per rad apparently did Increase as the 
Injection span became longer, such that the effectiveness (% incidence of 
bone sarcomas per 100 rads average skeletal dose) for an Injection span of 
m months could be expressed, for adults, as 
„ . „ 0,3% , 1.4% T -0.09 ml Effectiveness = -TTZ—-r- + T T ^ — T - 11 - e I . 100 rads 100 rads j_ J 
This expression approaches its limiting value of 
1.7* per 100 rads 
for injection periods longer than 5 years. 
In their study of over 600 adults who received 2^*Ra, the lowest 
skeletal dose at which a tumor was observed was 90 rads. This was not an 
Isolated Instance, they point out, because other sarcomas were seen at 
106 rads and 129 rads.'1' 
The purpose of this paper is to examine the doses delivered to the 
skeletal system from 22^Ra born in the decay chain of the systemically 
Injected radioactive contrast medium, Thorotrast. Specifically, we want to 
see if the low doses delivered by 224Ra to the skeleton of Thorotrast cases 
can be used to test the validity of the concept that a linear relation exists 
between dose and effect at low doses and low dose rates. 
The dosimetry of Thorotrast Is exceedingly complicated, due to the 
multiplicity of short-lived daughters, whose pathways through the human 
body are difficult to map. These complexities will be reviewed only as much 
as necessary to elucidate the behavior of 224Ra. That quantity of 224Ra that 
Is free to translocate will be estimated, and Its contribution to the skeletal 
dose calculated; this skeletal dose will then be used to find the expected 
occurrence of bone sarcoma in the Thorotrast populations under study. 
An ampule of Thorotrast contains TI1O2 in the ratio 25 g TI1O2 in 
100 ml Thorotrast, or about 22 g thorium per 100 ml. (These figures refer to 
Thorotrast produced in the United States; that produced elsewhere may con-
tain somewhat less thorium.) Depending upon its past history, the 
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228Th/232Th r a t l o 0f jms m a t e r ia l lies between 0.2 and 1.0. ' 3 ) For 
reference, 22 g of thorium contains 2.42 |iCl of the 1.4 x 101 0 year half 
period 232Th, and between 0.48 |iCi and 2.42 jiCl of the 1.9 year half period 
228Th. The quantity of 228Th and of 2 2 8 R B (half period 5.7 years) present In 
the ampule before injection (all radium Is probably eliminated at the time of 
preparation) Is a function of the Initial 22BTh/232Th ratio and the time since 
preparation. 
Since each microcurie of injected 224Ra delivers an average skeletal 
dose of only 0. 2 rad to an adult,"' and since it is evident that the quantity 
of 3.62-day 224Ra present in, say, a 50 ml Thorotrast Injection is not likely 
to exceed 1 nCl, this quantity, even if it were free to be carried via the 
blood to bone, would deliver only an insignificant skeletal dose. We will 
concern ourselves with the 224Ra produced in vivo, and examine its dis-
tribution after a steady state distribution of the Thorotrast daughter products 
haB been achieved. 
It is well to recall at this time that Thorotrast is a colloidal sus-
pension, and that the Th02 particles have sizes the order of 100 Å. The 
In vivo deposits are, of course, aggregates, and thus much larger. It has 
been postulated by Parr, et a l . " ' that alpha recoil processes may liberate 
daughter products from these particles, and since two alpha decays (232Th 
to 228Ra, 228Th to 224Ra) precede the formation of 224Ra, It does have 
opportunity to escape from within the aggregate. Since the ratios ot the 
various daughter products to the parent 232Th are considerably less than 
unity in many organs at long times after Injection, there Is no doubt that a 
considerable fraction of the daughter products do escape from the aggregates. 
Parr, et al. '3' have produced a set of estimates of the steady state 
distribution of Thorotrast daughters in various organs, based on an original 
set of "best estimates" by Marlnelll. '4' Relative to our problem, -the figures 
In Table I from these estimates are Instructive. 
TABIE I 
Thorium-Series Activities In Various Organs 
(50 ml Thorotrast Injected Intravascularly) 
(from Parr, etal .< 3 ' ) 
Organ Wet Weight Nanocurles In organ at steady state 
Whole Body 
Liver 
Spleen 
Red bone marrow 
Skeleton {marrow free) 
g 
70,000 
1,700 
150 
1,500 
7,000 
232Th 
1,250 
860 
210 
100 
15 
228Ra 
625 
430 
105 
25 
25 
228Th 
625 
390 
95 
30 
30 
224Ra 
580 
270 
67 
20 
- 50 
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It is also instructive to consider this set of "best estimates" in 
terms of the ratios of the radium isotopes to 232Th and to 228Th. These 
ratios are tabulated in Table n for several relevant organs. 
TABLE II 
Ratios of the Radium Isotopes to their Parent 
Thorium Atoms in Selected Organs 
Organ 
Liver 
Spleen 
Red bone marrow 
Skeleton (marrow free) 
2 2 8 R a / 2 3 2 T h 
0 .5 
0 . 5 
0.25 
1.7 
2 M R a / 2 3 2 T h 
0 .31 
0 . 3 2 
0 . 2 
3 . 3 
2 2 4 R a / 2 2 8 T h 
0.69 
0 .71 
0 .67 
1.7 
One could assume from the information in Tables I and II that ap-
proximately 30% of the 22*Ra formed in vlyo is associated with 232Th, and 
we will therefore assume that 70% of the 22<Ra i s not bound in Thorotrast 
aggregates. 
Very little 232Th Is found in the marrow-free skeleton, and it is 
likely that this thorium is not in aggregates, but deposited In bone as thorium 
atoms. If this were the case, no 224Ra would be associated with 232Th In 
bone. At the other extreme. If all of the 232Th (15 nCl) in the marrow-free 
skeleton were colloidal, then with this thorium would be associated 5 nCi 
224Ra. So, of the 50 nCi of 22^Ra In the marrow-free skeleton, we assume 
5 nCi or less (perhaps none) are in aggregates. 
Similarly, it appears as if 50% of the 22^Ra formed in vivo is associ-
ated with 232xh, so perhaps as much as 7.5 nCi 228Ra j n the marrow-free 
skeleton is bound in aggregates. This is the maximum estimate; it is 
possible that none of the Is in aggregates. 
The remainder of the 228Ra (between 17.5 nCi and 25 nCi) we will 
assume is deposited in bone. Since this is a long half life Isotope of radium, 
it will be distributed throughout the mineral volume. As it decays to 228Th 
and In turn to 22^Ra, it is likely that neither of these daughters is trans-
located from their site of origin. Thus, this 224Ra (between 17. 5 nCl and 
25 nCl) does not decay in the same locations as would injected 22*Ra. 
It should be noted that there is more 22BTh in the marrow-free 
skeleton than 228Ra, so that there may be a 228Th deposition in bone not 
associated with 228Ra. Since 228ih deposits on bone surfaces, the 2z4Ra 
born of this 228Th deposit might be expected to be free to translocate, and 
Indeed experimental evidence exists that Indicates that this is the case. >5' 
Thus it is only the 228Ra deposition in the bone volume that prevents 2MRa 
subsequently created from translocating, for 224Ra born of 228Th in thorium-
like deposition patterns in bone Is free to translocate. 
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Thus we will assume that 22*Ra not in aggregates and that not born of 
228pa in the mineral volume will decay In bone at the same locations as 
Injected 224Ra. Row much is this? It could be as much as SO nCi (total In 
bone) less S nCl (in thorium aggregates) less 17.5 nCi (created in the 
mineral volume), or 27.5 nCl. It might be as Uttle as 50 nCi (total In bone) 
less 0 nCl (In thorium aggregates) less 25 nCl (created In the mineral volume), 
or 25 nCi. 
We will assume that there are about 25 net in bone following 
a 50 ml Thorotrast injection which could be thought of as behaving similarly 
to injected 2 2 4 R a 0 n e might ask, how could this low a level of 224Ra be 
thought to be carcinogenic, when the lowest dose case (90 rads) to have a 
sarcoma in the Spiess-Mays' series received 448 |iCl 224Ra? It is instruc-
tive, before we consider the actual dosimetry, to ask how many 224Ra atoms 
decay on bone surfaces In each case. In the lowest-dose Spiess-Mays1 
case, an adult, for whom the authors assumed 1/10 of the injected atoms 
decayed on bone surfaces, we calculate: 
•J5 x 448 uCi x 3.7 x 104 dts/sec-uCt x 86400 ^ p x 3m^\!^n = 
7 . 5 x 1 0 disintegrations. 
224 Now 25 nCl Ra, steady state, decaying on bone surfaces, will yield, 
over a thirty-year period: 
25 x 10"3 uCl x 3.7 x 104 dls/sec-^Cl x 86400 -^jp5- x 365 ^ ^ x 30 yrs = 
8 . 8 x 1 0 disintegrations. 
Thus we see that, to a first approximation, the 224Ra decaying over 
a thirty-year period on bone surfaces following a 50 ml Thorotrast Injection 
into a standard man, yields about the same number of alpha particles 
adjacent to bone surfaces as occurred in a patient who developed a bone 
sarcoma following an injection of 224Ra. 
Spiess and Mays' ' calculate the average skeletal dose from injected 
224Ra by assuming that each decay yields 26. S MeV of a energy from 22*Ra 
and its daughters. This assumes 100% of the thoron decays in bone, which 
may not be the case at all, but since It is our Intention to compare our results 
with the predictions of Spiess and Mays, our dose calculation will be 
identical to theirs. In the steady state situation, with a constant concen-
tration of 25 nCl 224Ra In a 70 kg man with a 7000 g marrow-free skeleton 
the average skeletal dose rate is: 
100 
Dose rate (rads per year) = 365 ^ p x 51. 2 x cP^M • E R ^ ) rads/day 
•• 365 x 51.2 x 2 y * 0 p ° X26.5 
1
 1.8 rads per year. 
Similar calculations for a female of 56 kg (the mass used by Spiess 
and Mays) would yield 2. 2 rads per year. 
In Table III are listed the average skeletal doses for males (70 kg) 
and females (50 kg) at each of three Injection levels for three different 
observation times. 
TABLE III 
Accumulated Skeletal Dose (Rads) from 
"Translocatable" 224Ra 
Injection Level 
Males: 25 ml 
50 ml 
75 ml 
Females: 25 ml 
50 ml 
75 ml 
Skeletal Dose in Rads 
20 years 
18 
36 
54 
22 
44 
66 
30 years 
27 
54 
81 
33 
66 
99 
40 years 
36 
72 
108 
44 
88 
132 
It is apparent that these doses are exactly in the region of interest; 
20 to 40 years after Thorotrast injections. 224Ra doses range from 20 rads to 
more than 100 rads. Recalling that 224Ra cases showed sarcomas at 90 rads 
and above, a large enough population of Thorotrast cases should provide an 
excellent test of the linear hypothesis at these dose levels. 
Table IV shows the expected bone tumor incidence for a population 
of 1000 cases at each of three injection levels, using the two linear tumor 
incidence formulations of Spiess and Mays. Specifically, we use their 
original (I) prediction of 0.90% per 100 rads and also their modified pre-
diction (II) of 1.7% per 100 rads for protracted injection. 
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TABLE IV 
Expected Number of Bone Sarcomas per 1000 Cases 
Injection Level 20 years 
25 ml 
50 ml 
75 ml 
25 ml 
SO ml 
75 ml 
I 
1.6 
3.2 
4.8 
2.0 
4.0 
6.0 
II_ 
3.1 
6.1 
9.2 
3.7 
7.5 
11.2 
Let us apply these predictions to the Portugese Thorotrast follow-up, 
as reported by da Silva Horta and da Motta. (6) They have traced more than 
1000 cases for about 25 years, state that the average injection was about 
25 ml, and report no bone sarcomas. For such a population, assuming eoual 
division between the sexes, we would expect about 4 bone sarcomas from 
the protracted hypothesis and about 2 bone sarcomas from Spiess and Mays' 
original hypothesis. The probabilities of seeing none when 4 or 2 are ex-
pected out of 1000 cases at risk are 0.018 and 0.135, respectively. 
When we consider that a very large number of individuals have been 
Injected with Thorotrast (4300 estimated in the United States by Telles.Cl 
10,000 - 100,000 estimated world-wide by Faber'8)), the paucity of docu-
mented osteosarcomas is significant. A single case was reported by our 
group at Argonne; '9' This case was found on the basis of symptoms, and was 
not a part of any group under study. We know of one case reported in the 
Japanese literature, ' l u ' and of one case with a fibrosarcoma reported by 
Zik, et al. (ID 
The spontaneous primary bone cancer rate in Canada has been 
estimated to be 6.3 per million population; 58% of these were osteosarcoma, 
or 3.7 per million per year. (12' At this rate In a population of 10,000 
Thorotrast cases, two spontaneous primary bone cancers would be expected 
over a thirty-year period. It Is evident that those seen to date In the various 
Thorotrast studies fit this expected spontaneous Incidence. 
Thus, our dose calculations and an assumed linear relation between 
the skeletal dose from 224R 3 aruj bone sarcoma Incidence led us to predict 
that these sarcomas should be observed In Thorotrast cases, yet they are 
not. If our assumption of the state of 224Ra In bone Is correct, then the 
linear hypothesis as postulated by Spiess and Mays Is not valid at doses 
below 90 rads, or doses delivered at these low dose rates are not as effec-
tive, per rad, as doses delivered at higher dose rates, or both. 
This analysis has tacitly assumed that only the alpha particles from 
224Ra on bone surfaces contribute to the risk of sarcoma. We know chat 
30 years 40 years 
I 
2.4 
4.8 
7.2 
3.0 
6.0 
9.0 
n_ 
4.6 
9.2 
13.8 
5.6 
11.2 
16.8 
J_ 
3.2 
6.4 
9.6 
4.0 
8.0 
12.0 
n_ 
6.1 
12.2 
18.4 
7.S 
15.0 
22.4 
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^Ra distributed throughout the bone mineral volume is responsible for bone 
sarcomas in man. so that the alpha particles from 228Th and its daughters 
In the bone volume, following their creation in 228Ra decay in the bone 
volume, contribute to the sarcoma risk. Likewise, the alphas from 228Th in 
bone (probably on bone surfaces) must contribute some effective dose. Thus, 
considering the contributions ignored in this analysis, the absence of bone 
tumors is even more surprising. 
It is our hypothesis that the paucity of bone sarcomas in Thorotrast 
cases is a clear Indication of a non-linear relationship between dose and 
effect. For the 226Ra and 228Ra cases. a dose squared relation between 
dose and tumor incidence has been advanced by Rowland, et al. "*) to 
describe their results. In these cases the dose was delivered continuously, 
in contrast to the situation in the 224Ra injection cases , where the dose was 
delivered over a relatively short time period. It may be that the 226Ra and 
cases and the Thorotrast cases, in which the tissues adjacent to bone 
are subjected to continuous irradiation by alpha particles at very low dose 
rates, are characterized by a non-linear dose response relationship, whereas 
the 224Ra injection cases , in which the tissues are irradiated at a much 
higher dose rate over a relatively short time interval, are characterized by 
a linear dose response relationship. 
The conclusion must be tentative, and await more definitive radio-
chemical analyses of bone from Thorotrast cases. Nevertheless, it is 
definite that low alpha doses delivered on bone surfaces at continuous, but 
very low dose rates, have failed to produce bone tumors in Thorotrast cases , 
and this may imply that, in man, either there is a non-linear relationship 
between this dose and bone tumor induction, or a dose rate effect exists for 
alpha particle irradiation of the tissues adjacent to bone surfaces. 
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Chromosome Aberrations Caused by Thorotraat 
W. Kaniner, H. Muth, F, Tranekjer and U. Eorkenhagen 
Institut fdr Biophysik - Boris Rajewsky-Institut -
Universitat des Saarlandes 
HomburgfSaar) 
Abstract 
An attempt to find a dose-effect-relationship between radiation dose 
224 ( Ra-equivalent) and chromosome aberration yield (dicentrics and 
accompanying fragments) was made. An increasing statistical cor-
relation was found given by the Btraight line: 
y « 6.6 + 0.16 x 
(y • aberration yield, x • radiation dose) 
A computed curve for our values is the power function: 
y - 4 . 4 * 0 - 2 2 
Although the two relationships are statistically significant (significance 
level less than 1 %, respectively 5 %) we suggest that it is impossible 
to establish a dose- effect -relationship between radiation dose and chro-
mosome aberration rate in thorotraet patients, because the number of 
dicentrics scatters within large limits in different patients exposed to 
equal or similar doses. 
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Introduction 
This investigation is part of wider examinations in thorotrast patients 
made by the German thorotrast study group in Berlin, Heidelberg and 
Homburg (Saar) (Muth et al. 1971, Muth et al. 1973). In this study we 
try to obtain a dependence of the chromosome aberration rate from the 
radiation dose. In irradiated cells many authors found a relationship 
between radiation dose and number of damaged chromosomes both in 
vitro'and 'in vivo! PURROT, DOLPHIN et al. (1972) use this relation-
ship as a biological indicator in radiation accidents. However the re-
sults of other authors vary so much that it has so far been impossible 
to use their results as a biological indicator. In this paper it will be 
discussed if mere exists a significant relationship between chromosome 
aberration ratio and radiation dose as a base for the passible use as a 
biological indicator. (FISCHER et al. in 1966 reported a significant 
dose effect relationship in the chromosome aberration rate in 20 thoro-
trast patients). 
Material and Method 
68 persons of our thorotrast patients were selected for this investiga-
tion. (Because of technical causes no random selection was possible). 
They had been injected with 3 to 80 ml of thorotrast within the period 
1838-1947. The mean exposure time of these patients at the time of 
the chromosome aberration study was 29 + 3.7 years. 
Lymphocytes of the peripheral blood were cultured in vitro by known 
methods, used in most laboratories and described in detail in KEMMER 
et al. 1971. The culturing time including the Cole em id treatment was 
48 hours to be sure to find m eta phase s in first division. Chromosome 
preparations were analysed by scoring the chromosomes in the meta-
phase and determining the chromosome aberrations in a phase con-
trast microscope. All types of chromosome aberrations as terminal and 
interstitial deletions, multicentrics, dicentrics and rings with or without 
accompanying fragments were found and scored, but only the dicentric 
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chromosome aberrations with fragments were used as a measure for 
the radiation damage. 
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Fig. 1: Radiation induced chromosome aberrations (die + fragment) in 
Thorotrast patients. 
Control Group 
The blood of 70 persons of the same age who had not received any 
thorotrast injection or appreciable doses of radiation for therapeutic 
or diagnostic purposes was used for control. These control group is 
not identical with the control group "B", described in papers of 
LORENZ et al. 1973 and IMMICH 1973. The results obtained for this 
control group were in good agreement with published datas. In one of 
the controls did the chromosome aberration rate exceed the natural 
rate of two breaks per hundred cells. Only 1 dicentric was found in 
all persons of control group. We therefore assume that the chromo-
some aberrations found in our patients may indeed be attributed to the 
radiation effect of thorotrast. This assumption i s supported by the 
fact that the chromosome aberrations found in our study are charac-
teristical for radiation induced chromosome aberrations and not for 
aberrations induced by other a gent B. 
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Chromosome aberrations are only caused by thorotrast stored in the 
lymphatic system. In patients with perivascular deposits no chromo-
some aberrations were seen. Therefore we had only to take into con-
sideration the thorotrast activity effective in the RES. In thorotrast 
220 patients the thoron ( Rn) arising from the thorium decay series is 
eliminated in the exhaled air. Using the concentration of thoron mea-
224 
sured in the expired air it is possible to calculate the Ra-equiva-
lent value (GRILL.MAIER 1964). This value is directly proportional to 
the thorotrast activity in the RES. 
Results 
Chromosome aberrations were found in all patients with thorotrast 
deposits. The aberration rate was higher in comparison to the con-
trol group. The minimum rate was 1 dicentric/100 cells, the maxi-
mum 25 dicentrics/100 cells. 
224 
The results are presented in table 1 and figure 2. The Ra-equiva-
lent values (abscissa) correspond to the effective radiation dose. (The 
mean life time of lymphocytes is estimated at approx. 900 days 
(DOLPHIN 1972) and the exposure time is far more than mis time). 
|>l-mrri>->- iwr »HI »«Utt 
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Fig. 2: Do»e-effect relationship 
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Table 1 All values used in this investigation 
The ordinate shows the dicentric yield per 100 cell*. The break rates 
in relation to the radiation dose vary for different patients within wide 
limits. 
In seeking a statistical correlation of the relationship between the chro-
mosome aberration rate and the radiation exposure the large scattering 
of the values allowed only to assume that this relationship should be a 
linear equation, although other types of functional relationship could not 
be excluded. The regression straight line found is given by the fol-
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lowing function: 
y * 6.6 + 0.16 x Correlation coefficient 0.3352 
Significance level 1 % 
(y • aberration yield, 
x = radiation dose) 
However, the real relationship cannot be a straight line because -
apart from fundamental considerations - the regression straight line 
found does not cut the ordinate at the zero point. At dose 0 the 
aberration rate must be that of the controls. It was therefore sug-
gested that an estimated curve for the dose-effect relationship is a 
power function of the following type as widely used in investigations 
concerning radiation induced chromosome aberrations: 
y • k • x n 
The computed relationship is : 
0 22 
y • 4.4 x Correlation coefficient 0.2996 
Significance level 5 % 
(y = aberration yield, 
k = constant, 
x = dose) 
Discussion 
It i s obvious, that these results do not allow to use this method as a 
biological indicator for the radiation dose or damage, because the 
aberration yield of patients with similiar thorotrast amounts formerly 
injected varies within large limits. Besides it is surprising that the 
power exponent in the computet dose-effect relationship is less than 1, 
while in "in vitro" and in other "in vivo" experiments it is between 1 
and 2 (MOURIQUAND et al. 1971). There are many possibilities to ex-
plain these results: 
1. It is possible that "in vivo" damaged cells are eliminated by the 
body. 
2. The thorotrast-deposits in the RES are differently conglomerate 
(KAUL 1969, 1973, v. KAICK et al. 1973). Therefore the self-
absorption of the alpha-particles varies with the size of the thoro-
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tract conglomerations, so that the effective radiation doee and 
the radiation damage may be different in patients with the same 
thorotrast amounts in the RES. The effective radiation dose 
damaging the lymphocytes must therefore not be proportional 
to the amount of thorotrast formerly injected. The estimation of 
the elimination rate of thoron from Thorotrast deposits with dif-
ferent conglomerations i s difficult. 
3. The variance of the result« may be due to changes in the ratio 
of aberrant to normal cells in the lymphocyte pool, or changes 
in the relationship between the blood lymphocyte pool and the 
body lymphocyte pool. Examinations periodically made in two 
thorotrast patients show a variance in the dicentric aberration 
yield (Table 2 ). 
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Table 2 Dicentric yield in patients with different 
Thorotrast burdens 
4. In all Thorotrast patients relative high deposits of Thorotrast were 
found in lymph nodes independent on the total RES burden. That 
means that the effective radiation exposure of lymphocytes i s quite 
the same. This fact may explain that the chromosome damage In 
patients with lower amounts of Thorotrast injected i s relatively 
high. (Fig. 3.) 
To be sure that our results are not impared by errors of method 
we checked the method by irradiating lymphocyte cultures "in vitro". 
I l l 
The results obtained are in good agreement with those reported by 
other authors. Examinations in patients treated with radioiodine also 
gave results with good dose-effect relationships. 
Fig. 3: Thorotrast deposits in the RES in patients with lower (a) 
and higher (b) Thorotrast amounts formerly injected 
Conclusions 
In the present status we suggest that it is very difficult probably 
impossible to establish a dose effect relationship between radiation 
dose and chromosome aberration yield in thorotrast patients. The 
aberration yield cannot be used as a biological indicator for the 
radiation dose. 
Sponsored by EURATOM (Contract Nr. 031-67-3 PSTD) and by the 
Bundasminister (Or Forschung und Technologic (former: Bildung und 
Wiuenschaft) of the Federal Republic of Germany 
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The Edinburgh Thorotrast Serial - Report of a Cytogenetic Study 
by 
K.E. Buckton and A.O. Langlands 
MRC Clinical * Population Cytogenetics Unit, 
Weatern General Hospital. Edinburgh, 
Introduction 
The purpose of this paper i s to present the data derived from the 
study of cytogenetic damage in the peripheral blood leukocytes of per-
sons who had received intra arterial injection« of 23 2-thorium dioxide 
in the past. 
The study population was defined by the identification in the re-
cords, relating to the years 1926-1955 inclusive, in the Department 
of Surgical Neurology, Edinburgh, of 142 patients who had received 
Thorotrast in the course of cerebral angiography. Twenty-two of 
these patients died within one year of the injection, as a direct result 
of the disease for which they were investigated, and a further ten 
patients with permanent foreign residence (current status unknown) 
were excluded from the study. There remained therefore 110 patients, 
comprising 54 men and 56 women, in the study population. 
Results 
All 110 patients were successfully traced and information on the 
morbidity and mortality subsequent to the intra arterial injection of 
Thorotrast/ 
11$ 
Thorotrut obtained by interview, from the n p S u from doctors to 
queetioonairea and from the examination of hospital recorde relating 
to aubeequent boapltal admlaeiona. 
By December Slat. 1972, 60 daatfac bad baan notified and tha dis-
tribution of these deaths between malignant and non-malignant eauaca 
ia shown in Tania I, tofetbar with data relating to tba vomme of 
Thorotnat injected. 
A detailed report of tha lonf term hasard* in this group of patient« 
has already been published (Boyd et aL. 1968). Since mat report a 
farmer four liver tumours have bean notified to ua so that 8 ot the 19 
deaths due to cancer were due to a primer; tumour of the liver. 
These 8 liver tumours comprised S chnlanglorarfinwna«, 8 hepato-
ceUular . carcinomas and 1 haemanglosndonWHoina. The 
tumours ouciuied between 19 and 37 years altar injection (mean 87 
years); the patients having received between 14 and 71 ml Thorotrut 
(mean 32 ml). 
Since the 1968 report (Bordet aU. 1968) which included a death 
from aplastic anaemia and one from giant follicular lymphoma, a 
farther death from a blood dyscrasia baa occurred. The patient, a 
man, died from acute leukaemia 22 years after receiving 30 ml of 
Thorotrast. 
Cytogenetic Studies 
When/ 
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When peripheral blood i s grown in culture with phytohaemagglutinin 
the small lymphocyte can be induced to enlarge to form a blast cell and 
divide. If the cell is arrested in the metaphase stage of the division 
then the chromosomes in the cells can be examined. It has been found 
that the chromosomes in the small lymphocytes of persons who have 
been exposed to irradiation show chromosome aberrations. The 
and 
number of dicentric/ring aberrations in blood cells of persons exposed 
to known doses of external radiation i s proportional to the dose re-
ceived, and therefore the frequency of these aberrations can be used 
for dosimetry (DNSCEAR 1969). It was hoped that it would be possible 
to use chromosome damage in the small lymphocyte as a dosimeter 
also for internal emitters, especially for irradiation received from 
Thorotrast where the dose to the individual injected i s very difficult to 
assess. 
Fischer et al (1966) found that there was a positive correlation 
between the body burden of thorium in Thorotrast patients and the 
number of chromosome breakage events in their small lymphocytes. 
However this was only a correlation and the points on the graph are 
widely dispersed. 
In our original examination (Bocktonet aU. 1967) of the chromo-
some aberration frequency in 36 patients 33 of whom had been injected 
with known amounts of Thorotrast, we could find no significant relation-
ship between chromosome aberration frequency and dose, when dose 
was/ 
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was expressed as the product of 'mis of Thorotrast injected' and years 
since injection. It may have been that this was not a very good 
estimate of dose, but Hemphill and Hasselgren (1971) have reported 
that mis of Thorotrast injected gave a satisfactory estimate of body 
burden. 
Re-examination of our early data, together with additional new 
data on a further 8 patients indicates that there Is some association 
between chromosome aberrations and the volume of Thorotrast injected. 
In mis analysis the chromosome aberration data has been expressed in 
terms of the minimum number of chromosome breaks that would have 
been required to take place to produce the aberrations seen (e. g. one 
break for a deletion, 2 breaks for an interchange etc.). The associa-
tion found between the estimated number of chromosome breaks and 
mis of Thorotrast injected had a correlation coefficient of 0.3121 and 
was significant at the 5% level. When the number of chromosome 
breaks in 100 cells from 41 patients was plotted against mis of 
multiplied 
Thorotrast injected / by the years since administration (Fig. 1) the 
correlation coefficient was 0.3008 and was significant at the 10% level. 
The regression line shown in the figure was found to be given by the 
equation. Breaks = 33.47 + 0.028 (mis of Thorotrast x time since 
administration). The vertical line shows the confidence limits which 
are wide, and leaves no doubt that, in this situation, chromosome 
break frequencies are not a good parameter for dosimetry. This 
result/ 
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result i s not surprising, for the distribution of the thorium in the 
organs of the body after administration varies between patients 
and in some patients the thorium is largely retained in perivascular 
sites. Moreover, the method of weighting aberrations to give break 
frequencies is open to objection since at least some of the simple 
deletions are a consequence of two and not one break. 
In order to obtain a better estimate of the body burdens in our 
patients, 14 were submitted to whole body counting. This was per* 
formed by a linear scan of the whole body measuring the T^ray 
228 
emission, which was then calculated as nannocuriei of thorium . 
Table II shows the whole body counts for the 14 patients by increasing 
body burden. The cytogenetic results for peripheral blood sampled 
on the same day as the whole body counting are also given. The cyto-
genetic results in Table n are expressed as:-
1) Total number of unstable cells, i. e. cells with dicentric or 
ring chromosomes or acentric fragments. 
2) Numbers of dicentric and ring chromosomes, since these are 
the most characteristic and most easily Identified aberrations induced 
by Irradiation, 
3) Total number of stable cells, i. e. cells with abnormal mono-
centric chromosomes, although not easily identified, these cells are 
likely to be fully viable. 
*)/ 
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4) Total chromosome breaks, i . e . the mini mam Dumber of breaks 
in the chromosomes that would be repaired for the aberration« area to 
be formed. 
Comparison of the whole body count with the cytogenetic results 
shows no direct relationship with any of the parameters. On 11 of 
these patients a cytogenetic analysis had been done S to 4 years pre-
viously and it is interesting to note that mere has been very little 
change in the aberration frequencies in these patients in that time. It 
would appear therefore mat the relative number of damaged cells over 
this period of time after Thorotrast Injection remains relatively con-
stant. 
We have examined the chromosomes of a total of 59 of the patients 
in the Edinburgh Thorotrast series, among these patients we nave 
found 3 who have a clone of cells marked by a stable rearrangement 
of the chromosomes. The finding of a lymphocyte esse in an in-
dividual is a very rare event (Court Brown, 1967), therefore these 
clones in the Thorotrast patients are of considerable interest. Two 
of these cases have bees described previously (Buckton et al.. 196T). 
1) Case 19 in the previous report received 18 mis of Thorotrast 
during right carotid angiography at the age of 48. Thirty-one years 
later, when chromosome studies were done, he was found to have a 
clone/ 
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clone of abnormal cells marked by four rearranged chromosomes. 
This patient was suffering from a blood dyscrasia at the time of the 
cytogenetic examination from which he died shortly afterwards. On 
post mortem examination he was found to have Ca Lung. 
2) Case 10 in the previous report also received 18 mis of 
Thorotrast during right carotid angiography at the age of 49. Chromo-
some analysis twenty-two years later revealed that he had a clone 
marked by one abnormal No. 3 chromosome. In subsequent cytogenetic 
analysis the number of these clone cells has been variable as can be 
seen from Table III. There are no further chromosome studies on 
this patient as he developed a Ca. Bladder, for which he was treated 
with radiotherapy. He was alive on the 31st December 1972. 
3) Case 6 in the previous report received 17 mis of Thorotrast 
for right carotid angiography at the age of 37. On the first cytogenetic 
analysis twenty-one years later he was found to have two cells with 4 
abnormal chromosomes but this was not felt to be sufficient evidence 
for a clone. However, on chromosome analysis 4 years later eleven 
of the 100 cells analysed were found to have the same 4 abnormal 
chromosomes which were later identified with fluorescence as chromo-
somes 12, 14, 15 and 22 (Clone I). Also 3 more cells had another 
chromosomal rearrangement also involving 4 chromosomes which 
were later identified by fluorescence as both No. 6 chromosomes, 
chromosome/ 
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chromosome 7 and 22 (Clone H). Since 1966 we have made repeated 
observations on this man. The frequency of the two clones in the 
peripheral blood lymphocytes is shown in Table IV, the numbers vary 
with time but the clone cells do not appear to be increasing significantly 
since 1970. This patient remains well. 
Although cytogenetic analysis of the peripheral blood of Thorotrast 
patients has not proved useful for dosimetry, it is a useful guide to the 
level of biological damage present in the reticulo endothelial system. 
Where there is a high number of cells with stable rearrangements there 
would appear to be a high probability of finding a clone of cells with re-
arranged chromosomes. The clinical significance of these clones is 
unknown. They may provide an early indication of the development of 
malignancy, however this remains to be demonstrated. Further cyto-
genetic analyses of Thorotrast patients is certainly required. 
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Followup of Thorotrast Patients from Boston. Massachusetts 
and Ann Arbor. Michigan. USA 
by 
M. L. Janower, M. D. 
St. Vincent Hospital 
Worcester, Massachusetts 
Abstract 
72U patients who received Thorotrest for cerebral 
angiography and 315 control patients who underwent 
similar examinations were followed up to determine 
the incidence of radiation related morbidity and 
mortality. 42 of the Thorotrast patients and 29 
of the controls were subjected to extensive clinical 
and laboratory examinations. In the Thorotrast 
series, one case each of liver tumor, granulocytic 
leukemia, and non-alcoholic hepatic cirrhosis were 
found as well as two cases of localized thorotrastomas. 
The Thorotrast patients revealed evidence of early 
liver dysfunction by elevations in bromsulphaleln 
retention and alkaline phosphatase tests. The 
most sensitive indicator of radiation exposure 
was the high frequency of chromosome aberrations. 
Anemia, elevated white counts, and abnormalities in 
red eel 1 morphology were not found. 
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FoUowup of Thorotrast Patients frem Boston, Massachusetts 
and Ann Arbor, Michigan, USA 
INTRODUCTION 
Thorotrast did not receive the wide utilization in 
the United States that it did In many other countries in 
the world. An estimate'1} that less than 5000 patients 
received this contrast material does not seam unreasonable. 
Major concentrations of cases were located in Minnesota, 
New York, Pennsylvania, Michigan, Washington, D.C., and 
Massachusetts among others. No formal attempt has ever 
been made to organize a nationwide study in our country, 
and the status of most of the patients is entirely unknown. 
We were able to assemble a roster of over 700 patients 
who received Thorotrast for cerebral angiography and over 
300 control patients who underwent similar examinations 
with a non-radioactive medium (Olodrast). This work was 
performed between 1964 and 1970 and has been reported 
previously. 12'1M 
METHODS 
Only patients who had undergone cerebral arteriography 
were selected for the study because of the lack of any 
known relationship between central nervous system disease 
and malignancy elsewhere. The control series consisted 
of patients who had undergone cerebral arteriography 
In which a non-radioactive contrast material was used 
during time period of Thorotrast administration. At the 
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Massachusetts General Hospital*™", cerebral arteriography 
Mas performed in the operating room using an arterial 
cutdown technique under general anesthesia. A roster 
of 200 patients Mho underwent Thorotrast arteriography 
and a control roster of 13* patients ware assembled from 
the operating room log books. At the Laney C11nic'LC), 
a roster consisting of 175 Thorotrast arteriographic 
patients and 181 control patients was assembled from the 
medical record department. At the university of Michigan**', 
a roster of 3*9 patients who had undergone Thorotrast 
arteriography was assembled from the records of the 
radiology department; no control series was selected 
at this institution. 
The patient's original hospital chart was abstracted 
to ascertain his general health status as determined by 
the clinical impression and by pertinent laboratory tests 
performed during the arteriogram admission. In addition 
to the dose of Thorotrast, the patient's age, sex, and 
pertinent identifying information were also recorded. 
In instances of death, a copy of the death certificate 
was obtained to determine the cause of death. In living 
patients, the followup consisted of completion of a 
questional re dealing with the patient's current and 
past illnesses. This information was obtained by 
telephone and by mail. All information was verified 
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by contacting the family physician identified by the 
patient or by obtaining copies of the patient's previous 
hospital record. 
42 of the Thorotrast group and 29 of the control 
patients from the HGH were subjected to physical and 
laboratory examinations. Many of these patients were 
examined twice within a three or four year period. The 
physical examination was a standardized one with particular 
attention paid to signs of liver dysfunction or development 
of malignant tumors. Laboratory examinations included 
extensive tests of liver function tests (bilirubin, 
bromsulphalein retention, serum glutamic oxaloacetic 
transaminase, alkaline phosphatase, prothrombin time, 
thymol turbidity, cephalin flocculation, total protein 
and serum electrophoresis). A complete blood count 
including differentia) and red blood cell morphological 
analysis as well as chromosome analysis were performed. 
X-ray films of the entire body were obtained. The 
patients exposed to Thorotrast underwent whole body 
counting In order to measure their body burdens of 
radioactivity. The control patients underwent similar 
examinations excluding whole body counting. Ho patients 
from the LC or UH were examined. 
ADMISSION CHARACTERISTICS 
The most cannon indication for cerebral arteriography 
were the expected ones: namely, aneurysm, subarachnoid 
hemorrhage, and tumor. Approximately W % of the patients 
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underwent arteriography for a variety of other conditions 
including seizures, vascular disease and headache. The 
indications for arteriography for the control series 
was similar to those of the Thorotrast patients. The 
median dose of Thorotrast administered at all centers 
was 2k cc..being 28 cc. at the HGH, 12 cc. at the LC 
and 30 cc. at the UM. 
The median age of both the Thorotrast and control 
patients at all centers was kk years and the patients 
were approximately evenly distributed between males 
and females. Of the patients receiving Thorotrast 
approximately 72% did so prior to 1949. The cause of 
death was related to the presenting neurological disease 
in 70% of the patients; approximately 5% of the patients 
died of non-central nervous system malignant tumors. 
FOLLOWUP 
At the MGH it was possible to locate 199 of the 200 
Thorotrast patients. Of these, 70 were living while 
129 were deceased. All but 9 of the controls were 
located. At the LC 167 of the 175 Thorotrast patients 
and 172 of the 181 control patients were located. The 
numbers living were 69 and 80, respectively. At the UM 
310 of the 3k9 cases were studied; 71 were alive and 
239 were dead. The mean duration of followup for the 
living Thorotrast patients was 22 years and the maximum 
periods of followup were 2k, 27, and 28 years at the 
MGH, LC and UM, respectively. Of the living Thorotrast 
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patients, 60% at the MGH, 98% at the LC and 91% of the 
UH, were followed for at least 20 years. Total person 
years among the Thorotrast patients was 7249 years as 
compared to 3720 years among the controls. The remaining 
characteristics of the controls were similar to the 
Thorotrast group. 
RESULTS OF THE CLINICAL F0LL0WUP 
37 malignant tumors were detected in the Thorotrast 
patients, and 13 in the control series; taking person-
years into account, there was no increased incidence 
In either group. In regards to the usual Thorotrast 
associated malignancies, one case of liver cancer 
occurred in both the Thorotrast and control series. 
Three cases of leukemia occurred in the Thorotrast 
series, only one of which was granulocytic in type. 
Three cases of lung cancer occurred in the Thorotrast 
series and two in the control series while no bone tumors 
were found. Of non-neoplastic Thorotrast attributable 
disease, there was one presumed non-alcoholic cirrhosis 
in the Thorotrast patients and two cases of thoratrastomas. 
No cases of aplastic anemia were found. 
RESULTS OF LABORATORY EXAMINATIONS 
The techniques used In the examination of the 
patients have been given elsewhere^) and will not be 
repeated In detail here. X-ray films revealed the typical 
pattern of deposition of Thorotrast in the liver, spleen 
and periportal lymph nodes. No relationship was apparent 
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between the size and density of these organs and the 
amount of Thorotrast administered. Films of the bones 
failed to reveal evidence of alteration in bony trabecular 
pattern. 
37 of the 42 Thorotrast patients underwent whole 
body counting using the meter-arc technique with an 
l; x 4 Inch sodium iodide crystal connected to a 400 
channel analyser. The gram equivalents of 232 T n were 
calculated and were shown to closely correlate with 
the amount of Thorotrast originally administered. The 
whole body burdens ranged from 0.1(2 to 2.51 gram 
equivalents of * Th, with an administered dose of 30 cc 
resulting in a body burden of between 1.0 and 1.5 gram 
equivalents. 
Slightly more than <t0% of the Thorotrast patients 
revealed evidence of early liver dysfunction as indicated 
by elevations in the bromsulphalein retention (greater 
than 10%) and alkaline phosphatase (greater than 5 
units) tests. A dose-response was not evident in relating 
Thorotrast-years or calculated liver dose In rads to 
these abnormal Hver function tests. 
Chromosome analysis on peripheral lymphocytes 
was performed using a modification of the method of 
Moornead etal < 5 ). The blood was obtained before 
x-ray examination and cultured for 48 hours. The 
metaphase nuclei of 50 cells were counted in 25 cases. 
A ring, dicentric, or rearrangement was counted as two 
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breaks each and a fragment as one break. There was a 
striking excess of breaks among the Thorotrast cases 
with a median of 34 and a range of 0-113. The control 
series did not reveal such changes. There was no indication 
of a dose-response relationship. 
All other laboratory studies failed to show significant 
differences between the cases and control series. In 
general, the laboratory tests in the controls were 
unremarkable. Specifically, there was no evidence of 
abnormality of the erythrocyte morphology, no anemia, 
and no elevation of white cell count. 
DISCUSSION 
The present study has several unique features 
including the use of a control group as well as the 
results of rather extensive physical and laboratory 
examination of "tl of the living Thorotrast patients. 
The relatively low incidence of malignancy in 
the series'"' (one hemangioendothelioma, one granulocytic 
leukemia,) may be partially explained by the relatively 
small doses of Thorotrast used as well as the short 
followup period. Previous reports have suggested that 
liver tumors are more prone to develope In patients 
who received more than i»0 cc. of Thorotrast In which 
a time period of more than 30 years had lapsed^8' 
since the administration of the Thorotrast. 
In the relatively extensive set of clinical and 
laboratory tests, apparent effects of Thorotrast were 
13<» 
seen In the bromsulphalein and serum alkaline phosphatase 
tests which showed evidence of early liver dysfunction in 
about one half of the patients. The best indicator of 
Thorotrast exposure was the aberrations In the chromosomes 
Although there has been a previous suggestion that these 
abnormalities are dose dependent' ' we were unable to 
confirm such a relationship. Our failure to find 
abnormalities In red cell morphology and our lack 
(12) 
of cases of anemia1 ' is also of Interest. 
In the course of the study, three possible 
Thorotrast attributable deaths from cases not in our 
series were uncovered. These Included one case of 
cholangiohepatoma, a hepatoma and a case of aplastic 
anemia, respectively. Pertinent demographic data was 
not available for these cases. 
The Thorotrast patients represent an unreplaceable 
potential source of information on the long term effects 
of chronic radiation in humans. It is unfortunate that 
the lack of government funds has temporarily signed 
the death knell of continuation of the present study 
or of future studies 1n this area In the United States. 
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Follow-^p n-f *Tp1ah Thorotraat caaea. 
by 
H. Faber. 
The Finsen Laboratory, 
The Finsen Institute, 
Copenhagen, Denaark. 
The teaporary reaulta of the follow-up of 1.005 Thorotrast in-
jected patiente are presented. Among the 756 patients who did 
not die froa the neurosurgical disease 712 havs died. 26 died 
froa hepatic tuaors of which 11 were the typical Thorotrast in-
duced hnaaangloendothelloaaa all with a latency period above 
15 years. A further 11 died froa leueeaia fcith latency period 
aa low aa 7 - 8 years, the expected rate of death froa all the-
se tuaora la less than 5. Ih« follow-up continues. 
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In long tera studies like the present epidemiological 
follow-up of Thorotrast injected patients it ia necessary with 
intervals to make a complete inventor;' on the state and corre-
lations in the observations collected. Only in this way will it 
be possible to find the actual points of interest and to regi-
ster the new developments taking place in the group under ob-
servation. 
The preparation Thorotrast was used in Denmark from 
1935 until 1947 and the follow-up of the group was started at 
the Finsc.ilaboraty in 1949. 
The follow-up has been laborious and only during recent 
years has it become absolutely evident how important the follow 
up has been. Due to a massive underestimation of both size and 
type of effect and of latency periods between injection and in-
duced malignant tumors the project was started as an acute stu-
dy - while it is now quite evident that it will be my successor 
at the Finsenlaboratory who will conclude the study. 
The patients had all been admitted to the two neurosur-
gical departments in Denmark and had during their stay here 
been examined with an intravenous carotid angiography. 
A thorough search through the case histories of these 
departments has disclosed 1.009 patients where colloid Thorium 
dioxide was injected. A further number of cases ia known who 
are not included but who might have been injected. They have 
had an arteriography performed at the time when iodine com-
pounds again were becoming available, but there is no note in 
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the case history of what contrast medium has been used. 
Both groups are subject to a continous folio* op, prima-
rily by a control of all Danish death certificates bet combined 
with a periodical verification of the status of those known to 
be alive, the radioactivity and the aaovnt of Thorotremt has 
only been •ensured in a small number of patients. In moat of 
the dead the prescence of Thorotrast baa been verified through 
autopsy, at hospital admiaions or by radiography. Otherwise the 
information from the case histories has been considered valid. 
The distribution of the patients according to sex and time of 
injection can be seen from Table I. 
The amount of Thorium dioxide injected varied as seem 
in Table II. 
During the first years after the injection a medier of 
the patients died from the neurosurgical disease, for which 
the arteriography was pertarmed. This group shall not be consi-
dered further. The rest of the patients have since 1949 shown 
a constant yearly mortality from all causae. (Hg.I). The rate 
of death has for the males been 7,6 persons per year and for 
the females 4,0 per year. If this rate of death continues until 
the disappearance of the group, this will require a further 
observation of 30 years for the males and $7,$ years for the 
females. At time of the last death, the age of the youngest 
surviving person should be 65 years for the male and 87 years 
for the female. The calculation may thus be reasonable. 
The main causes of death are the ones expected frem a 
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nixed groan with an aga distribution aa tha present one, ant 
with eardioeaacular diaaaaaa aa tha aoat fnanun ona. A relative 
large nonner of auicidea and accidente la observed, hut thia 
aaat in all probability ba dna to tha underlying raaaon for 
beepital asaleeion, haad aehaa and apilapaia. Only tao groups 
of nnn anllgnant dlaiaeoa ahall ba •tntlonad. Aaong tha daad 
ara f oaad 8 eaaaa ahara bapatie cirrhoala haa baan tha eanaa of 
death, aa tha occurence of thia diaaaaa ia not registered in this 
country tha incidence ia ralatioa to tha expected can not be 
evaluated. It ia h a m r intonating that the onaner of casta 
appear to be inereaaing with tiaa. Of tha 8 only 3 died leaa 
than 25 yeara after the Thorotrast injection, the other 5 
appaarad later, up to 51 years after the injection, this could 
support the possibility of a dependency of the cirrhosis on 
the thorotraat. 
the other act of dieeaeee are the non-leucealc haeaato-
logJcal diseases, the aaaber of caaea with these diseases vera 
increased above the expected in the ABCC studies in Japan (1,2). 
In the present Material there haa hoverer been no'lnerease du-
ring recant years in the naaber of these cases - the fire pre-
Tiously published (3) are still the only ones known. 
Ina greateat interest ia hoverer centered on the inci-
dence of all types of cancers in the notarial. In Pig. II ia 
seen the year by year emulative rise in verified cancers, dead 
or diagnosed, in relation to tha expected incidence for a group 
of peraona with identical age and aex aa calculated from the 
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Danish -cancer register data corrected for the expected inciden-
ce of brain tumors. As the presence of such a tumor could be 
the reason for entrance into the material it was deleted in 
this estiaate. 
It can be seen that the sales for a nuaber of years have 
shown an increase above the expected. This increase which has 
been growing Tear by Tear. The incidence for the feaales stayed 
for sos* years below the expected curve, but during recent years 
this group baa also risen above the expected. 
The localisation of the malignant tuaors and the leuce-
alas is given In Table III together with estimates of the expec-
ted Incidence calculated on the basis of the cancer register 
data. It will be evident that two tumor localisations are of 
main interest, the tumors of the liver and the leuceaias. 
Is far as the other tumors are concerned the observed in-
cidence Is well below the expected in practically all cases. 
Only the pulmonary cancer will give rise to special comments. 
Is we heard there is a continuous excretion of Thoron in the 
breath, and significant dose to the bronchi can be calculated. 
In the present material the overall incidence is 8 eases with 
4 expected which oould fit a radiation carcinogenesis. It is 
however significant that although 0,5 caseB were expected aaong 
the feaales none are seen. If Thorium through Thoron should 
represent a carcinogenic haxard In itself an identical in-
crease of 2 tumor oases should have been observed In both 
sexes. As this lb not the oase it would be prudent to reserve 
the judgement on the Thorium dependency of thess tumors, at 
1H2 
least on the basis of this material. It is interesting that the 
Portugese investigators have taken the same position, althsogh 
for a somewhat different reason (4). 
Two main groups of liver tumors are found; the haaaangio-
endotheliomas and the more common hepatoeholangio carcinomas. 
The first mentioned tumor has repeatedly been shown both 
in human experiences (5) and In animal experiments (6) to be a 
type of tumor intimately connected with Thorotrast deposits in 
the liver in man and in the spleen in some animals like the 
rabbit. 
In order to evaluate the carcinogenesis in the liver tu-
mors and the leucemias a knowledge of the pattern of appearenee 
in relation to the time after Thorotrast injection is necessary. 
If there is a difference In the provoking mechanism among the 
Thorotrast tumors themselves or in comparison with the other 
tumors found in the Thorotrast patients this could be evident 
from the pattern of appearance with time. (Fig.5). 
The cumulative Incidence of those tumors where no causal 
relation to the Ihorotrast is suspected rises by a straight line 
starting Immediately after the injection. 
The Thorotrast Induced tumors however show quite a diffe-
rent pattern. The curve shows a latency period without any tu-
mor and this latency psriod varies among the different malignan-
cies. 
As was to be expected the leucemias have the shortest 
latency period of not more than 5 - 7 years. The curve for the 
»3 
riae in cumulative number follows reasonably esse* to s straight 
line although a seailogmrithmie plot say give s sore straight 
line. 
The curve for the liver carcinoma* and the one for the 
haeawngioendotheliomas have latency periods close to 15 years. 
Both rise reasonably rectilinear with tis* and it la doubtful 
whether these two curves can he considered different. The slops 
of the curve for the hasaangioendotheliosss is not too signifi-
cant due to the snsll number of esses. 
It is difficult to coapsre the observed incidence be-
tween the groups of patients followed in different countries, 
it can however be mentioned that the rate of appearance and the 
latency period for the naeaanglosas is practically the sen* 
in the Danish and in the Portugese amterisl which is of approxi-
mately the same sise (Pig.4). 
In the evaluation at these curves a certain unreliabili-
ty has to be recognised, is of January 1973 it is 38 years 
since the first patient was injected with Thorotraot. It ia 
however only 27 years sines this happened to the last one. This 
means that only that part of the curves in Pig. 3 which covers 
the first 27 years after the injection represents completed ob-
servations. During the next years more cases will probably ap-
pear, and they may change the last part of the curve. 
It is interesting that no eases of leuuemie have appeared 
later than 23 years after the injection, and that the sane is 
the case with the non-leucenie haeaatslogical diseases. This 
itu 
nay be a sign that the spatial distribution of the irradiation 
to the bone narrow has become such tnat no radiation is recei-
ved by the sensitive cells. This is not very probable and the 
significance of this observation can as far as the Ihorotrast 
patients are concerned not be resolved fro« this material alone, 
this presentation of the factual information obtained by 
close to 25 years of follow up of this group of patients wist 
lead to the conclusion that an increase in leuceaias and in cer-
tain liver tumors has been observed. Out of some 250 dead 28 
have died from Ihorotrast induced liver tumors and 10 of leuce-
mia and they show no sign so far of a decrease in rate of ap-
pearance. On the other hand no new tumors which can be ascribed 
to Ihorotrast have been found from this survey. 
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The year by year decrease in surviving patients. 
Pig. II. 
The cumulative Incidence of malignant tumors and leucemlas com-
pared to the expected calculated from Danish Cancer Register 
data after exclusion of brain tumors and taking the actual age 
and sex into consideration. 
The cumulative incidence of tumors and leu-
cemias according to year after injection. 
Pig. IV. 
Comparison of Danish and Portugese 
hsemangioendotheliomas. 
Year of 
i n j . 
1935-38 
1939-41 
1942-44 
1945-46 
TOTAL 
Sex 
H 
P 
H 
F 
H 
P 
M 
F 
Table I . 
Thorotrast pat ients according 
of i n j e c t i o n , sex and type of 
Total 
material 
No. 
51 
43 
133 
84 
203 
143 
178 
170 
1.005 
Dead fro« 
neurosurg. 
d i sease 
Ho. 
11 
7 
18 
10 
62 
42 
61 
38 
249 
Material 
proper 
No. 
40 
36 
115 
74 
141 
101 
117 
132 
756 
to year 
death. 
Dead 
No. 
22 
18 
58 
36 
55 
22 
53 
48 
312 
l i v i n g 
No. 
18 
18 
57 
38 
86 
79 
64 
64 
444 
Living 
* 
45 
50 
50 
51 
61 
78 
55 
64 
Relative Uitr i taUm of laleotec 
doe* of Thorioa dioxide aolvtlon. 
Injoettd All M M leaeenlae 
5 - 9 
10-19 
20-29 
30-39 
40-49 
SO 
43 
Ti 
a 
5 
1 
8 
76 
16 
22 
21 
16 
8 
14 
19 
43 
38 
41 
27 
7 
5 
3 
15 
70 
15 
fable i n . 
Observed and azpactad emnear by region. 
Oaatro- la tes t . 
Frinary l i v e r 
Haeaangio* 
Puis . 
Pleurae 
Breaat 
Female g e n i t . 
Male g e n i t . 
Leuc. 
Other haeoatol 
Ottaere 
Males 
observed expected 
a 
10 
7 
8 
5 
0 
0 
2 
. J 
5 
12 ,9 
0 ,36 
0 
3 ,5 
<0 ,02 
3 ,5 
2 ,7 
: PeamlM 
observed expected 
5 
7 
4 
0 
0 
2 
6 
0 
5 
4 
8 , 2 
0,25 
0 
0 ,5 
© , 0 2 
6 
7 ,6 
2 , 0 
Al l 
observed expected 
13 
17 
11 
B 
3 
2 
6 
2 
1 
9 
2 7 , 1 
0 ,63 
0 
4 , 0 
< 0 , 0 4 
6 
7 ,6 
J .5 
4 , 7 
50 (32) 33 »3 
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Statsticel Problems of Thorotrast Studies 
•J 
H.Iaaieh 
Department of Kedicel Documentation end Statistics of The 
University of Heidelberg, D-59 Heidelberg, Federal Republic 
of Germany 
Abstract 
A cross-section study on the toxicity of thorotrsst demands 
s control-croup. The postulates in order to establish a con-
trol-proup are discussed. Evaluation of data will be perfffø-
mefl for she first tine as soon as the collection of the whole 
universe under study has Keen terminated. 
Introduction 
This paper should like to infor« you on various ideas which 
have affected us during- the planning period of the Geraan 
thorotrast study. 
?Jl£_?i2iS_3H£2£i22 
The Analyst has to answer the question: Given any pathologi-
cal finding in members of the carrier-rBroup. Has this finding 
heeing produced by the toxicity of thorotrast or not? E.G.: 
Under onehundred male thorotrast carriers you will find three 
patients suffering fro« a carcincnia of the prostata. Are the-
se carcinomas caused ^y th.orotrest or no*? The question leads 
to the hypothesis: 
•"he coincidence of thorotrsst-administrstion 35 y*ars ego 
aw' the present eercino«e of prostata has been produced hy 
cance only. 
Then the analyst has to decide, whether the hypothesis has 
to be re.jeeted or not. This is possible by means of a con-
l<tS 
trol-group only. That is the reason why the main problem in 
the present Gemen study runs »s follows: 
How tg establish s Control-group? 
With sufficient energy it is relative easy to find a large 
group of thorotrast carriers. However, it is a very difficult 
task, to define a control-group, because the following postu-
lates eust be- fulfilled: 
(i) The borderline between the two groups Bust be defined 
(ii) The groups must be comparable with regard to tine 
(iii) The groups Bust be comparable concerning age and sex 
( or race, if necessary) 
(iv) The intensitiy of physical, radiological and laboratory 
examination Bust be equal. 
Ad (i): The first postulate demands nature consideration. It 
seems to be the simplest Banner, to compare the thorotrsst-
cerriers with patients, who have received another contrast-
injection. However,this method is not practicable,because in 
1935 through 19*1 all patients requiring a contrest-injecti-
onheve received thorotrast without any exception, at least 
in Germany.That is the reason why we have defined the bor-
derline als follows: Patients, who did receive thorotrast 
versus patients, who did not receive thorotrast, without 
respect of the underlying disease. 
Ad (ii): The so called historical comparison is a very bad 
one, because you will get a doubtful conclusion in every 
ease:If you detect any distinction between the carriers and 
the control-group, you cannot decide, whether the distincti-
on is true or produced by the lag of time between the hospi-
talisation of the carriers and the hospitalisation of the 
control-group. That is the reason why we collect the control-
group out of the no-thorotrast-patients of the same time 
( 1955 throug 1941 ) and the same hospital. 
Ad (iii): The method of matched pairs is the most common one 
to fulfill the third postulate. However, the structure of the 
control-group is predetermineted by the structure of the car-
rier-group. Neither the carrier-group is collected randomly 
ISO 
nor the control-group. That is the reason why in the Gexaan 
study the control-group has keen drawn according to the B 
as the first letter of the surneae. This aetiod is a pseudo-
rcndom one.For evaluation reasons suhseaples according to 
age and sex are provided koth fro« the carrier- and the con-
trol-group. 
Ad (iv):The way of ohteining ceteaeaaestie data as well as 
the physical, radiological aadllehoretory examination of the 
still living patients under study is standardized. The rela-
ted data sheets are standardised also. 
Evaluation of a Cross-section Study 
The collection of a sufficient large seaple koth of carriers 
and of control-patients is a tiae consuming process. If you 
wish to evaluate the data of the already collected patients 
stepwise, e.g. yearly, then the independency of data is not 
guaranted. F.i.: The first onehundred patients evaluated af-
ter the first year are included in the 25o patients evaluated 
after the second year and so on. This way enahles you to re-
ject the hypothesis very early, only ky the lack of indepen-
dency, and not kecause a true difference ketween the eerrier-
and the control-group. That is the reason why the evaluation 
of data cannot ke performed till then the collection of all 
patients under study has keen terminated. 
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Development and Improvement of the Questionnaires 
by 
P. Schmidlin, G. Kagner* 
Institute of Nuclear Medicine, German-Cancer-ltesearcn-
Center, Heidelberg 
Institute for Documentation, Information and Statistics, 
German-Cancer-Research-Center, Heidelberg 
Two points of view are decisive for the documentation of the 
data occurring in the Thorotrast-research project: 1. Coaplete 
acquisition of all important data, as far as possible, and 
2. suitable coding with a view to the statistical evaluation by 
the computer. 
For the data acquisition we chose questionnaires containing 
on the left side the corresponding questions which axe to be 
answered on the right side either coded or in free text. The 
coded information of one questionnaire can be transferred to one 
punched card. 
In its present form the data set comprises a total of 5 
questionnaires• the so-called medical record questionnaire, 
three clinical questionnaires and a final questionnaire for 
deceased or lost patients. 
The data processing is devided into the following parts: 
1. The collection of Medical reccrd data. It consists in 
transferring the essential data from the patient hospital 
record to the medical record questionnaire. The informa-
tion thus acquired consists, above all, of personal data, 
administrative information, diagnoses and information on 
possible thorotrast application. 
2. The examination of the patient. It begins with the case 
history which is recorded on the clinical questionnaire I. 
This includes several questions referring to the time 
prior to the thorotrast injection. The results of the 
clinical examination are recorded on the clinical 
questionnaire II, while the results of the X-ray exami-
nation, of the dosimetric determination of thorotrast 
deposits, and the thorium content of the breathing air 
as well as the lab data are recorded on the clinical 
questionnaire III. 
3. Recording the data of deceased or lost patients on the 
final questionnaire. In the case of deceased patients, 
this information is mostly furnished by authorities or 
physicians. 
4. The results of the re-examinations within the framework 
of the follow-up study are provisionally recorded on the 
same questionnaires. 
The data in the questionnaires is recorded partly in free 
text, partly in a coded form. Information that is fixed in free 
text only is not included in the evaluation. The codes to be 
used are printed on the questionnaires whereever possible. As a 
rule, provision is made for simple yes/no-answers for qualita-
tive information, O always indicating "no", 1 indicating "yes" 
and 9 indicating "missing Information". Where more than one 
answer is possible, simple numerical codes were chosen, if the 
features are exclusive. Where features are not exclusive, the 
1-2-4-code is used. Diagnoses are coded according to the KDS-
code of clinical diagnoses by Immlch. 
lij 
With quantitative Information, the actual figures are 
entered. The questions on the questionnaires are phrased in 
such a manner that they can be used both for thorotrast- and 
control-patients. 
The difficulties in tracing thorotrast patients are in-
creased by the fact that with many persons assumed to be thoro-
trast patients the name of the contrast medium used is not 
mentioned in the medical record and one may only conclude from 
the manner of application that thorotrast has been employed. 
With part of these patients this assumption is confirmed by the 
subsequent examination, while with others no evidence of thoro-
trast can be shown. In addition, there is a further group of 
patients where thorotrast has been used according to the infor-
mation in the medical record, butwhere there is no longer any 
evidence of such application. In order to be able to differenti-
ate among all these possibilities, the code distinguishes the 
following three groups: 
Group 0 = control group 
By this we understand those patients where there is no indi-
cation what so ever of thorotrast application either in the 
medical record or in the course of clinical and biophysical 
examination. 
Group 1 - thorotrast doubtful 
By this we understand those patients where thorotrast 
application is suspected, but where there is no longer any evi-
dence of thorotrast today. 
Group 2 - thorotrast positive 
By this we understand those patients where there is sure 
evidence of thorotrast today. 
Allocation to one of these three groups is, therefore, 
effected according to the thorotrast findings in the clinical 
examination. Group 1 forms an inhomogeneous group which, how-
ever, has to be taken into consideration in the evaluation. The 
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case history details furnished by the patient as to whether he 
knows that he received a thorotrast injection or whether he is 
of the opinion that he received such an injection are of merely 
informative character. 
The following numbers provide data identification and re-
cord linkage: 
1. A document-number which is used continuously throughout 
all medical record questionnaires; 
2. a specific identification number referring to the patient 
which is centrally allocated; 
3. a current number of the series of clinical examinations 
which is allocated by the respective examiner. 
The choice of items to be covered in the study gave occasion 
to numerous discussions and deliberations, in which clinicians/ 
biophysists and statisticians took part. To begin with, first 
experiences were gained from some hundred thorotrast and control 
patients within the framework of a pilot study. The final 
questionnaires were then received with the aid of the results 
of the pilot study. The most important points of view in the 
selection of features were the assumed relevancy of information 
to the problem to be studied, the question of reliability and 
validity of the information as well as the question of the costs 
of getting the actual facts. 
The following groups of data are mainly covered: 
Patient's case history with respect to thorotrast injection 
and possible surgery or other therapy which might be connected 
with the thorotrast injection; clinical symptoms which might in 
any way be related to liver damage, granulomas or loss of ner-
vous functions due to paravascular deposits, thorax X-rays of 
the empty abdonen and of the contrast medium deposit with locali-
zation, dosimetric measurements of thalllum-208 in the whole 
body, liver and spleen and of ra^don-220 in the air exhaled, 
haemogram, bilirubin, ferments and bromsulphthalcin tast. Mean-
i»» 
thile further •easureswnts. such as liver scintigraphy, alpha-
Eoetoprotein and ultrasound diagnostics have been included in 
the routine. 
The decision as to the fore in which these new methods as 
veil as the results of the follow-up study are to be Incorpora-
ted in the statistical evaluation will depend on further teats. 
ise 
1. Inquiries: Collected on Code-«" 
Extract fro« 
medical record 
2. Patient examination: 
Case history 
Clinical examination 
X-ray ) 
Dosimetry ) 
Laboratorium ) 
3. Termination: 
Data of deceased 
or lost patients 
4. Follow-up: 
Re-exafl»ination 
medical record questionn-
 01 
aire 
clinical questionnaire I 02 
clinical questionnaire II 03 
clinical questionnaire III 04 
final questionnaire 
provisionally on the 
clinical resp. final 
questionnaires 
This work vas supported fay the Bundesmirviaterium fttr Wissen-
schrvft und Technoloeie (former: Bilding und Wissinsohaft) and 
EUHATOM. 
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Actual status of the German Thorotrast Study 
by 
G. van Kaick and K.E. Scheer 
Institute for Nuclear Medicine, 
German Cancer Reaearch Center, Heidelberg 
Abstract 
The German thorotrast study is a supra-regional 'compound-
research program", containing clinical and biophysical examin-
ations of thorotrast patients and a control group. The causes 
of death were ascertained for those thorotrast patients who 
died later than 3 years after the injection of thorotrast or 
3 years after their hospitalization. A follow-up-study was 
started 1972. Up to now, 12 000 patients belonging to the 
thorotrast and control group were researched) 800 thorotrast 
patients and 600 members of the control group were examined. 
The causes of death were ascertained for approximately 950 
thorotrast carriers and 800 persons of the control group. 
At the present time it appears that thorotrast carriers have 
a higher incidence of liver tumours, liver cirrhosis, leukemlas 
and aplastic anaemias. 
The German thorotrast study Is new in relation to the 
other thorotrast investigations in other countries. Since 1968 
we are working in a supra-regional compound research program, 
in which the following institutions are involved! 
1) Institute for Nuclear Medicine, German Cancer Research 
Center, Heidelberg 
2) Institute of Documentation, Information and Statistics, 
German Cancer Research Center, Heidelberg 
3) Instituts for Biophysics of the University of the 
Saar Territory, Homburg 
4) Nuclearmedical Department of the Clinleum steglltx 
of the Free University at Berlin 
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The thorotrast program is supported by grants from the 
German Ministry for Science and Technology, and EURATOM. 
The German thorotrast study is seriously handicapped as a 
result of World War II. The records in many hospitals and 
registration offices were destroyed. Many patients moved re-
peatedly during, and after the var. Lastly, the division of 
the country makes It impossible to reach a large number of 
thorotrast carriers, or obtain their medical documents. 
We searched for thorotrr*>t patients in SO hospitals through-
out the Federal Republic of Germany. Our search for thorotrast 
carriers was, however, only successful in 30 hospitals. 
Primarily we looked for patients who had received thorotrast 
for angiography. He also examined 14 patients with thorotrast 
residues at the site of injection, after fistulography. We 
found only 2 patients with residues of thorotrast In the 
region of renal pelvis, after retrograde pyelography. The 
patients in our study received thorotrast during the years 
from 1934 to 1949. The control group was selected In each 
hospital in accordance with the criteria explained by 
Professor IMMICH. 
First of all, I would like to present a short statistical 
review. 
patients ascertained 
patients examined 
patients deceased 
( > 3 years post inj.) 
( < 3 years post In). 
Thorotrast 
cjrouD 
6000 
800 
950 
Control 
g r o w 
6000 
600 
800 
resp. not traceable) 4250 4600 
To date 6000 thorotrast cases and 6000 control persons were 
researched. Approximately 80% of these persons have died 
In the meantime. During the last 4 years we were able to 
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examine 800 livlag thorotrast patients and 600 persons of 
the control group. The cause of death was elucidated for 
those patients who died more than 3 years after the Injection 
of thorotrast, in the case of control groups sore than 
3 years ofter hospitalisation. Up to now 950 cases in the 
thorotrast group resp. 800 cases In the control group, could 
be traced up to the tine of their death. The remaining 4250 
persons in the thorotrast group resp. 4600 in the control 
group, have been disregarded because they died within less 
than 3 years after the thorotrast injection, or their hospi-
talization. The most common cause of death in these cases 
was the disease present at that time. A small number of 
persons have not been traced up to now, and are still being 
searched. 
The study is not yet finished. The numbers are not permanent, 
and are still changing. We have consciously evened up the 
values In order to clearly show the differences in size. 
After patients have been found, often after time-consuming 
correspondence, we sent them a letter inviting them to 
Heidelberg or Homburg for an ambulant examination. Host 
patients accepted our invitation, after some hesitation. The 
control group offered greater difficulties. 
The examination includest anamnesis, general state of health, 
laboratory findings. X-ray examination of the abdomen, 
thorax and site of injection. The thorotrast patients as 
well as the control persons have to undergo whole body 
counting and determination of the exhaled thoron. 
A certain number of patients was not able to come to Heidel-
berg or Homburg for reasons of old age or illness. These 
patients are examined in their heme by a physlclon and a 
biophysist. An equipment. In order to measure the exhaled 
thoron is carried along by car. Excepting whole body 
counting and X-ray examination all programmed examinations 
can be performed. 
All above mentioned findings ere recorded on date sheets. 
The final evaluation will be done by means of a computer. On 
this topic Dr. SCHMIDLIN has already reported. The method of 
examination Is identical for both, thorotrast and control 
patients. Supplementary examinations had been performed or 
arranged in the sense of snail project studies or for clinical 
reasons. You trill understand that no definite statements on 
the clinical investigations can be given at the present time 
in order to prevent any influence on the final evaluation by 
the computer. Some special clinical findings however can be 
reported subsequently. 
The cause of death could be ascertained in 950 patients of 
the thorotrast group resp. in 800 of the control group who 
died later than 3 years after injection Of thorotrast resp. 
3 years after hospitalization. 
Tab. 2 Causes of death among deceased patients 
Thorotrast patients Control patients 
( 950 > ( 800 ) 
liver tumours 78 5 
liver cirrhosis 64 22 
leukemia 15 2 
aplastic anaemia 10 O 
tumour* of the lung 28 22 
tumours of the bone 3 0 
Tab. 3 Fatal blood dyscraslas among deceased patients 
Thorotrast patients Control patients 
' »50 ) ( 8O0 ) 
acute leukemias 13 1 
aplastic anaemias 10 O 
C M L 2 O 
C L 0 1 
Information on causes of death we obtained from health 
offices, from medical death certificates, from hospital re-
cords, records of post mortem examination and private notes 
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of physicians. The figures of the tables demonstrate that 
pristary tunours of the liver, liver cirrhosis and diseases 
of the bone marrow occur at a much higher frequency in 
thorotrast patients. Tumours of the liver are to one third 
hemangioendotheliomas, to one third cholanglocellular- and 
to one third hepatocellular-carcinomas. The average latent 
period in the cases investigated by us is about 23 years. 
Concerning diseases of the bone marrow the incidence of acute 
leukemias and aplastic anaemias is dominating in the thoro-
trast group. One case of chronic lymphatic leukemia wast 
up to now, detected only In the control group. The average 
latent period of leukemias in this study is only IB years. 
Though thorotrast is highly accumulated in the spleen we 
did not find, up to now, a single primary tumour of this 
organ in our thorotrast patients. Lymphosarcomas occur 
nearly similarly In both groups. The lungs, too. are con-
siderably exposed to radiation. The rate of tumours of the 
bronchus, however, is not essentially higher than in the 
control group. 
Finally I would mention our follow-up-study which was started 
some months ago. He re-invited the patients of both groups, 
who had been examined more than 2 years ago. Approximately 
10% of these patients died in the meantime. The cause of 
death of 30 persons in the thorotrast group resp. 27 in the 
control group could be elucidated. In the thorotrast group 
6 persons died of a primary tumour of the liver and 2 of 
leukemia. These numbers Indicate that the incidence of 
thorotrast-lndueed neoplasias is still Increasing. It is 
therefore highly desirable to continue the follow-up of 
previously studied thorotrast patients in the different 
countries. He have started our follow-up-study at the end 
of the last year. Final data sheets are not yet prepared 
- not without a good reason. It is hoped that the discussion 
at this international conference might lead to some recommen-
dation« for uniformity in data collection in follow-up-
studies in all national thorotrast programs. Such an unifor-
mity will permit to compile the data and to perform a world-
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wide evaluation of the largest involuntary experiment on 
radiation effects on humans which ever occurred. 
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Special Clinical Findings among Thorotrast Patients 
by 
G. van Kaick, D. Lorenz and I. Drings 
Institute of Nuclear Medicine (Director: Prof.Dr.K.E.Scheer) 
in the German Cancer Research Center, Heidelberg 
Abstract 
The outstanding, probably thorotrast-induced, diseases 
among the 800 examined patients are 4 tumours of the liver, 
many liver cirrhosis, one case of chronic myeloid leukemia 
and a lot of long term sequelae caused by paravascular in-
jection. Since the liver is the most commonly injured organ 
of thorotrast carriers we developed a step-wise diagnostic 
schedule consisting of laboratory tests. X-ray examinations, 
sonography, celiac arteriography and laparoscopy. For the 
necessary follow-up-studies we hope, in this way, to keep 
the diagnostic stress within tolerable limits, while obtaining 
satisfying diagnostic results. 
Having up to now presented our thorotrast program from a 
statistical point of view, let me now report some clinical 
findings. 
He found 4 cases of liver tumours,and one case of a chronic 
myeloid leukemia 27 years after injection of thorotrast (1). 
A correlation between these diseases and thorotrast can be 
considered. 
He had one 65 years old patient with an extended hemorrhagic 
pleural effusion. An extensive paravascular depot in the 
neck had run far off into the mediastine and even embraced 
the aortic arch. The suspicion of a thorotrast-induced neo-
plasia was a reasonable assumption. The careful examination 
+)Supported by grants from the German Ministry of Science 
and Technology and BOKATOH. 
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including digital rectal palpation shoved a metastasing car-
cinoma of the prostate with osteoplastic metastasis; a con-
nection with the thorotrastosis surely did not exist. 
As to non-neopLastic thororast effected diseases we already 
mentioned numerous forms of hepatopathy ranging from fibrosis 
to cirrhosis of the liver. We frequently observed loag term 
sequelae caused by paravascular thorotrast deposits. With a 
3-tent period from 15 to 25 years these patients had a 
paresis of the embraced nerves caused by thorotrast granuloma: 
paresis of the nervus recurrens with hoarsenes; paresis of 
the nervus sympathicus with classical HORNER-syndrom, some-
times accompanied by paresis of the nervus hypoglossus with 
atrophy of the related half of the tongue. Deposits which 
extended far cranially into the neck caused paresis of the 
nervus accessorius with atrophy of the muscular system of the 
shoulder. Deposits extending more caudally caused paresis 
of the phrenic nerve, resulting in a one sided phrenoplegia 
(2). 
The vessels, too, are compressed by the thorotrast granuloma, 
as for example the vena jugularis. In some cases a suspected 
occlusion of the carotis was excluded by arteriography; there 
was a free passage of the contrast medium, and we supposed 
that the symptoms were caused by another cerebral disease. 
A suprainguinal spreading of the thorotrast along the iliacal 
vessels resulted in a paravascular thorotrast granuloma, 
vhich was able to embrace the crossing ureter. The obstruction 
of the ureters caused stenosis, after a latent period of 15 
to 25 years, which resulted in 4 cases to hydronephrosis 
vhich necessitated unilateral nephrectomy* In 3 cases the 
stenosis of the ureter was attended by occlusion of the vena 
iliaca. The artery seemed to be more resistant to the com-
pressing thorotrastoma (3). Zn some cases we saw a chronic 
fistular inflammation around the thorotrast granuloma. We 
never found sarcoma at the edge of the thorotrast granuloma. 
les 
Since the liver Is the most frequently Injured organ In 
thorotrast patients we tried to combine various diagnostic 
methods to obtain a detailed diagnosis; some of these special 
methods do not belong to our official program. 
First our examination program was enlarged to include the 
determination of alpha-1 -fetoprotein, indicating hepato-
cellular carcinomas (4). We performed this investigation in 
200 thorotrast cases and found 2 positive reactions. One of 
these patients had a hepatocellular carcinoma, the other a 
chronic myeloid leukemia. 
X-ray examination of the upper abdomen is routinely performed 
on each patient. The evaluation of 500 roentgenograms showed 
6 different types of thorotrastosis, which are schematically 
represented here. 
Type 1: Deposits of thorotrast are only visible in the peri-
portal lymph nodes, while liver and spleen give a normal 
organ shadow. 
Type 2: Granular deposits are recognizable in the spleen. 
Type 3 i Small deposits of thorotrast lie on the edge of the 
liver . The spleen appears more compact and the number of 
thorotrast-ftiled periportal lymph nodes increases. 
Type 4: A diffuse, granular or striped pattern of the liver 
is visible. 
Type 5: A coarae-neshed contrast pattern now appears. The 
liver is exactly visible and the spleen becomes metallic 
compact with a chain of parasplenic lymph nodes. 
Type 6: This group is characterized by massive aggregations 
of thorotrast particles, sometimes in spider-form figures. 
The deposits in the liver are irregular and distorted. 
It looks as if "type 6" includes changes in the structure 
of the liver parenchyma in the sense of a livex cirrhosis, 
often attended by enlargement of the spleen. 
One of the patients, examined in 1968 and re-examined in 1972, 
showed a change from type 5 to 6. Four years ago the 
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roentgenogram showed a regular meshed contrast in the liver. 
Now we see thorotrast accumulations and a considerable 
diminution in the size of the liver with an average reduction 
of S cm In height, accompanied by a simultaneous enlargement 
of the spleen. 
We have compared these types of deposits with the known in-
jected quantities of thosotrast. Type 1 appeared most commonly 
in cases of paravascular injections, or when the recipients 
were children. Type 2 was found most frequently among patients 
who had received 1 or 2 ampulles of thorotrast for carotid 
angiography. Patients classified as type 5 or 6 generally 
received 40 to SO ml thorotrast. In our follow-up-study 
6 patients died having primary liver tumours. 5 patients 
belonged to type 5 or 6, only one belonged to type 3. 
It must be noted that various methods of X-ray examination 
will bring somewhat different roentgenograms. Besides, 
a relation appears to exist between the various types and 
the quantity of thorotrast deposited in the liver. 
Sonographic examinations can only be performed in our insti-
tute for a short time. Since this method does not expose 
the patient to radiation, it is especially appropriated for 
the examination of thorotrast patients (5). The normal, 
clinically "sound" thorotrast liver gives no striking sono-
gram. In cases of irregular tomographic findings a scinti-
graphy of the liver was performed. Our experience shows that 
the fibrotic state of the liver cannot be determined by 
means of sonography, but we had a good correspondence to 
scintigrams in many cases of liver deforming processes. 
The scintigram of thorotrast carriers may be completely 
normal in spite of large deposits of thorium dioxide; a 
diffuse fibrosis of the organ, however, cannot be excluded. 
Only a small number of patients demonstrated scintigraphic 
changes indicating a liver cirrhosis (6). 
A more exact diagnosis"in cases of diffuse degenerative 
alterations in the liver is given by laparascopy combined 
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with biopsy vinder sight, and histological examination of the 
obtained material, lie do not perform blind ponction because 
of the high risk of intra-abdominal bleeding, since many 
cases of hemangioendotheliomas have been described in the 
liver of thorotrast carriers. Moreover, the blind punction 
often fails to reveal a liver cirrhosis (7). 
The celiac arteriography is especially appropriate to recog-
nize neoplastic diseases In the liver because most of thoro-
trast-induced liver tumours are highly vascularised. This 
method has an advantage over the laparascopy, in that the 
whole organ can be seen. Some of our patients showed circum-
scribed accumulation defects in the scintigram in the region 
of a big thorotrast deposit. We then performed celiac 
arteriographies,without finding a tumour. He suspect that 
scarring and hyalinisation occurs at the site of the thoro-
trast deposit, and that this tissue is similar to a thoro-
trast granuloma. The only operable tumour of the liver 
disvovered by celiac arteriography was a cholangiocellular 
carcinoma (8;9). 
The thorotrast population has a high risk in developing 
degenerative and neoplastic diseases of the liver. The nec-
essary control examinations should not be a stress for the 
patient. The examination carried out in different steps, 
beginning with an exact physical and laboratory examination, 
keeps the patients' stress in tolerable limits, while giving 
satisfying diagnostic results. 
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Medical Proble— Concerning the Control Croup 
by 
D. Lorenz, W.J. Lorenz and 6. van Kalck 
Institute of Nuclear Medicine 
German cancer Research Centex Heidelberg 
Abstract 
Within the German Research Project THOROTRAST besides pa-
tients who have received a Thorotrast injection there were 
also examined patients of a control group« which was selected 
according statistical points of view. It is reported about the 
difficulties and problems which occur at the performance of 
the examination of the control group. 
Introduction 
The control group In the German Research Project TmOROVkAST 
is composed of patients whose names begin with the letter B, 
and who were treated at the saw time and in the same clinic 
with the patients having received Thorotrast. Professor Imnlch 
and Dr. Schmidlin have reported in detail about the selection 
of these patients. The patients of the control group are exa-
mined in an identical way to the Thorotrast patients. 
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Performance of the Study 
Difficulties with the control group of the research endeavor 
begin with the gathering of clinical data within the clinics. 
Clinic directors reluctantly gave insight into the documents 
of the Thorotrast patients, understanding the necessity, but 
often made it difficult to obtain informations on patients of 
the control group. Host clinic directors are. not convinced of 
the necessity to examine patients in the control group, and are 
afraid that this might violate the physician's code of ethics. 
The first, and often the most difficult problem facing our co-
workers, who make the patient investigations, consists in over-
coming this resitance, and in convincing the directors of the 
necessity for the control group. 
The problems associated with the second phase result, when 
patients who were selected, according to statistical conditions, 
are found again, and were sent a first letter. This letter in-
forms the patient that our investigations had discovered that 
he had been in a particular clinic at a specific time, and that 
we are interested in his present state of health, and in his 
health during the Intervening period of time. Simultaneously we 
ask the patient to fill out a questionnaire. 
Most patients answer the questions willingly. Some patients, 
however, are disturbed by our investigation and ask for clarifi-
cation. In this group are especially those patients who were 
previously treated in neurologic or psychiatric clinics. Their 
clinical treatment is an unpleasant memory to these patients, 
especially if they have married in the meantime. 
In a second letter we give the patient the information asked. 
Simultaneously we explain the reason for the investigation. We 
inform the patient that we would like to invite him to a free, 
precautional, examination. Many patients quickly decide to cone 
to Heidelberg (HD). others, however, are sceptical and seek the 
advice of their relatives, or their family physician. Most phy-
sicians recommand that the patients take advantage of the check-
up. In some cases it is only the intervention of the family 
physician which persuades the patient to travel to HD. However, 
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S O M family physicians dissuade the patients with the argument 
that they are only to be used as guinea-pigs. Fortunately only 
very few patients permitted themselves to be negatively influ-
enced, and cow to the check-up. Some even come against the ad-
vice of the family physician. The fear to be a guinea-pig is, 
however, subconsciously present in almost all patients. This is 
the reason for explaining to the patients, in our letter of in-
vitation, the exact procedure of the examination. 
The examination consists of three parts, a clinical, a radio-
logical, and a biophysical examination. Kith the exception of a 
single blood withdrawal from the vein of an arm, our patients 
are not inconvenienced. Most patients are alert to any changes 
in the examination, and expect the examination to progress in 
the promised manner. This is especially true if a lumbar punc-
ture, a suboccipital puncture, or an encephalography has pre-
viously been performed. The willingness of patients to subject 
themselves to this examination is also correlated to age, sex, 
social status, present state of health, and the desire to travel. 
Elderly people in retirement, who are active and healthy gene-
rally enjoy coming to BO for their check-up. Self employed per-
sons are generally not easily persuaded to come. 
Once a. patient has made the decision to come for the check-
up, it is important that he is welcomed, and is accompanied by 
one of our co-workers for the various examinations. 
The clinical examination offers the most Important contact 
between patient and physician. The physician attempts to win the 
confidence of the patient, and to overcome the last resistance 
against the check-up. This Is best accomplished while the case 
history is obtained. Then follows a physical examination, for 
which we reserve sufficient time. This method tends to bring 
about, in nearly all cases, a favourable patient-physician-rela-
tionshlp. This is expressed by favourable remarks of the pati-
ents, and their letters of thanks. Mien we began with our 
follow-up examinations last year we received unusually large 
numbers of acceptances, to the examination. The patients who 
came for their second examination to HD regularly asked to be 
reconsidered for a third check-up. 
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The family physician of the patient receives a detailed letter 
with the results of the examination. This letter contains the 
most important anamnestic dates and results of the check-up. We 
also make suggestions for further diagnostic steps, and give re-
commandations for the treatment of the patient. 
Fro« the physician's point of view, however, the follow-up 
examination, of the patients in the control group, is unsatis-
factory for the following reasons: 
Due to the Thorotrast Research Project's examination scheme 
the patient is only in HD for a few hours of one day. For this 
reason the out-patient diagnostic work must remain incomplete 
in many cases. Should we, for example, discover a hypertonic 
disease, we are not able to perform all the necessary examina-
tions to find out the reason for this disease. Therefore we must 
request the family physician to take care of the final diagnostic 
work. It is also impossible for us to perform the treatment. We 
can only give some therapeutical recommendations to the family 
physician. The work with the family physician is, in most cases 
successful, especially after the completed examination. Thus the 
diagnostic and therapeutic recommendations are generally accep-
ted. After we have examined their patients, the physicians do 
not longer look upon us as competitors. Moreover we have the 
impression that the family physicians consider us to be an unex-
pected but acceptable assistance. 
a further problem of the control group is the fact that many 
persons having come to HD were made to "patients" by us. These 
patients felt healthy and did not have the intention to go to a 
physician. The subjects discovered during or after our examina-
tion made a treatment for an illness necessary. 
Results 
He now have the first results of the examination of the con-
trol group. Preliminary, and very careful, evaluations show that 
coronary and vascular diseases are most common. The second po-
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sition is taken by diseases of the liver. The pulmonary organs., 
gastrointestinal discomfort, excessive weight, diabetes, dege-
nerative diseases of skeleton, gall bladder diseases, and dis-
function of the kidney and the urogenital system follow. One of 
our patients had a circumscribed ovarial carcinoma, which was 
still operable. Bone marrow diseases and acute leukaemia were 
not found in patients of the control group. Two patients of the 
control group had a thorotrastosis. In arriving at this diagno-
sis it was shown how important it is that all patients of the 
control group are examined with the whole body counter. 
Case Reports 
Our report shall end with three case reports. These cases are 
examples for the fact, that some patients of the control group 
suffered from serious diseases which were unknown to them. In 
June 1970 we examined a 70 year old woman and found a tumour in 
the left lower abdomen, and an enlargement of the corresponding 
inguinal lymph nodes. We therefore requested that the family 
doctor refer the patient immediately to a gynaecologist. One 
month later this patient was operated on a left sided circum-
scribed malignant, ovarial tumour. A postoperative therapy was 
carried out with Endoxan. At the present time the patient's con-
dition is good. 
The follow-up examination of a 55 year old man resulted, in 
a diagnosis of tachyarrhythmia absoluta with atrial fibrillation, 
ventricular extrasystolia, severe left sided myocardial damage, 
severe hypertonia, symptoms of coronary decompensation in the 
sense of lung and liver congestion, suspected encophalopathla 
due to high blood pressure and peripheral vascular obstruction. 
Because of his poor state of health we Immediately referred the 
patient - supported by the family physician - to a hospital. 
One 80 year old man was found to have a Morbus Paget. He 
made the diagnosis during the follow-up examination. The radio-
logical examination revealed the typical changes in the area of 
the pelvic bones, with a distinct kyphoscoliosis of the thora-
IT« 
deal vertebral column and with a greatly increased alkaline 
phosphatase. 
Conclusion 
Summarizing, we are able, to say that the follow-up examina-
tion of patients in the control group of the Thorotrast Research 
Program is extremely advantageous also from the physician* s 
point of view since many cases of undiagnosed diseases were dis-
covered which led to therapeutic measures. In this manner an 
originally conceived method for statistical purposes resulted 
in work of great value for the individual patient. 
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Thorotrmst injuries in Japan occurred after 1945, of which 
94 autopsy cases were accumulated up to 1970. These autopsy cases 
consisted of 60 cases of sell giant tumor of the liver and 9 cases 
of blood diseases. Examination of Thorotrast-adainistered autopsy 
casss in Japan has revealed, among other things, that about on« 
half of all Thorotrast-adainistered cases were war-woucded ex-
servicemen and that the dates of injection in these were concen-
trated between 1932 and 1944. Based on this preliminary finding, 
the authors conducted a follow-up study on 147 Thorotraat-admini-
stered war-wounded ex-servicemen after a lapse of 31 to 36 years 
from Thorotrast injection, and found that 6 cases of malignant 
tumor of the liver, 1 case of leukemia, 1 case of thrombocyto-
penic purpura and 5 cases of cirrhosis of the liver had occurred 
among the samples. The incidence of these diseases in the saaples 
was shown to be significantly higher than that in the controls-
Further, clinical examination was conducted on 45 samples select-
ed from among the above mentioned 147 Thorotrast-injeeted war-
wounded ex-servicemen. In liver function test, lowering of pro-
tein metabolic rate and foreign body discharge function was ob-
served, while blood examination indicated decrease of erythro-
cytes, leucocytes, hemoglobin value and thrombocyte count. These 
findings in the samples were significant in comparison with the 
controls. Finally, the total number of Thorotrast-administered 
persons living in Japan as of 1972 was roughly estimated at 5.000. 
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Introduction. 
Thorotrast has been used clinically in Japan between 1928 -
1954. 
After 1937 this contrast medium was used chiefly in former 
army hospitals for the diagnosis of traumatic diseases in war-
wounded servicemen. 
In 1943, the first report of Thorotrast injury was hepatic 
cirrhosis, discovered after autopsy (11). In 1951. the first oc-
curence of hepatic cholangiocarcinoma following Thorotrast admi-
nistration was reported (12). Since then, a number of reports on 
Thorotrast injuries have been collected. 
In studying Thorotrast injury eases in Japan (3, 7) the au-
thors conducted a survey of available autopsy records of persons 
known to have been given Thorotrast. About half of these were war-
wounded ex-servicemen injected with Thorotrast for diagnostic pur-
poses at former army hospitals. 
A follow-up study of some of these war-wounded ex-service-
men was undertaken. 
1. Survey of Thorotrast-adnlnlstered Autopsy Cases in Japan. 
Between 1945 and 1970, a total of 94 Thorotrast-administered 
autopsy eases were collected, consisting of 77 males and 17 fema-
les. 
The ages of these autopsy cases at the time of Thorotrast 
adainistration ranged from 5 to 59 years. The ages of all Thorcw. 
trast-adminiatered cases at the time of death ranged from 35 to 
72 years. 
Of the 87 Thorotrast-adainistered autopsy cases reported be-
tween 1958 and 1970, 73 are recorded in the Annals of Pathologi-
IT? 
cal Autopsy Cases in Japan '. 
From these records the ratio of Thorotrast-administered au-
topsy cases to the total autopsy cases by causes of death was as 
follows: Malignant hepatic tumor - 0.5*; Leukemia - O.lSt; apla-
stic anemia - 0.4*; hepatic cirrhosis - 0.1*; lung carcinoma, pan-
creatic carcinoma, bone sarcoma and malignant retroperitoneal tu-
mor - 0.1 - 1.4*. 
Kltabatake (6) has observed Thorotraat deposition shadows 
in 0.9* of all living cases of malignant hepatic tumor whose 
X-ray films he has examined. This figure is in close accordance 
with the results obtained in this study of autopsy cases. 
A breakdown of Thorotrast-administered cases by causes of 
death is given in Table 2. Of the 94 cases listed in this table, 
Thorotraat administration is considered a factor in the causes of 
death in 91 cases. 
Among the various malignancies, Thorotrast-induced malig-
nant hepatic tumors are, as shown in Table 3, exhibit a histologi-
cal incidence markedly different from that of non-Thorotrast-in-
duced primary malignant hepatic tumors. (7). For example, the ra-
tio of incidence between Thorotrast-induced and non-Thorotrast-
induced cholangiocarcinoma is about 10:1, while that of liver 
cell carcinoma is 1:11. Also, hemangioendothelioma of the liver, 
which ordinarily accounts for only 0.2*, that is, one out of 500 
malignant hepatic tumors, occur in 10 of the 60 Thorotrast-admi-
») The Annals of Pathological Autopsy Cases in Japan have been 
annually compiled and published by the Japanese Pathological 
Society since 1958. The latest issue thus far published in 
the 1970 edition. 
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nistered autopay cases. 
the tiae intervals between Thorotrast administration and 
the onset of malignant hepatic tumors were 11 to 35 years in the 
34 cases for'which this information was available. The average 
latent period between the group given large amounts (40-100 ml) 
of Thorotrast did not differ from the group given small amounts 
(5-39 ml). 
As to the 9 autopsy cases of blood diseases, these consisted 
of three cases of acute or subacute myeloid leukemia, two cases of 
erythroleukemia and four cases of aplastic anemia. It is highly 
interesting to note that erythroleukeaia, a very rare blood di-
sease in Japan, was discovered in two out of the nine cases (Ta-
ble 2). In those of the cases on which chromosome examination (12) 
was conducted, an increase of abnormal chromosomes was observed. 
Thorotrast-induced fibrosis of the liver, spleen and upper 
abdomen lymph nodes was observed in almost all cases, frequently 
resulting in the reduction of the liver weight to less than 800 
grans and in "chalk Spleen" weighing less than 20 grams. Fibrosis 
of the liver, (Thorotrast cirrhosis), was the proximate cause of 
death in 12 cases, accounting for 12.80 of the causes of death 
in the total Thorotrast-administered autopsy cases. 
To summarize, the foregoing results of our survey of Thoro-
trast-administered autopsy cases in Japan has disclosed a high in-
cidence of malignant hepatic tumors, cholangiocarcinoma and heman-
gioendothelioma in particular, along with f recent occurence of 
blood diseases, and the presence of liver and spleen fibrosis in 
nearly all of the cases. 
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2. follow-up 3tudy on 147 War-wounded B»-3ervicemen given Thoro-
trast. 
A. Follow-up Study: 
From a surrey of 15.000 case hlBtory records, mostly per-
tained to war-wounded ex-servicemen, a total of 147 cases of Tho-
rotrast administration were collected. 
Prom 1963 to 1964, that is, 22 to 27 years after Thorotrast 
was administered to the 147 cases a follow-up study was conducted. 
By means of a questionalre 139 of these cases were traced, og whom 
112 were alive. 
Then, from 1972 to 1973, that Is, 31 to 36 years after Tho-
rotrast administration, the authors conducted a second follow-up 
study, this time obtaining information about 142 cases of which 
85 were living. 
Of these 133 had been given Thorotrast intravascularly and 
these formed the study grants. 
The Thorotrast-administered group had been given Thorotrast 
between 1937 and 1943* (Pig.4). Their ages at the time of admini-
stration ranged from 20 to 39 years, but 83Jf had received injec-
tion at ages between 20 and 29. 
The diseases which had originally led to the injection of 
Thorotrast were traumatic diseases in 131 cases. The majority of 
these were traumata of the head and cervical region and traumatic 
aneurysm in the upper or lower extremities. The amount of Thoro-
trast administered per patient ranged from a minimum of 5 ml to a 
maximum of 75 ml. (Fig.6). 
By causes of death, malignant tumors in the Thorotrast-ad-
ministered group accounted for 11 oases including 6 malignant he-r 
patlc tumors, 3 cases of gastric carcinoma, 1 case of rectal car-
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cinoam and 1 case of laryngeal carclnoam, vhile blood diseases 
accounted for 2 cases (one case each of acute myeloid leukosis 
and thrombocytopenic purpura), liver cirrhosis for 6 easea and 
other diseases for 22 cases. Causes of death could not be known 
or determined in the remaining 11 eases. 
As causes of death, malignant hepatic tumors in the second 
follow-up study included 3 cases of cholanglocarcinoma, 1 case of 
hemangioendothelioma and 2 cases of liver carcinoma, against 3 ca-
ses of cholangiocarcinoma in the first follow-up study. Ion-hepa-
tic malignant tumors as causes of death, not found in the first 
follow-up study, included 3 cases of gastric carcinoma, 1 ease 
each of rectal carcinoma and laryngeal carcinoma In the second 
follow-up study. The number of fatal blood diseases - one ease 
each of myeloid leukemia and thrombocytopenic purpura remained 
unchanged between the first and the second follow-up study, while 
liver cirrhosis increased from 2 cases in the first follow-up stu-
dy to 5 cases in the second. Deaths due to other diseases also in-
creased from 13 in the first follow-up study to 22 in the second. 
{Table 7). 
Control groups and control population: 
War-wounded ex-servicemen who had been inmates in the same 
hospitals at about the same time aa the Thorotrast-administered 
cases but who bad been given sugiuron (an organic iodine contrast 
medium) were compared with the Thorotrast-administered group, 
(control Sroup A). Likewise, 1.330 ex-servicemen who had never 
been given any contrast medium were selected as Control Broup B. 
Further, based on the welfare Ministry population statistics (14), 
Japanese males in the same age bracket as the Thorotrast-adminmte-
red cases, that is, aales aged 20 to 44 years in 1940, were seise-
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ted as a Control Population. 
Control Group k was used to study the effects of ear inju-
ries plus non-radioactive contrast medium, and Control B to study 
toe effect* of war injuries per se. The Control Population, mean-
while. was aade to serve as basic controls against the Thorotrast-
adainistered group and Control Qroups A and B. 
Compared with Control Group B and with the Control Popula-
tion, the Thorotrast-adminiatered group exhibited a significant-
ly higher mortality rate. 
As for aortality rate for diseases, the Thorotrast-admini-
stered group contained a significantly larger nuaber of deaths 
due to malignant hepatic tuaor than the Control Oroup B and the 
Control Population at a critical level of 0,5% and significantly 
larger number of deaths due to leukemia and liver cirrhosis than 
Control Population at a critical level of 5jt. Bo significant dif-
ference was found to exist among the controls except liver cirrho-
sis between Control Oroup B and Control Population. (Table 10). 
Mortality rate of blood diseases was significantly increa-
sed in the Thorotraat-administered Oroup than in the Control 
Oroup B and Control Population (a critical level of 5* in the 
former and 0.5% in the latter). 
B. Clinical Examination Cases Oiven Thorotrast: 
45 cases who had been injected with Thorotraet were selec-
ted froa among the cases under follow-up study and clinically 
examined in comparison with 32 controls selected froa the same 
sample frame. These two clinically examined groups are hereafter 
referred to as "clinical" thorotrast-adainistered group and "cli-
nical" control group, respectively. 
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1. X-ray examination of upper abdominal region: 
X-ray films of the upper abdominal region were taken of 44 
of the 45 "clinical" Thorotrast-administered cases, revealing 
lymph node shadows in 43 cases. Among these, shadov of the spleen 
was observed in 36 cases and Thorotraat deposition shadow of the 
liver in 28 cases. The single case in which Thorotrast deposition 
shadow was not observed in any of these organs or lymph nodes was 
a case who had been administered 5 ml of Thorotrast. Ho abnormal 
X-ray film shadow was observed in any of the "clinical" controls. 
(Table 14). 
2. X-ray films of Thorotrast injection sites: 
X-ray films of Thorotrast injection sites were taken of 40 
of the 45 "clinical" Thorotrast-administered cases, revealing re-
sidual shadows In 16 cases. Palpation also revealed the presence 
of Thorotrastoma at injection sites in these cases. (Table 14). 
Of these, 7 had Thorotrastoma in the cervical region, 7 in 
the upper extremities and 4 In the lover extremities. In two of 
the cervical Thorotrastoma cases vocal cord paralysis and paraly-
sis of nerve recurrens were also present, while two of the upper 
extremity Thorotrastoma cases were accompanied by impairment of 
motor capacity. 
3. Radioactivity measurement by use of scintillation counter: 
Linear scanning was conducted by use of a scintillation 
counter on 20 of the "clinical" Thorotrast-administered cases, 
revealing the presence of radioactive substance in 8, 
The scanning values showed a marked rise in the upper ab-
domen and at Thorotrast injection/extravasation sites. However, 
133 
cases, who had been given large amounts of Thorotrast did not 
necessarily prove positive in scanning, which aade it difficult 
to ascertain the existence of any definite relationship between 
the aaounts administered and the scanned radioactivity levels. 
(Table 14). 
4. Liver function test: 
Liver function test was conducted on 40 "clinical" Thoro-
trast-administered cases and 31 "clinical" controls, revealing 
disorders of protein metabolism and foreign body discharge func-
tion in the former, is regards protein metabolism, while no signi-
ficant difference was noted between the "clinical" Thorotrast-ad-
ministered group and the "clinical" control group in the amounts 
of total serum protein and albumin or in the zinc sulfate test 
and thymol turbidity teBt results, decrease of A/S ratio to less 
than 1.29 was seen in 19 out of 36 "clinical" Thorotrast-admini-
stered cases and in 4 out of 31 "clinical" controls. 
As for the serum globulin test, increase in excess of 3.48 
g/dl was observed in 15 of 36 "clinical" Thorotrmat-adminiatered 
cases as against 4 out of 31 "clinical" controls. In protein frac-
tion, studied for 13 "clinical" Thorotrast-administered cases, 
shoved decrease of albumin in 10, increase of alpha-globulin in 
12 and increase of gamma-globulin in 7. To sum up, protein meta-
bolism in Thorotrast-administered cases was characterised by a 
lowering of A/0 ratio and an increase of serum globulins, parti-
cularly alpha— and gamma—globulins. 
In the foreign body discharge function test, examination of 
bromsulfalein (BSP) 45 min. value showed an increase of over 6)J 
in 14 of 33 "clinical" Thorotrast-administered cases, but no such 
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increase m a obaartad in any of tb.« 5 "clinical" control* exaai-
ned. The rata of increase la tha "clinical* Ihorotraat adainiete-
rad group «aa low (up to 14)1) in 11 eaaea and high (15)t-30Jt) la 
3 caaaa. 
BnzjB« activity m a azaainad with raapaet to 001, OPT, al-
kali-phoaphataao and anylas«, bil« aataboliaa with raapaet to uri-
ne urobilinogen.and scran lipid with raapact to aeroa oholaatarol. 
Thaaa taata revealed no significant diffaranea of results batwaan 
tha "clinical" Thocotrast-sdainistered group and tha "clinical" 
control group. (Fig. 8 ) . 
5. Peripheral blood oiaalnation: 
Peripheral blood ezaaiaation aaa conducted on 38 "clinical" 
Thorotraat-adalnlstared oaaaa and 22 "clinical" controls. With 
regard to tha caaaa where leukocyte count waa found to have de-
creased to leas than 4.000 erythrocyte count to less than 
3.5OO.O0O, haaatocrit to lam than 40jf and heaoglobin to lean 
than 80)£, no significant difference was noted between the con-
trol group, However, coaparad with ordinary Japanese amies in the 
sane age bracket, the incidence of aneaic, heaoglobinopsnic and 
leukopenic cases was significantly higher in the "clinical" Tho-
rotrast-adninistered group at a critical level of 0.1J( O.ljt 
O.ljt and 5%, respectively. 
In 10 out of 26 "clinical" Thorotraat-ada1nlstared cases 
and 1 out of 19 "clinical" controls, throabocyte count waa found 
to hare decreased to less than 100.000 (Pig. 9, Table 17) 
6. Urin« analysis: 
In the general urine test, urobilinogen positive (+ to +++) 
results were obtained in 7 (25.9)*) out of 27 "clinical" fhoro-
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trast-administered cases, but no abnoraal manifestations were 
found in any of the "clinical" controls. 
In suonary, the results of the foregoing clinical »lamina-
tion were as follows: 
In the cases who had been intravascularly injected with 
Ihorotrast in amounts in excess of 5 ml per capita. X-ray film of 
the upper abdominal region revealed Thorotrast deposition shadows 
in the liver, spleen or upper abdomen lymph nodes at a detection 
rate of 97.75*. Scanning by scintillation counter, meanwhile, re-
vealed Thorotrast deposition in 40J< of the cases. 
Thorotrastoma was found to havs occured in 45.0£ of the sub-
ject cases. Liver function test revealed protein metabolism dis-
orders and a lowering ol foreign body diacharge function, while 
a decrease of hematocrit value and thrombocyte count was obser-
ved in blood test. 
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Epidemiological Follow-up Studies of the Portuguese Ihorotrast 
Series (up-dated results). 
by 
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Abstract. 
Spidamiological studies in Portugal of about 5U( of 2.500 
patients injected with Thorotrast mainly for cerebral angiogra-
phies between 19JO and 1995, and of a smaller group of controls 
(injected for similar purposes with non-radioactive contrast 
drugs), followed up until the end of 1972. The Thorotrast popu-
lation has shown a gross excess of malignancies and of severe 
fibrosis in the liver and in the tissues around blood vessels 
where the drug intended for intravascular use has been spilled 
and retained. According to a statistical analysis of the Portu-
guese data, the excess malignancies are leukaemias and other ra-
pidly fatal blood dyscrasias, liver tumours of which the most 
frequent type is the haemangioendothelioaa which is practioally 
"Thorotrast specific" and the total number of malignant tumours, 
even excluding liver tumours. There is a slight excess of lung 
cancer too. 
The findings are discussed at some length, particularly the 
significance of local granulomata, liver fibrosis (causing a cli-
nical picture similar to that of liver cirrhosis), fatal blood 
dysorasias, liver tumours, lung cancer and malignant bone tu-
mours. 
19* 
Introduction. 
The Portuguese Thorotrast research group conprises within 
its experience the biggest group of individuals injected with tho-
rium dioxide followed up for the longest period of time recorded. 
An appriciable number of caBes (tbout half of all the injected) 
have been lost in the 40 years and more of possible follow-up and 
the lack or at least modesty of dosimetry studies due to lack of 
local facilities restrict in part the value of its experience. 
The total number of cases followed since injection and the statis-
tical and epidemiological cata collected have however contributed 
to the interest and importance of the data collected until now 
by the "Portuguese Thorium Dioxide Research Oroup". 
Although data from the pathological and epidemiological in-
vestigations carried out by the Portuguese Thorotrast Study Oroup 
have been published in some papers I1'2'''*'''0' '»8>"/ 5^ ,1
 pre_ 
sented at a few international meetings we thought it could have 
some interest to up-date the results and to summarize the data 
so far ascertained in the epidemiologic study of the Ihorotrast 
series which began in Portugal in the early I960's. 
In this communication we will only summarize, in a brief 
form and with the help of a few tables, the statistical results 
ascertained and up-dated until the 31st December 1972. 
Methodology of the epidemiologic study. 
The basic data for the approximately 2.500 patients known 
to have received Thorotrast in Portugal) come from the records 
of certain Portuguese hospitals (mainly from Lisbon) where that 
drug had been used as a radiological contrast medium from 1930 
to 195$. mainly for rerebral angiographies (Table 1). 
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Because thorotraat nas nach »ore widely used in hospitals 
than any other intravascular radiological contrast drug between 
1930 and 1950, especially for cerebral angiographies, it was im-
possible to collect a perfect control group. Hoverer, in order 
to improve the estiaate of risk for possible thorotraat sequelae, 
a partial control group of patients Batched for age. sex and ge-
neral type of disease at the tiae of investigation, but injected 
with a non-radioactive control drug was assembled from patients 
systeBically injected between approximately 1940 and 1955 - al-
though a few have been injected between 1930 and 1940. It was 
possible in this way to collect I960 control case records, in 
the sane Banner and fron the same hospital as the Thorotraat ca-
ses (Table 1). 
The aethod of tracing the eases for subsequent investigati-
ons which was identical for both Thorotrast and control popula-
tion has already been described '''''. 
Results. 
Until the end of 1972, the results of the epidemiological 
investigation and follow-up studies of both Thorotrast and con-
trol populations can be summarized in the following Tables (Ta-
bles 1 to 7). 
Success of tracing and follow-up of the cases (Table 1). 
Of the 2.433 individuals who have received Thorotraat, 1.231, 
that is almost 5l£, nave been traced and are either alive or 
certified dead. The percentage of successful tracing according 
to type of injection (Table 1) vary, being highest for the syste-
mically injected cases (1.039 among 1.918 cases, that is 541*) 
and smallest for the peri-nasal inatalation cases (192 among 515 
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cams, that is 77%). traced case* appear to be distributed ap-
proximately in the same Banner as the complete Ihorotrast group 
as has been reported previously **'''. 
tracing was somewhat less successful with the control popu-
lation, probably because fewer basic data were available. Only 
797 cases, that is about 41Jt of the total nuaber of controls, 
•ere traced (table 1). Also here the traced cases are distribu-
ted approximately in the sane Banner as the coaplete control po-
pulation according to the analysis reported elsewhere ( . 
•waber and causes of death (tables 2, 3. 4, and 5). 
Among the fhorotraat and control cases traced the causes 
of death and other lesions considered as probably due to late ef-
fects of a radioactive internal emitter permanently retained in 
cells of R.B. System according to our previous knowledge of Iho-
rotrast movement within the human body and its local action, we-
re mainly the following: malignant tumours in liver and other 
R.B.S. organs, leukaemia and other serious blood dyscrasias, ot-
her malignancies, liver fibrosis and local granulonata. These 
last lessions were found in the tissues where the drug intended 
for intravascular use was accidently spilled. 
Of the 1.231 Thorotrast cases traced, 918 (74.5*) had died 
by the end of 1972 (table 2). 664 of these, that is about 72* of 
the dead, died of causes apparently not related to the radioac-
tive contrast agent - many of them within the first five years 
after the Ihorotrast instalation from the disease for which the 
drug was used as a diagnost tool '*; In 77 individuals (8.4*) 
m) In principle, malignancies occuring within these first five 
years were discarded and considered "not related". 
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the cause of death could not be ascertained with a reasonable 
degree of accuracy. Finally, in 177 (19.3*) the certified and 
as far as possible (even by autopsy) ascertained cause of death 
•as due to disease or dondition considered as very probably re-
lated to the specific radioactive effect of the Thorotrast ab-
sorbed and retained in the R.B.S. '. If we consider only the 
892 (85.9*) deaths certified among the 1.039 systeaically injec-
ted cases so far traced, the nuaber and percentage of deaths at-
tributed to totally unrelated causes, unknown causes and causes 
possibly related to the radioactive effect of Thorotrast were 
respectively: 644 (72.2*), 74 (8.3*) and 174 (19.5*) (Table 2). 
Of the 26 deaths registered among locally injected cases, only 
3 (11.5*) could be attributed to Thorotrast (Table 2). 
Among controls, 545 i.e. (68*) had died by the end of 1972 
and the nuaber and percentage of deaths attributed to the same 
three "groups of causes'* - "unrelated", "unknown" and "suspected" 
- were respectively: 495 (90.8*), 32 (5.9*) and 18 (3.3*). This 
last percentage should be compared with the corresponding one 
among Thorotrast cases - almost 18* (Table 2). 
The main causes of death ascertained among the 1.231 Tho-
rotrast cases traced, are shown in the first column of Table 3* 
Only local granulomata, liver fibrosis, leukaemias and other ma-
lignancies, especially liver tumours, are specified among the 
"suspected" causes of death in this table, since these seem lilce-
(») Leukaemia and other fatal blood dyscrasias, malignant tu-
mours (specially liver tumours), liver fibrosis and fatal con-
sequences of local induced granulomata. 
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ly to be associated with the radioactivity of Thorotrast retai-
ned in the body for years and could therefore be considered as 
late effects or long-term sequelae of this drug. In the same 
table the number of deaths observed among controls is given ac-
cording to the same causes of death mentioned above (Table 3)-
As it can be seen the proportion of deaths attributsd to 
leukaemia and other quickly fatal blood dyscrasias and to malig-
nant tumours among Thorotrast eases is very nigh indeed. Particu-
larly striking is the number of liver tumours, of which the hae-
mangioendothelioma iB the more frequent type found among the ca-
ses vith histological confirmation (Table 4) and practically 
"Thorotrast-specific". In fact among 12.835 autopsies and 88.001 
biopsies performed by one of the authors at the Faculty of Medi-
cine of Lisbon, during more than 35 years, of the 17 liver hae-
mangioendotheliomas found all but one were diagnosed as Thoro-
trast cases. 
Of the 192 cases who have received the drug locally death 
was attributed to Thorotrast only in 3 (Table 3). In two cases 
death was due to a malignant tumour developed on the edge of a 
Thorotrast induced local granuloma: a carcinoma of the rectum 
developed on the periphery of a post hystero-salplngography pe-
ritoneal granuloma and a retroperitoneal sarcoma developed on 
the edge of a post-retrograde Thorotrast granuloma. The third 
death occured suddenly, almost immediately after a cerebral ven-
triculography performed with Thorotrast. 
Among the control population the number of deaths from li-
ver cirrhosis (6) and especially from malignant tumours (12) is 
relatively much smaller than among systemically injected eases; 
199 
there were no deaths fron any blood dyscraeia and none due to a 
locally induced granulosa (Table 3). 
Because of the particular interest in the malignancies in 
our series we have prepared two »re tables including details 
on nalignant tua-iura (Table • ) and fatal blood dyscrasia (Ta-
ble 5) which have caused death 3»ng the Thorotraat and control 
groups. However the alloted space and tine for each conaunicati-
on does not allow us to show all the statistical tables nor to 
discuss all the results in detail in this i n—mill ill inn 
Mean injected dose and mean latency period. 
On Table 6 the »an injected dose of the usual Heyden Tho-
rotrast solution and the Bean latency period (between injection 
and death) are given for a few selected causes of death aenag sy-
steaically injected Thorotraat cases. 
Only liver fibrosis and naligaancies have been chosen for 
this table, since they represent the nore important and severe 
of possible Thorotrast induced late sequelae. Local granuloaata 
were not included, since they do not depend on the quantity of 
systeaically injected drug, but only on the occurence of extra-
vascular spillage. The »an latency period, froa injection to 
death, is of the order of 21 years. 
It is curious to reaark that the »an injected dose usually 
increases with the severity of the late effect, being highest 
for haeaangioendotheliOBaa, liver fibrosis end acute leukaeaias 
(Table 6). In all these causes of death the »an dose is above 
the general aean dose for the total systeaically injected Thoro-
trast oases. 
The latency period between adalnistration of the drug and 
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death is highest for liver fibrosis and liver tumours, especial-
ly haemangioendotheliomas (almost 28 years on the average). It 
is interesting to see how the latency period of leukaemias (20 
years) approaches that of aplastic anaemias (a little less than 
24 years), which may suggest that at least some cases of aplastic 
anaemia could well have been acute aleukaemic leukaemias, as has 
been mentioned l4''»''. 
Discussion and Conclusions. 
The present communication amplifies and confirms the re-
sults previously reported from the Portuguese Thorotrast series 
since 1965 (+'5.6,7,8)_ 
The results indicates that Thorotrast when retained in the 
human body, either through systemic administration or when stop-
ped in the tissues after local administration, is capable of in-
ducing local fibrosis where it stays and, in some cases, after 
more years, malignant degeneration as well as the target organs 
are these containing S.E.S. cells, especially the liver and the 
bone marrow. Thorotrast action can also be exercised in tissues 
where the drug is deposited outside the blood vessels as in the 
case of local granulomata, developed in the place where the drug 
is spilled during intravascular administration and where it stays 
for a long period of time. 
Comparison of these causes of death (local granulomata, li-
ver fibrosis, fatal blood dvscraeiaa and malignant tumours) be-
tween syBtemieally injected Thorotrast cases (») and control pa-
ts) Only the 1.039 systemically injected Thorotrast traced cases 
were used for this comparison, since the all 797 control cases 
were systemically injected. 
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tlents with indication of the respective prevalence rates for 
each condition considered In both series,is shown in Table 7. It 
is clear from such a comparison that the prevalence rates of the 
main causes of death considered as having a probability of being 
due to the radioactive late effects, are much higher among the 
Thorotrast series than among controls, even if the rates were 
calculated not in relation to the 1.039 cases traced but to the 
total 1.918 systemically injected Thorotrast cases - on the very 
unlikely assumption that all causes of death in the total Thoro-
trast population and related to Thorotrast had appeared only in 
the cases we were able to trace. 
It is true that in such a peculiar diseased population as 
our series, that increases yearly by new cases and is losing so-
me through death or disappearance, and followed up for many but 
a different number of years, prevalence rates are certainly in-
sufficient. They may even be misleading when true risks of death 
ehall be ascertained according to causes. In order to try to esta-
blish these risks with more accuracy a statistical analysis was 
performed (*) according to a methodology described and published 
by the authors in other papers * ' . The results are summarized 
in Table 8. The analysis has shown that the number of deaths ob-
served among the control population was higher than was to be 
(*) uy Srs. J. Pais Morals and J. lopes Figueira, using the re-
sults ascertained until 31 December 1970"'. It must be added 
that the results ascertained since that date do not alter the 
conclusions of the statistical analysis but only reinforce them, 
since the number of malignancies has increased proportionally 
more than the number of newly traced cases. 
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expected from the general Portuguese population, duly corrected 
for the peculiarities aentioned above, for the following speci-
fic causes of death (7th revision of the International Classifi-
cation of Diseases) - Table 8 (a summary of three statistical 
tables published in another paper ' • " ) : 
Malignant neoplasms of the larynx (A-49. of the 7th revisi-
on of L C D . - for both sexes together and for females. 
Malignant neoplasm of the bronchus and lung (A-50) - for 
both sexes together and for males. 
Malignant neoplasm of the bone (A-$6) - for both sexes to-
gether and for females. 
Malignant neoplasm of all other and unspecified sites (A-
57) including practically only liver tumours - for both se-
xes together, for males and for females. 
Leukaemia and aleukaemia (A-58) - For both sexes together, 
for males and for females. 
Lymphosarcoma and other neoplasms of lymphatic and haemato-
poietic system (A-59) - for both sexes together. 
A-45, A-50, A-52, A-54, A-56, A-57 - for both sexes toge-
ther, for males and for females. 
A-45, A-50, A-52, A-54, A-56, A-59 - for both sexes toge-
ther, for males and for females. 
As above, but including only the cases with histological 
confirmation - for both sexes together, for males and for 
females. 
Cirrhosis of the liver (A-105) - for both sexes together 
and for males. 
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These results reinforce those previously reported in a fev 
papers ^•*»:>»'' ' and confirm the conclusions previously drawn. 
The incidence of primary liver tumours and especially of 
haeoangioendotheliomas, is now appreciably greater than previ-
ously reported by our group. If all cases of liver tumours, in-
cluding the cases without histological confirmation - accepted 
as liver tumours because of the striking clinical similarity 
with the confirmed cases - are considered,then the excess of li-
ver malignancies among our Thorotrast series is really stagge-
ring. 
The total amount of malignant tumours is also above the ex-
pected. Carcinoma of the bronchus and bone sarcomas may have the 
greatest interest in our series, because of the possible radia-
tion effects of thorium and of its daughters on the lung and on 
the bone. The incidence of lung cancer in Thorotrast cases can 
be of great interest because It may provide an indication of a 
pure lung radiation risk, from excreted thoron, without an asso-
ciation of dust inhalation such as that existing among miners 
working with radioactive material, such as uranium w / . However, 
since the number of observed deaths from lung cancer (carcinoma 
of the bronchus) although significantly above expected (Table 8), 
has not increased since 1963 and when ve do not know the tobacco 
habits of the Thorotrast population, we must consider our re-
sults as equivocal in this respect. However it seems that the in-
crease of lung cancer among Thorotrast cases is not marked. 
As for the bone tumours, of which we have only 2 confirmed 
cases In our Thorotrast series (of the third case no positive or 
negative confirmation could be obtained), our results seem to In-
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dicate that the bone tissue radiation in Thorotrast cases (due 
primarily to alpha particles) is probably lower than in the ra-
dius cases with comparable burdens . 
Ihe most striking finding in our series, besides the extra-
ordinarily high incidence of liver tumours, is the very high in-
cidence of fatal blood dyscrasias, particularly of acute leukae-
mias. There is a very gross excess of leukaemias and other rapid-
ly tatal blood dyscrasias among our Thorotrast group, while there 
is a total lack of such ciases among the control population (Table 
6). He may assume that probably most or at least some of our 
aplastic anaemia or fatal purpura cases, were aleukaemic forms 
of acute leukaemia, as the similarities of the respective clini-
cal courses and even of the mean injected doses and mean latent 
periods (Table 6) suggest. He may conclude that this great ex-
cess represents in fact a radiation induced or precipitated con-
dition or group of conditions. 
Such results are qualitatively similar to those from other 
Thorotrast series, namely the Danish group (lead by Prof. Faber), 
and to those reported in externally irradiated populations, such 
as among the therapeutically irradiated ankylosing spondylitis 
patients (Brown, Abbatt, Lea and Doll) ' . Nevertheless our re-
sults show some differences from those reported in externally ir-
radiated populations, such as the latent period, which for Thoro-
trast cases is about 20 years, which is slightly more than the 
double of the latent period for externally irradiated cases (5 
to 7 years among the irradiated ankylosing spondilitis patients). 
We do not know the reason for this difference but it is probably 
due to the fact that the total alpha irradiation from Tborotrast 
and daughters has a different biological effectiveness than 
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X-ray Irradiation and also because, while is one acts at once, 
that from Thorotrast is delivered rather slowly over a conside-
rable period of time and is irregularly distributed in the R.B.3. 
cells of the blood forming organs, according to the peculiar me-
tabolism of Thorotrast and its movement within the human body 
(3.5)_ 
Another important difference is that the risk for individu-
als injected systemically Thorotrast of developing such fatal 
blood dyscrasias seems to be appreciably greater than the one 
externally irradiated individuals, while this last risk is of 
the order of a 6 to 8 fold increase over the "natural" risk of 
developing leukaemia, there is probably a 12 to 16 fold increase 
in risk among the Thorotrast patients - or at least among the 
Portuguese Thorotrast patients described in this communicati-
on . As we have already written in a paper prepared two years 
d) 
ago "Thorotrast, under the conditions prevailing in our sy-
stemically injected population, represents the most potent human 
leukaemogen yet reported". 
Two more years of follow-up and collection and analysis of 
results have maintained our previous opinion. 
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Liver Studies in the Thorotrast Patients - Laboratory and Cli-
nical Pindia-TS (3tudv of 175 Cases) 
by 
Maris Helena Tavares, M.D. 
A. Sarpgoea, M.D. 
J. da Silva Horta, M.D., D.H. 
Department of Pathology. Faculty of Medicine, University of 
Lisbon, Portugal. 
Abstract. 
In 175 non-selected patients injected with thorium dioxide, 
laboratory tests and clinical studies have bean done. 
The clinical complaints most often are related to the ga-
stro-intestiruil pathology* mainly concerning the liver. The labo-
ratory tests dinclone a serum dysproteinemia (low albumin and in-
creased cc-2 and -A-globulin) and increased levels of alkaline 
phosphatase. The search for a-fetoprotein has been negative in 
all the 10 cases in which it has oeen. possible to perform this 
test. 
/u^ ong the 25 cases with histological liver examination, 11 
liver tumours have bee.i found (4 hemangioendothelioma?, 5 cholan-
giocarcinomas and 2 adenocarcinomas); the remaining 14 cases dis-
closed hepatic fibrosis. 
Key-words: Thorotrast - Thorium dioxide - Hemangioendothelioma -
Cholangiocarcinoma - Protein electrophoresis - Alkaline phospha-
tase - Alphafetoprotein. 
This study was supported by a grant from the United States Pub-
lic Health Service no SC 00068, formerly HH 00039. 
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Introduction. 
Systemically injected Thoro tr-.'st will S3 deposited in the 
R.B.S. especially in the liver, spleen 'xrA "Tributary lym^h no-
des. The liver is t.a organ with multiple functions tir:t c.n ecsi-
ly be checked by laboratory tests* ~id r.l?o on organ 'tccepsiblo 
to histological examin-stior. through bio^y. Since Thorotrast in 
found in great concentration in the liver it is therefore justi-
fiable to study the ltvsr in the Thorotr-;?t patient c. 
Material and Methods. 
The non-selected pctientn ^tudisd were- 17!> ir. n'unber, of 
which 86 were men and 89 women, vrith ages ringing fro^ i 22 to 
87 years; the quantities of Thorrvtr'.st received went from 1 to 
70 ml (but were unknown in 19 eases) n.ad the time elapsed nince 
reception of the drug ra.nged from 10 to 41 years. 
The laboratory tests ^erf crated, the methods used and the 
normal values are listed in Table I. 
In 25 eases material was available for histological exami-
nation (from 17 liver biopsies and 8 necropsies). 
Clinical findings. 
The Thorotrast patients often presented general dyspeptic 
complaints, such as flatulence dyspepsia, nausea, vomiting! so-
me also complained of pain in the right or left upper abdomen; 
only in a few cases we found increased intestinal transit. 
Though in the majority of cases the liver is not palpable, in 
some cases it is enlarged and the lower edge is 2 or 3 cm below 
the costal margin, with a firm, smooth and painful surface. 
In the 11 cases with histological examination in which the 
2m 
diagnosis has been a malignant liver tumour (4 hemangioendothe-
liomas and 5 cholangiocarcinomas and 2 adenocarcinomas) the cli-
nical picture was the same in all cuses, with jaundice and asci-
tes, pain in the right upper abdomen, loss of weight, weakness 
and loss of apetite; all the symptoms increased progressively 
until death occured, always between 3 and 9 months from the on-
set of the symptoms. 
In other 13 cases, the clinical course was in all points 
similar to the one just described, but the histological confir-
mation of the liver tumour was not available. 
Table I 
Laboratory Teete Performed, MathoaB UPed* and Hormal Valoee 
Test 
Total M r n protein 
Protein 
electrophoreiia 
albumin 
globulin 
Glutamic oxaloacetic 
trenesmlneae (GOT) 
Qhttuiiic pyruvic 
transaminase {OPT) 
AlkaUM pbMphataae(AP) 
Serum bilirubin 
Bromsalfaleln 
Alpbsietoprotein 
14 
1* 
* 
)t 
Method 
Wolf son. Conn, Calvary 
and lehibalwitfa changes) 
Grossman and Hannig 
Karmen 
Wroblewaki and 
LaDot 
BodansU and ghinowara 
MsUory and Evelyn with 
changes by Oucei and 
Watson 
lfaietr, at el . 
— « — — - • 
Normal value« 
• . J - i e m . / l o e m l . 
otaaram 
« - • » 
»- •* 
• - •» 
1 2 - 1 4 % 
1 4 - 1«% 
ender 40 U / m l . / 
min. 
ander 40 D / m l . / 
mja. 
8 - 4 C Bodanaky 
ffonjatanai-l— 
t h a n O . M m f . / 
IMml .TDUl- leM 
Iban l . l aag . / lMml . 
• - • * of reteallun 
altar 40mln. 
aafnUVa 
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Laboratory results 
The results obtained are summarized in Table II. 
Table n 
Times Reported for Each Laboratory Test and Per Cent of Abnormal Results 
Test 
Total serum protein 
Protein 
electrophoresis 
albumin 
globulin 
Glutamic oxaloacetic 
transaminase (GOT) 
Glutamic pyruvic 
transaminase (GPT) 
Alkaline phosphatase (AP) 
conjugated 
Bilirubin 
total 
Bromsulfalein 
Alphafetoprotein 
<*J 
*t 
A 
r 
Times 
reported 
151 
165 
163 
163 
163 
163 
146 
144 
154 
103 
106 
65 
10 
Normal 
141 
48 
141 
50 
100 
47 
114 
127 
46 
80 
91 
36 
10 
Abnormal 
10 
117 
22 
113 
63 
116 
32 
17 
108 
23 
15 
29 
0 
Per cent of 
abnormal 
results 
6.6 
70.9 
13.4 
69.3 
38.6 
71. 1 
21.9 
11.8 
70.1 
22.3 
14.1 
44.6 
0 
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The £re:itcr.t frequency of abnormal results was found in the 
jrotcii electrophoresis, with low serum albumin (70.9£) and in-
cre--3«d c 2 ("3-3!) and • (71.1.5) serum-ciobulins. Increased le-
vclr of -jlKaliio phosphatase was the more frequently found abnor-
mality among e.isymstic activities (70.1.1); the transaminases 
showed abnormal vs. Vacs in only a small number of cases. Bromsul-
iihalein was pcrforued only in a little more than one third of 
the cases, but it was abnormal in 44.6 per cent of the cases; 
it *».s never performed in patients with jaundice or congestive 
cardiac failure. 
Only recently (just in 1973) it has bean possible for us 
to begin the search for a fetoprotein in the serum; that is why 
«e nave only 10 cases, all of them negative. Of these 10 pati-
ents, 6 h:.d *^:i histological examination of the liver - in 4 Of 
those, only fibrosis was found, but the other 2 showed a malig-
nant tuxour. 
Comments. 
The general symptoms most often found among the Thorotrast 
pvtients concern the gastro-intestinal system. Frequent are the 
ge.ieral non-specific symptoms suoh as flatulence, nausea and vo-
nitins, but with a certain frequency we find more severe symp-
toms such as jaundice, ascites, pain in the right upper abdomen; 
thin Inst group of symptoms has been found in every patient who 
presented a liver tumour, and death always occured in a short 
tim<; (3 to 9 months after the onset of symptoms). 
Concernir.^ the differences from the normal values of the 
laboratory teat results, most evident was the serum-dysproteine-
EIR consisting in low albumin and increased alpha 2 and gamma-
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globulin values; also important has been the increasing of the 
alkaline phosphatase values, very high in the cases with ? ma-
lignant liver tumour. The search for alphafetoprotein, in the 
cases in which it was possible, was always negative, even in the 
2 cases with histological confirmation of a liver tumour; never-
theless this Is not surprising because these 2 tumours were not 
hepatomas, and the hepatoma seems to be in fact the type of tu-
mour in which the alphafetoprotein appears. 
Ve should like to point out that the clinical and laboratory 
alterations presented by that group of patients are more related 
to the time elapsed since the reception of the drug than to the 
quantity received. Thus, of patients with over 25 years since inn 
jection almost all of them showed clinical and laboratory test 
differences, and the liver tumours of this group only appeared 
in patients with 29 years or more since injection. 
Thames are doe to Professor Carlos Manso {Chief of the Depart-
ment of Chemistry - Hospital de Santa Maria) who studied the 
alphafetoproteins, and to Dr. Fernando Brito Barros (assistant 
of the Department of Biochemistry of the Hospital de 3anta Ma-
ria) who performed the laboratory tests. 
Ilt 
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liver Ultrastructurai THn^Hn/re in Patients Injected with 
Thorotrast. 
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Abstract. 
Liver biopsies from patients injected with Thorotrast were 
examined by electron microscopy. Alterations of the mitochondria, 
smooth and rough endoplasmic reticulum, bile oanaliculi and hyper-
trophic Golgi complexes were found. The presence of numerous mul-
tivesicular bodies is remarkable. 
Thorotrast structure is described. Aggregates of this mate-
rial were found in the Kupffer and histiocytic cells accompanied 
by needle like structures and surrounded by dense collagen. Thoro-
trast was seldom seen in the hepatocyte. 
These findings were identical in all the cases and more in-
tense in the patient injected the longest time ago. 
Although stressing that the lesions are not specific, the 
authors suggest that they may represent an adaptative reaction 
to Thorotrast. 
Additional key-words: liver, Thorotrast, Solgi apparatus, mito-
chondria, smooth endoplasmic reticulum (SER), rough (RER), lyso-
some, bile canaliculi. 
This survey was carried out with the full support of the U.S.Pub-
lic Health Service Research Grant no EC 00068, formerly grant 
no RH 00039 and with the cooperation of the University of Lisbon. 
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Introduction. 
The distribution of Thorotrast and the lesions it causes 
1 7 ^ 
in human ' and animal liver tissue "* have been the subject of 
numerous studies in optic microscopy. However, as far as we know, 
ultrastructural studies are still limited to experimental work on 
rats * • and have not yet been carried out on human liver tis-
sue. 
The conclusions of these experiments are contradictory. 
While some investigators conclude that no ?ignificant changes DO-
'S 6 
cur besides storage of the material *
 t others hold that there 
is sufficient evidence to suggest that Thorotrast causes tissue 
damage and therefore presume that it is a question of dosage and 
interval of observation . The pathogenic mechanisms suggested 
have been radiation damage and foreign body action. 
7 
In our human material we observed liver cell atrophy 
and necrosis of isolated cells or groups of cells including aci-
dophilic degeneration and Mallory hyalin. These findings, the 
lack of ultrastructural studies of human liver biopsies, the di-
versity of opinions at experimental level and the possibilities 
afforded by the specialized nature of our research group have 
prompted us to carry out this work. 
Material and Methods. 
Liver biopsies from six patients injected with Thorotrast 
40/29 years ago were examined. The material was paraffin embedded 
and sections stained with H.E. For electron microscopy double fi-
xation in 3/< glutaraldhiede-caccodylate and 1% OsO. in veronal 
acetate buffer was followed by dehydration and Epon embedding. 
Sections 1 n thick were stained with toluidlne blue ; adjacent 
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thin sections stained with uranyl-acetate and lead-citrate° were 
studied in a Philips 300 electron microscope. 
Observations. 
Paraffin embedded material showed no liver cells damage 
apart from steatosis. Thorium dioxide was seen in augmented Kupf-
fer cells and in macrophages in portal tracts. Fibrosis could be 
found in some portal tracts and surrounding efferent veins always 
related to Thorotrast deposits. In one case of jaundiced patient, 
an adenocarcinoma probably from the bile tract was detected. 
The observation of thick sections by light microscopy re-
vealed: binucleated cells, nuclear polymorphism, hypertrophic nu-
cleoli and nuclear vesicles. Small vesicles were found in some 
hepatocytes either surrounding the nucleus or scattered through-
out the cell. Iiipophuscin granules and lipid droplets were also 
detected (Pig. 1). Hepatocytes with very few mitochondria at the 
periphery were observed. Kupffer cells some of which are packed 
with Thorotrast particles are augmented in number. In some areas 
histocytes containing the same material are surrounded by dense 
connective tissue. 
At the ultrastruetural level the nuclei show membrane in-
dentations nuclear bodies as well as cytoplasmic invaginations 
containing organelles such as: lipid inclusions, ribosomes and 
endoplasmic reticulum (?ig.2). Many of the hepatocytes contained 
centrioles and microtubules. 
Mitochondria vary in number, shape and size (reaphing 
5 x 1.3 u ) . Some show a less electron-dense matrix than others. 
The orientation of the cristae is irregular and very often occur 
in stacks of parallel lamellae centrally or peripherally located 
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in the matrix. They are often curved or annular and dilated (Pi«. 
3 a, b, c). Sone mitochondria contain paracrystalline structures. 
na-iy opaque granules and a few lipid droplets (Fig. 4 a, b ) . Mito-
chondria with myelin-like figures were sometimes found in lyso-
aomes. 
Vesicular smooth endoplasmic reticulum is increased in num-
ber with areas of tubular elements sometimes arranged in parallel 
arrays. 
Rough endoplasmic reticulum was present in lesser quantity 
and dilation was irregular and in patches. In some areas of the 
vesicles the ribosomes are detached. There is cytoplasmic vacuo-
lation due to dilations within the cistsrnae of the endoplasmic 
reticulum. Sone show myelin-like figures. Sue to this and the rup-
ture of the vesicles this alteration is sometimes so striking 
that it gives the impression that the organelles are either of 
lamellar structure or concentric vesicular profiles. 
Hypertrophic Qolgi complexes composed of larger vesicles 
of varying sizes and elongated cisternae is the rule (Fig. 6 a). 
Some vesicles contain moderately electron-dense material and rod-
like profiles (Pig. 6 b ) . 
Many fat droplets and myelin-like figures occuring in or 
out of the lysosomes are observed. 
lamellar bile pigment deposits, enclosed in vacuoles, are 
observed near the Oolgi apparatus and the canaliculi (Pig. 7 a ) . 
Host of the lysosomes contain lipids of different electron 
density, opaque flncculent material dispersed in a fine-granular 
matrix, as well as myelin-like concentric systems of menbranes. 
Some autophagic vacuoles contain ferritin only or a great variety 
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of organelles: mitochondria, glycogen and ribosomes. In all cases 
many multivesicular bodies (Fig. 8) were found. In one of the pa-
tients a few rhomboedric structures were observed. They are ei-
ther free in the cytoplasm or within the lysosomes. The sizes va-
ry between 450 x 850 A and 180 x 4000 A. These structures do not 
contain any electron-dense material (Fig. 9). 
The canaliculi show many different aspects: some appear 
normal with small digitiform microvilli (Fig. 7 a ) , others pre-
sent several grades of lumen distension with either absent or 
oedematous and hypertrophic microvilli. 
The microvilli of the intercellular space frequently pre-
sent similar alterations (Fig. 7) Thorotrast was never present in 
the canaliculi. The Junction zone was always preserved. In the 
space of Disse and the intercellular spaces there were bands of 
collagen fibers. 
The endothelial cells appeared normal with very few pyc-
notic vesicles. Kupffer cells contained polymorphic inclusions. 
Inside these lysosomes there are aggregates of Thorotrast partic-
les (Fig. 10) which are always accompanied by long needle-like 
structures (Fig. 11). Some Kupffer cells contained long microvil-
li with vacuoles (Fig. 10 a). Others show a degenerative aspect 
with few organelles, many vacuoles and abundant Thorotrast agglo-
merates (Fig. 10 b). In some areas Thorotrast and cell debris-fil-
led macrophages appears surrounded by large bands of collagen. 
Thorotrast deposits are unique in appearance due to their density. 
They are ultimately composed of small particles (40 - 90 A in si-
ze), which are grouped in aggregates 1000 - 3200 A wide, and the 
latter in much larger deposits of irregular shape. In three cases : 
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only Thorotrast deposits were found in the hepatocytes. Die depo-
sits were few often surrounded by a double membrane and composed 
of fine particles. 
SaSBSntSj. 
The results of this work are limited by the fact that the 
material is obtained only through needle liver biopsies which 
means restrict area. Although all the observations were Bade on 
patients who had been injected many years ago the damages we 
could see were relatively recent and not the initial ones. For 
the same reason it is impossible to describe the stages of the 
circulating Thorotrast, nor is it possible to evaluate the lesi-
ons step by step froa the very beginning of injections. In spite 
of this and taking into consideration the experimental results of 
other authors we believe that the explanation for the only small 
quantity within a few hepatocytes lays In: a) the increased pha-
gocytic activity of lupffer cells, b) the non observation of free 
Thorotrast particles in the sinusoids and c) the restricted pino-
cytotic activity of the hepatocytes. To this we .Oght add the lar-
ge size of the aggregates, perhaps due to the long intervals be-
tween injections and liver biopsies, and the dense bands of fibro-
ses surroimding them. This last factor also applies to the exten-
sive deposits of thorium dioxide is other orga-is, particularly 
the spleen, thus keeping it from re-circulation. Ve suggest that 
there is a relationship between Thorotrast particles and the need-
le-like structures both of which are always found together. 
The results of this study are similar in some respect« to 
those in rats reported by Orampa . However, besides nuclear alte-
rations we found that the lesions were more intense in the orgs-
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nellea, particularly In the smooth endoplasalc reticulum, Oolgi 
coaplex and mitochondria. 
The strikingly high frequences of neclear Invaginations, 
hypertrophic nucleoli and membrane indentations may reflect a 
high nuclear activity. 
although only one patient was jaundiced all cases showed 
bile pigment to a greater or lesser end a large nuaber of alrea-
dy described lesions of bile canaliculi. The above facts say be 
related to the incipient lesion of some of these organelles which 
have not yet reached sufficient intensity to show clinical syap-
toas. 
Rhonboedric crystalline-like structures were only observed 
in the patients with carcinoma. Might there be any relationship 
between these structures and the patient's tuaour? 
In each case, all the lesions found were identical but sore 
intense in the patient with tumour who had been injected the lon-
gest tin« ago. These observations are in accord with the obser-
vations already described at light microscopic level by other au-
6 7 
thors and by ourselves . 
Although all these findings are not specific we wonder 
whether they represent an adaptive reaction to thorium dioxide 
with degenerative and regenerative features. 
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Figures. 
Fig. 1 Liver cell illustrating the cytoplasmic variolation (T) 
as dilations within the cisternae of the endoplasmic re-
ticulum (BR); lysosomes (L) z 9.000. Inset: thick secti-
on enclosing this area z 1.200. 
Fig. 2 Several hepatocyte nuclei shoving cytoplasmic invaginati-
ons containing: lipid inclusions, vesicles, ribosomes 
and endoplasmic reticulum, a z 7.600 b z 15.200. 
Fig. 3 Liver cells with irregular mitochondria, curved and an-
nular cristae and lamellar stacks parallel to the menbra-
ne. The matrix has low electron density, a z 36.800 
b x 28.900 c x 53.900. 
Fig. 4 Enlarged cristae-dilated mitochondria with parallel fila-
ments scattered in the matrix; the electron density of 
the matrix is lower than usual; granules of varying den-
sities are also frequently observed In these organelles, 
x 53.900. 
Fig. 5 Dilations within the cisternae of the rough endoplasmic 
reticulum, containing myelin-like figures and concentric 
vesicular profiles appearing as lamellar structures, 
x 28.900. 
Fig. 6 Solgi region of active liver cells. A prominent QoLgi 
apparatus (8) is present, composed of small vesicles and 
granules of varying density; rod-like profiles can be 
seen in some of these granules, x 23.500. 
Fig. 7 a - Peribiliary regions in hepatocytes. Bile pigment con-
taining vacuoles (BF) and hypertrophic Qolgi complex 
(8) x 18.700. 
b - Dilated bile canaliculus. Kote fibrillar material in 
the lumen and absence of microvilli, x 23.500. 
c - Oedematous and hypertrophic microvilli in the inter-
cellular space, z 23.500. 
Fig. 8 Liver cell with multivesicular bodies (KB) and hypertro-
phic smooth endoplasmic reticulum, z 9.700. 
Fig. 9 Rhomboedric crystalline-like figure (a) free in the cyto-
plasm (b) in lysoaome. z 53.900. 
:?ig. 10 Kupffer cells (I) packed with Xhorotraat aggregates (Th) 
a - showing degeneration z 6.000; b - Kupffer cell with 
long microvilli, Thorotrast deposits and vacuoles, 
z 8.400. 
Fig. 11 Thorotrast aggregates in lysosomes of two different 
Kupffer cells. Note the needle-like structures always 
accompanying them, z 53.900. 
22T 
References 
1. Baserga, R., Yokoo, 11. and Henerger, G.G.U960). Thorotrast induced 
cancer in man. Cancer 13: 1021 
2. da Silva Horta, J. (1956). Late lesions in man caused by colloidal thorium 
dioxide (Thorotrast). Arch Path. 62: 403-418. 
3. Huguenin, R., Nemours, A. and A1 Dot, G. (1932). Les hepatites et les 
cirrhoses experimentales au bioxyde de thorium. 
Ann. d'anat. Path. 9: 263-279. 
4. Grampa, G. (1967) Liver distribution of colloidal thorium dioxide and 
development of liver epithelial tumors in rats. 
Ann. N.Y. Acad. Sci. 145: 738-747. 
5. Hampton, J .C. and Rosario, B. (1967). The distribution of colloidal 
thorium dioxide in mouse liver after intravenous injection. 
Ann. N.Y. Acad. Sci. 145: 533-544. 
6. Tessmer, C.F. and Chang, J. P. (1967). Thorotrast localization by light 
and electron microscopy. Ann. N.Y. Acad. Sci. 145: 545-575. 
7. da Silva Horta, J. (1967). Late effects of Thorotrast on the liver and 
spleen and their efferent lymph nodes. Ann.N.Y.Acad.Sci. 145: 676-699. 
8. Trump, B . F . , Smuckler, E.A. and Benditt, E .P . (1961). A method for 
staining epoxy sections for light microscopy. 
J. Ultrastruct. Res. 5: 343-348. 
9. Reynolds, E.S. (1963). The use of leadcitrate at high pH as an electron-
opaque stain in electron microscopy. J. Cell. Biol. 17: 208-212. 
The authors are very grateful to Dr. A. Saragoca who performed the liver 
biopsies and to Dr. C.Monteiro for her interest and valuable suggestions. 
We would also to extend our appreciation to Miss I. Alvarez for her teoonical 
assistance and to Miss T. Varejao for preparation of the photographs. 
This work was carried out in the Electron Microscopy Unit of the Faculty of 
Medicine of Lisbon. 
228 
2a 
229 
230 
231 
Vi! 
. fc\LJff. *a 
& • 
*Fi $* £'•*« 
L»1-IJ» 
^K 
9a 9b 
232 
10a 10b 
11 
233 
Tumours developed in People injected with th-rimn dioxide 
(Thorotrast) (Portuguese Sxperlence) 
by 
J. da Silva Horta 
Department of Pathology, Faculty of Medicine of Lisbon, Portugal. 
Abstract 
In this paper we discuss the tumours appearing in people 
injected with Thorotrast: 15 cases of liver hemangioendothelioma, 
1 hemangioendothelioma only of the bone-marrow, 1 reticulosarco-
ma, 9 cases of cholangiocarcinoma, 2 hepatomas and 5 cases of tu-
mours on the edge of great deposits of Thorotrast. All these ca-
ses have been histologically confirmed from biopsy or autopsy. 
Comments are given concerning the genesis of such tumours. 
Keywords: Thorotrast. Hemangioendothelioma. Cholangiocarcinoma. 
This survey was carried out with the full support of the U.S. 
Public Health Service Research Orant no EC 00068, formerly grant 
no RH 00039 and with the cooperation of the University of Lisbon. 
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Introduction. 
Since the first case of tuaours appearing in people injec-
ted with Thorotraat published by Mac Mahon in 1947 , many others 
hare been described especially by the Scandinavian, lorth-Ameri-
can, Japanese and Portuguese authors. 
Material and Methods. 
The aaterial on which our experience is based, not only of 
neoplasias but also of other types is shown in Table 1, 
TABLE I 
Total nuaber of biopsies, autopsies and splenectomies performed 
in patients injected with Thorotraat in Portugal 
Time elapsed 
since administration 
of Thorotraat 
Less than 3 years 
From 3 to 41 years 
Total 
Biopsies 
16 
74 
90 
Autopsies 
153 
57 
210 
Splenec-
tomies 
12 
12 
and the 33 tumours of the reticuloendothelial organs and on the 
edge of thorotrastomas are shown in Table 2 and 3. The material 
came from biopsies and autopsies. We have performed microscopy 
with several methods of staining2', in bright and dark fields, 
historadiography and recently electron microscopy (Philips Micro-
scope EH 300). The results obtained have bean compared with the 
epidemiological data4. 
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Results concerning tumours. 
I - Tumours of the reticuloendothelial organs (Table 2) 
These are solitarv liver tumours or sore rarely multiple 
tumours of the liver, spleen and bone marrow or only of the liver 
and the bone marrow. 
With the exception of one case a polymorphic reticulum cell 
2 
sarcoma all are hemangioendotheliomas and carcinomas. 
Our hemangioendotheliomas have been described in detail in 
previous papers•'• . Since the lew Tork Symposium in 19*6, the 
observed cases have in general shown the same morphology; never-
theless there is something more to add, as will be done in this 
paper. 
The hemangioendotheliomas stem from the reticuloendothelial 
cells that join together in capilnr structures (fig. l) and are 
accompanied by the proliferation of reticular fibers. Less common 
is the picture of a solid tumour, but in every case there is al-
ways neoformed capilars. In the liver we can also see pictures of 
pure endothelioma: the endothelial cells of the sinusoids grow 
into the lumen, giving origin to solid images where we can find, 
here and there, empty spaces evidently of capillary nature. Ve 
see several blood lakes of different sices, some of them so large 
that they hava already been seen at the macroscopic examination 
during the autopsies or even when the patient was alive, through 
a peritoneoscope. 
The tumour invades and destroys the normal structures of 
the organs in which it exists, but very seldom it contains Thoro-
trast corpus-cules. In a few cases the capillary of the liver he-
mangioendothelioma invades the portal spaces (fig. 2) and the ra-
mifications of the portal vein (fig. 3) reaching the lumen of the 
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Mentioned ramifications and the vails of the bile canaliculi. So-
ne liTer hemangioendotheliomas cause ganglionar and pulmonar me-
tastasis. One of the patients died from a hemoptysis resulting 
from th« ci—in i i cation of blood lakes with the bronchial lumen 
(fig. 4) (case 15). 
The other kind of 'unour which developed in the liver is 
the hepatoma (only 2 cases, where the structure does not differ 
from other hepatomas in people not injected with the drug) and 
two types of cholanglocardnomas: one with great glands with mu-
cus (fig. 5), another with small glands and an extensive fibrous 
stroma (fig. 6). again we practically did not find Thorotrast gra-
nules in these tumours. One grew along on the outside of the ex-
tra-hepatic billiary system with compression causing an obstruc-
tive jaundice (case 24). These glandular tumours are also the cau-
se of metastasis in the lymph nodes of the hepatic hilum. 
During the current year we have observed, during the autop-
sies, two eases of tumours involving both the gallbladder and the 
liver. 
II - Tumours on the edge of great Thorotrast deposits (Table 3). 
In 1967 we nave mentioned 2 spindle cell sarcomas of the 
neck (cerebral angiography). Our collaborator Helen Kahn publis-
hed one case of cholangiocarcinoma around a liver thorotrast oma 
and an adenocarcinoma of the common hepatic bile duct just at the 
place where a thorotrastoma caused by a portography was in con-
tact with the epithelium of th« duct. There is also a fifth ade-
nocarcinoma on the edge of a great thorotrastoma in the liver cap-
sule, but after the necropsy, we have some doubts and think it 
could just as well be a carcinoma of the gall bladder which has 
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not been diagnosed. At List, there Is a patient Injected with the 
drug in Portugal for an hysterosalpingography which developed a 
carcinoma of the rectum (case published by Catel ). 
TABLfi III 
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Comments. 
Some comments have been published in 1967 '''' and 1968 . 
At present we think we have sufficient data in order to 
group the different cases systematically. 
In the first place we want to state without fear of being 
misunderstood, that we can speak of tumours induced by Thorotrast, 
and this both on the basis of morphological and epidemiological 
q 
data. Very important are the comparative studies of R. Swarm-" 
between man and experimental animals. 
Hemangioendotheliomas - almost all of them are liver tumours, 
but we hive one case in which 5 organs are affected, and in an-
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other only the liver and the bone marrow (the patient had previ-
ously been submitted to a splenectomy). He have seen only on* ca-
se in the bone narrow. Of course there are tumours vith metasta-
ses. He are however convinced that the "originally multicentric 
hemangioendotheliomas" are more frequent than we have previously 
thought. The hepatic location always appeared to be the first be-
cause it practically was the basis of the clinical symptomatology 
with the liver as a central organ of metabolism. It is often due 
to a tumour at this place that death oceurs through a heaoperito-
neua. On the other hand, at the autopsy not every bone is cut, 
and sometimes no bone at all. Our conviction about the existence 
"t multicentric hemangioendotheliomas began some time ago. 
Other structures can appear, such as the ones mentioned in 
the excellent paper of R. Swarm" that explains the names of thane 
tumours: Kupffer cell tumours, angiosarcomas and hemangiosarcoaas. 
He have seen such structures in our cases, but according to our 
opinion they only represent the polymorphism of a tumour that is 
essentially formed by bemangioendothelial cells. 
Another problem is to know if simple hemangiomas can be re-
lated to the Thorotrast injection. He have one case like this, 
taut statistical data do not allow us to reach any conclusion. 
Liver epithelial tumours - In our series we have 11 hepatic 
carcinomas, but apart from 2 old cases of bepatocarcinomas (earn« 
27 and 28), we are now finding pure cholangiocarcinomas. Though 
the Japanese literature often is difficult to read, the direct 
contact we had with one of the Japanese authors with great expe-
rience in the matter, Miyakawa10, and what we heard in Vienna in 
1965 from Teukanoto11, told us that in Japan the adenocarcinomas 
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have appeared first and the hemangioendotheliomas only later. In 
Sweden there are equal figures for hemangioendotheliomas and car-
cinoses (Blomberg and al. , Hassler and al. ', Dmlgren ). Ac-
cording to R. 3wara, in the United States the heamngioendothelio-
q 
•as are the majority . 
with basis only on Morphologic data, we can affirm that in 
the Lisbon Institute of Pathology only one case of liver hemangio-
endothelioma has been found in a person not injected with Thoro-
trast; all the other cases belong to the Thorotrast population. 
We think that this fact is very iaportant in order to incriminate 
Thorotrast in the origin of liver hemangioendotheliomas. 
we wish to call the attention to the case in which death 
occured after wi heaoptysis caused by lung »etastases of a liver 
hemangioendothelioma. He had been expecting such occurence for 
sometime, and it happened in our case 15. 
Concerning the picture of the invasion of the structures 
in the periportal space by the tuaour we know that it happened In 
a few cases. He have however never found a free coaaunication be-
tween the tuaour capillaries, open into the blood lakes and on 
the other side into the luaen of bile canalicuii, but we think it 
•ight be deaonstrated in order to explain the aelena in soae peo-
ple injected with the drug due to heaobilia. So far we have inter-
preted such cases only by the rupture of esophagic varices due to 
portal hypertension originaling in the hepatic fibrosis). 
About the liver epithelial tumours, the existence of 2 ne-
patoaas in our series is not significant. The saae can not be 
said about the adenocarcinomas. These adenocarcinomas caae froa 
the intrahepatic bile ducts. We think that the first type with 
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great glands full of mucus may come from the great ducts such as 
In the adenocarcinomas found in Hong Kong in people infested by 
the "Clonorquis Siniensis* . These tumours are at all points si-
milar to the Thorotrast tumours even with the presence of mucus. 
The second type may come from the small ducts or, according to 
Enriques and col. (cit. Popper) from "hepatoblastoa", indiffe-
rent cells capable of being the origin to hepatocytes and bile 
duct cells. It is true that pathologists know how rare the pure 
liver adenocarcinomas are. In our cases of systemic injection of 
Thorotrast we found a non-pure adenocarcinoma. We can not see a 
reason not to mention the cases of primitive liver tumours as 
hepatocarcinomas. cholangiocarcinomas and hepatocholangiocarcino-
mas. leaving the term of adenocarcinoma for practical purpose, to 
the carcinomas of the extra-hepatic billiary ducts and the gall-
17 bladder, as suggested by Albertini . 
This year we have already had a patient with a tumour (glan-
dular-type carcinoma) in which the gallbladder and the liver con-
stituted a tumoural mass to autopsy. 
It is impossible to know if a tumour from the liver invades 
the gallbladder or if it is the opposite. Macroscopic observation 
of each case can make our opinion pend to one or other side. In 
a second oase from the current year, also an adenocarcinoma, the-
re was only a tumour at the place of the gallbladder at autopsy. 
The way the cut surface looked was compatible with a liver tumour, 
and furthermore there mas immediate contact between the tumour 
and a great capsular fibrous zone, with Thorotrast in great quan-
tities on the side facing the tumour. This could be one of those 
eases near great Thorotrast deposits, already mentioned by R. 
2142 
Swarm in his paper in Vienna'. It 1B possible that it has been 
a cholangiocarcinoma invading the gallbladder mainly through the 
18 
lymphatics. In a paper published years ago we can see the im-
portance of the lymphatic pathways through the hepatic bed of the 
gallbladder, mainly in the presence of liver historadiographiea 
(fig. 17 of the paper). 
Tumours on the edge of great deposits of thorium dioxide. 
The tumours on the edge of Thorotrast granulomas ("Thoro-
trastomas"), are related to the normal structures affected. In 
that way the ones due to arteriography will be sarcomas as in 2 
of our cases (of the neck). In the case of ascendent pyelography, 
in which the great deposits are near the kidney, the tumours will 
be carcinomas. Also of the same type are the carcinomas that ap-
pear after the installation in the peri-nasal sinuses, but we 
have none of these cases despite of the great number of injecti-
ons performed in Portugal. This may be because a scraping of the 
mucosa of the sinus was performed with the removal of Thorotrast 
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if the contrast was retained for some days, which should sig-
nify the existence of a sinusitis. 
This non-existence of tumours in such a big group of per-
sons (177) is an indication against the carcinogenic action of 
the drug. 
If in an ascendent pyelography the Thorotrast goes to the 
retroperitoneal space, the tumours that can be found will be sar-
iq 
comas, as in the case of Zollinger . One of our cases around a 
central thorotrastoma of the right lobe of the liver was an hepa-
to-cholangioma, and in the case of an intra-operative attempt of 
portography in which the mucosae of the hepatic common duct was 
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affected by Thorotrast, the tumour found was an adenocarcinoma. 
We may think that when Thorotrast ia no longer used, th«m 
considerations have no practical interest in the sense of an ex-
trapolation, but we have to remember that in the future the liver 
or some other organ may be exposed in another radiation incident. 
Bone sarcomas. 
In our series ve have 2 cases of sarcoma, but with no histo-
logical confirmation; nevertheless the clinical picture and the 
21 
radiographics are very suggestive. Recently Altner and ml. pub-
lished such a case with confirmation by biopsy. 
Having in mind the classical work of Sartland on the liai-
nous clock-painters, we must observe whether more will appear. 
Tumours of non reticuloendothelial organs. 
A number of such tumours has been published isolated by 
other authors, but the epidemiological studies of our cases do 
not allow us to establish a cause-effect relationship. 
Legends of figures. 
Fig. 1 Liver hemangioendothelioma. 
Fig. 2 Liver hemangioendothelioma. Invasion of the wall of a 
portal ramification. 
Fig. ? Liver hemangioendothelioma. Heoplasic thrombosis of a 
portal ramification. 
Fig. 4 Low magnification. Lung metastasis of a liver hemangio-
endothelioma. Death caused by hemoptysis. 
Fig. 5 Cholangiocarcinoma. Great glands with mucus. 
Fig. 6 Cholangiocarcinoma of small glands and much stroma. 
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Pathological findings in the RES (liver, spleen, lymph nodes, 
bone marrow) of thorotrast patients (histological an auto-
radiographic investigations) 
K. WEGENER*, H. WESCH**, H. KAMPMANN** and R. ZAHNERT*** 
Institute of Pathology, University of Heidelberg; Institute 
of Nuclear Medicine, German-Cancer-Research-Center, Heidelberg; 
Versorgungsarztliche Untersuchungsstelle, Stuttgart 
Abstract 
A report is given about pathological and autoradiographical 
investigations of 17 patients, who received intravascularly 
unknown quantities of thorotrast. Different late lesions had 
originated: Fibrosis of the liver in 7 cases, cirrhosis of the 
liver in lo cases, hemangiosarcoma of the liver in 6 cases, 
cholangiocarcinoma and hepatocellular carcinoma in 3 cases 
respectively, fibrosis and atrophy of the spleen in 15 cases, 
benign hemangioma of the spleen in 1 case, fibrosis and atro-
phy of the lymph nodes near the porta of the liver in all ca-
ses, thorotrastoma in 6 cases. 
13 patients died from complications of thorotrastosis: coma 
hepaticum, exsanguination, cancerous cachexia and hemorrhagic 
diathesis. A patients died from peptic ulcer, heart insuffi-
ciency, heart infarction and embolism. In lymph nodes, bone 
marrow and thorotrastomas no tumors had developed. 
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There are only hypothetical ideas to explain the different tu-
mor rates in the liver, and all other organs of the RES: 
a) Different self-absorption of alpha-rays in the liver in 
contrast to that of the spleen, lymph nodes and thoro-
trastoma. 
b) Spreading of thorotrast over a greater area in the liver 
than in lymph nodes and spleen. 
c) Necrosis of tumor cells in lymph nodes, thorotrastoma and 
spleen by the same radiation by which they had become ma-
lignant . 
I would like to report about pathological and autoradiogra-
phical investigations and their results which we obtained du-
ring the past 4 years. 
We examined 17 deceased patients - It men and 3 women - bet-
ween 16 - 72 years old who partly received several injections 
of thorotrast during 1939 and 1915 and who died 2k - 3o years 
later. Injections of thorotrast were given because of inju-
ries of arteries in 6 cases, artery occlusion in 2 cases, ar-
terio venous aneurysm, brain embolism, brain tumor and epi-
lepsy in 1 case respectively. In 5 cases the reason for the 
injection maintained obscure. All patients received intra-
vascularly unknown quantities of thorotrast (fig. 1). 
77o specimens of all parenchymal organs and numerous other 
tissueB have been analysed histologically and autoradiogra-
phically. The content of thorium-232 was determined in 2.5oo 
specimens of the same parenchymal organs and tissues by means 
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of neutron activation analysis. Dr. WESCH told you about these 
quantitative investigations and I shall refer myself to those 
data. Different late lesions had originated in the organs af-
ter a range of latency period from 24 - 50 years: The livers 
of the 17 patients showed fibrosis in 7 cases, cirrhosis in 
lo, malignant tumors in 12 cases, that is to say: 6 hemangio-
sarcomas, 3 cholangiocareinomas and 3 hepatocellular carci-
nomas (fig.2). 
The livers with fibrosis and cirrhosis are shrunken and firm 
and in most cases of human thorotrastosis you are macroscopi-
cally unaLle to decide which of the two processes is in pro-
gress just in moment. 
Fibrosis of the liver means hyperplasia of fibroblasts and 
collagenous fibers, first of all in the periportal region and 
to a much lower proportion in the lobules of the liver. But 
shape and architecture of the Glisson*s trigons and of the 
lobules are preserved. Thorotrast is dispersed as fine gra-
nules principally in the periportal regions but also in the 
liver cells, the Kupffer cells and in the macrophages of the 
Glisson's trigons. Fibrosis may proceed in the direction of 
cirrhosis at any time (fig.3). 
Cirrhosis however means degeneration and regeneration of li-
ver cells combined with fibrosis and inflammation. The limi-
ting membranes of the lobules against the periportal regions 
are broken up and pseudolobules are formed. By these proces-
ses the special structure of the liver is destroyed, the vas-
cular system is altered and followed by portal hypertension 
with all its consequences (fig. 4a and 4b). 
Thorotrast is also irregularly dispersed as fine granules in 
hepatocytes, in Kupffer cells, in macrophages and between the 
collagenous fibers. It is not yet clear why some patients de-
velop fibrosis and others cirrhosis despite of an identical 
latency period. Possibly it depends on the amount of thoro-
trast injected. 
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Hemangiosarcomas are spongy congested tumors which diffusely 
infiltrate the liver. 
The stem cells of these tumors are the Kupffer cells. They 
partly grow network-like and build up partly thin blood ves-
sels of different size. Big parts may undergo necrosis (fig. 
5). 
Thorotrast is usually deposited in very small amounts in the 
center of the tumor in greater amounts at the margin. 
Cholangiocellular and hepatocellular carcinomas mostly are so-
lid and limited tumors, developing uninodularly seldom multi-
nodularly. 
Both tumors infiltrate and destroy the liver and metastasize 
into the lymph nodes at the porta of the liver. Both neoplasms 
contain more thorotrast at the margin than in the center as 
already shown in hemangiosarcomas. But the absolut quant it iy 
of contrast medium is larger in the center of the carcinomas 
than in hemangiosarcomas. 
One cholangiocarcinoma showed erythrocytes in the luaina of 
the tubules. That means that the tumor had invaded blood ves-
sels by using the basal membranes of capillaries as a "guide 
rail" (fig.6). 
The surgeons were highly astonished about this diagnosis be-
cause the tumor had looked arteriographically like an heman-
gioma. 
In trying to interpret these results and correlate them with 
the data of neutron activation analysis I think the following 
may be stated: 
1. There is no specific late lesion in the liver of thoro-
trast patients. Late lesions extend from fibrosis to dif-
ferent tumors. 
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2. Different late lesions may depend on 
different amounts of thorotrast injected, 
different distribution of thorotrast in the liver as demon-
strated by Dr. WESCH, former or later diseases of the liver, 
for instance hepatitis. 
3- The observation that tumors of the liver may develop multi-
nodularly corresponds to the irregular distribution of tho-
rium-232 in the organ with numerous "hot spots" of very 
high concentration. 
4. Probably liver tumors in some cases do not develop directly 
by the action of thorotrast but indirectly by the Hay of 
cirrhosis, because we know that cirrhosis of the liver 
without thorotrast is accompanied by primary liver cell 
carcinoma in 151. 
In the cases with hemangiosarcoma however the action of 
thorotrast is probably responsible for the development of 
the tumor because hemangiosarcomas are very rare spontane-
ously developing tumors in patients with cirrhosis. 
Late lesions of the spleen are fibrosis and atrophy or dystro-
phy. Only in one case we observed a benign hemangioendotheli-
oma, in a second case a malignant one. But probably the latter 
was a metastase of a hemangiosarcoma of the liver. Lymph nodes 
develop fibrosis in all cases. We never saw any kind of lympha-
tic tumor or system disease. 
In 6 cases parts of the contrast medium had been injected peri-
vascular ly. Consequently a thorotrastoma developed but no tu-
mor (flg.7). 
Fibrosis of the spleen is mainly seen around the trabecula. 
Thorotrast accumulates here and the particles form compact is-
lets. Therefore self-absorption of alpha-rays is much higher 
that is to say much fewer cells are exposed to rays than in 
the liver. In my opinion this is one important factor for the 
very small spleenic tumor rate (fig.8). 
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The intima cells proliferate and produce fibers narrowing the 
lumen of trabecular arteries. Arterial-stenosis, consecutive 
inadaequate circulation and fibrosis lead to strong atrophy 
of the spleen. The organ weighs only about 2o - 3o gr compa-
red to the-normal weight of 12o - 13o gr. 
In the case with benign hemangioma thorotrast was scattered 
in small spots around lakes of blood in the red pulp. 
Otherwise the contrast medium was deposited in low amounts in 
the intercellular spaces of the reticulum without any vital 
reaction. 
I told you a short time ago that lymph nodes of all cases had 
developed fibrosis as late lesion. This is not quite correct. 
Properly speaking we observed two different pictures: 
Small quantities of thorotrast form small intercellular depo-
sits in the reticulum without any reaction of cells or fibers. 
We found this way of deposition in lymph nodes of the neck, 
of the hi lus of lungs, of the pelvis and along the arteriae 
femorales, that is to say in lymph nodes far away from the 
porta of the liver (fig. 9). 
On the other hand the parapancreatic lymph nodes and the lymph 
nodes at the hilus of the liver and along the way of a para-
vasate contain many particles with marked fibrosis around 
them. 
The fibrosis is accompanied by dystrophy and atrophy of the 
reticulum and destruction of the follicles and their germinal 
centres. Dr. WESCH has told you, that the lymph nodes near by 
liver, pancreas and spleen often contain more thorotrast per 
gram tissue weight than areas of the highest concentration in 
the liver. Nevertheless no neoplastic lesion or system disease 
had developed in one of the 78 investigated lymph nodes. 
As in the spleen self absorption is high in those fibrotic 
lymph nodes and therefore the possibility of tumor formation 
is low (fig.lo). 
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The same reflections are applicable to thorotrastomas in the 
sjrrounding of which a marked fibrosis had developed. 
ihe influence of thorotrast as a foreign body is impressing in 
the thorotrastoma suggested by the foreign body giant cells. 
It is remarkable that none of the 17 patients showed any tu-
mor or system disease in the bone marrow. Particles of thoro-
trast are deposited here intra- and intercellularly without 
any reaction in the reticulum as in the red pulp of the spleen. 
In areas with hematopoiesis - for instance in vertebral bodies -
we observed in some cases activation that means hyperplasia 
of stemm cells. 
In all other organs and tissues of the 17 patients we did not 
find any late lesion near the small deposits of thorotrast. 
One remark as to the main cause of death: 
13 patients died from direct or indirect complications of 
thorotrastosis: from 
coma hepaticum, from 
exsanguination from hemangioma or oesophageal piles 
from cancerous cachexia or hemorrhagic diathesis. 
4 patients died from complications which had nothing to do 
with thorotrastosis: from peptic ulcer, heart insufficiency 
heart infarction and embolism (fig. 11). 
Investigations are lacking how different late lesions come 
about despite of identical concentrations of thorotrast. 
There are only hypothetical ideas: 
1. Different self-absorption in the organs of the RES may be 
an important factor, I discussed this. 
2. It may be of importance that thorotrast spreads over a 
greater area in the liver than in lymph nodes and spleen. 
In lymph nodes and spleen radiation is concentrated on a 
small space. Therefore necroses recur more often and the 
transformation of the organ is so remarkable. 
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This transformation runs over a period of ten years and 
more in the liver. But it catches snail groups of cells 
and is accompanied by constant regeneration. 
3. Tumors are seldom in spleen, lymph nodes and thorotrasto-
mas because those cells, which had become malignant by 
the radiation of thorotrast undergo necrosis by the same 
radiation. 
If this would be true it must be true for the liver too, 
or one must assume, that thorotrast is constantly displa-
ced so that there is no possibility for the discussed 
phenomenon. 
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Legends: 
Fig. 1: Data of the 17 autopsied patients. 
Fig. 2: Late lesions of the liver of the 17 patients. 
Fig. 3: Fibrosis of the liver with periportal collagenous 
hyperplasia but without destruction of the limi-
ting membrane. 
Fig. 4: Cirrhosis of the liver with periportal fibrosis, 
a + b inflammation and destruction of the limiting 
membrane. 
Fig. 5: Henangiosarcoma of the liver with a blood vessel 
in the middle of the picture. 
Fig. 6: Chclangiocarcinoma with erythrocytes in the lu-
men of the tubule. 
Fig. 7: Late lesions in the spleen, in the lymph nodes 
and in thorotrastoma. 
Fig. 8: Fibrosis of the spleen with accumulation of 
thorotrast around the trabecula; proliferation 
of intima cells of an artery (middle of the pic-
ture). 
Fig. 9: Deposition of thorotrast in lymph node without 
vital reaction. 
Fig. lo: Fibrosis of lymph node with thorotrast in the 
network of the collagenous fibers. 
Fig. 11: Main cause of death of the 17 thorotrast patients. 
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Historadioeraphles and Autoradiographies from fieces of Organs 
of People Injected Systemically with Thorotrast. 
by 
J.da Silva Horta 
J.Houra Nunes 
Department of Pathology, Faculty of Medicine, University of 
Lisbon, Portugal. 
Abstract 
Autoradiographies were done in organs from people injected 
systemically with Thorotrast. The great amount of a tracks found 
in the liver and the spleen in comparison to the amount existing 
in other organs, explains why it is in these organs, especially 
the liver, that the greatest number of neoplasias appear. 
Historadiography has proven to be a good method to detect 
the thorium dioxide in the organs. 
Key-words; Thorotrast - Historadiography - Autoradiography -
Tumour. 
This survey was carried out with the full support of the U.S. 
Public Health Service Research Orant no EC 00068, formerly grant 
no BH 00039 and with the cooperation of the University of Lisbon. 
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Introduction. 
The hiatoradiographies and autoradiographies studied by us 
in people injected with Thorotrast haTe different purposes. 
The historadiograpny is a very good aethod to detect the 
drug; it has been very useful, with saall power, to allow us to 
evaluate the degree of fibrosis of the liver, spleen and tribu-
tary lyaph nodes. Our initial work has been done with the colla-
1 2 boration of Jean Collate ' . 
when the particles of thorium dioxide rest for a while, 
they induce the proliferation of fibrous tissue - of particular 
importance is hepatic fibrosis. Ve have several tiaes published 
our results, in English only in the papers froa the lew Tork mee-
ting and the Vienna meeting . 
The autoradiographies have been used as a control of the 
examination by simple light microscopy, in order to find the pla-
ces where the tumours induced by Thorotrast are formed. It is a 
control because the results of our epidemiological studies had 
proved already which were the organs most susceptible to the 
formation of such neoplasias . 
Material and methods. 
For historadiography we employed the extra-soft rays from 
8 to 10 kV with a long exposure time (about 5 minutes). The ap-
paratus used was a Philips BW 1009. 
The autoradiographies are done from 5 p cuts embedded in 
paraphin to which stripping film (Kodak IS 10) applied. The time 
of exposure was from 30 to 45 days. They were developed for 5 
minutes in D 19 B (Kodak) and fixed with Unifix (Kodak). The ob-
servation of the cuts, stained with henatoxilin and eosin, was 
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made with a magnification of 400 tines. 
The present paper Is just a preliminary note, because these 
studies are slow and our material great enough. 
For the time being we have studied cuts from the liver (1 
case), spleen (1 case), lymph nodes (1 case), pancreas (3 cases), 
thyroid gland (2 cases), lung (8 cases), bowel (1 case) and sto-
mach (1 case). 
ResultB 
There is a great difference between the amount of a tracks 
found, on one side, in the liver and the spleen where great 
amounts are present and in the other organs, where they may be 
negative, or where only one or two tracks are seen in the whole 
of the slide. 
In the liver the a tracks have been seen rising from the 
Kupffer cells og in the big scars from the histiocytes that 
contain the thorium present. In the spleen it is difficult to 
recognize the cells from which the a tracks originate because 
they are so numerous, but with small power we can see that they 
probably come from elements of the Billroth cords, from the en-
dothelium of the sinus and from the histiocytes in the fibrous 
tissue. 
In other organs the a tracks start fro« histiocytes, usual-
ly perivascular, that contain thorium. We have been especially 
interested in the lung, where we found a tracks in 4 of the 8 
studied cases, always starting from the macrophages free within 
the alveoli. 
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Comments. 
As »• stated before, due to the quantity of our material and 
the way in which we select the organs for study, this coaaunica-
tion is just a preliminary note. The patients we studied repre-
sent by no means a homogeneous group. Even so these samples gave 
UB some not unexpected indications: the liver and the spleen, 
which have the largest number of a tracks, are the organs that 
present tumours in our histologically studied material. We have 
not yet studied any case of bone marrow but according to our 
experience we expect to find an important a radioactivity. 
Our results, though provisional, are in accordance with the 
ones from K. Wegener et al. . Nevertheless the reason given by 
these authors in order to explain the existence of a smaller num-
ber of tumours in the spleen than in the liver (the storage of 
greater quantities of Thorotrast in the spleen than in the liver 
gives rise to a greater selfabsorption of radiation"), must be 
slightly corrected in face of our material. Usually when we do 
a histological examination of a spleen from an old case, there 
is practically only Thorotrast and collagen; there are no more 
cells left and it is impossible as we have already stated-5 that 
tumours can be formed. 
We have been particularly interested in the existence of 
several a tracks in the gallbladder and the lung. As shown by 
hiatoradiographies the lymphatic net between the liver and the 
hepatic bed of the gallbladder is a very rich one. Several tiaes 
we found Thorotrast in the mucosae of the gallbladder from our 
cases. In the above mentioned paper we have shown a conclusive 
mlcrophoto that reproduces the Fazio's scheme in experimental 
works. As we have said in our first communication, during the 
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present year we hare observed two eases of adenocarcinoma of the 
liver and the gallbladder that can hare stewed either fro« the 
liver with later invasion of the gallbladder, or exactly the op-
posite way. These cases have been to autopsy, and even during 
this it has not been possible for us to reach a conclusion. If 
they were hemangioendotheliomas, the option should be easy, but 
they ware both adenocarcinoma. 
The lungs were studied in a greater number of cases because 
of the interest of Professor Ibrinelll in the lung carcinomas in 
the presence of radioactive radiation. Although our epidemiologi-
cal investigation did not disclose a larger number of such tu-
mours than in normal people, it must be pointed out that in 4 or 
8 cases we found a tracks, although the density of these tracks 
are very much inferior to the density found in the liver and the 
spleen. On the other band, lung studies with the light microsco-
pe did not show any particular picture in our cases. 
Legends of figures. 
fig. 1 - autoradiography. Scars with Thorotrast. 
Fig. 2 - Autoradiography. Spleen, numerous a tracks. 
Fig. 3 - Autoradiography. Liver. Numerous a tracks. 
Fig. 4 - Autoradiography, a tracks originated in the Kupffer 
cells with Xhorotrast. 
Fig. 5 - Oallbladder. Jfamerous e tracks. 
Fig. 6 - Lung, a tracks originating in the alveolar macrophages. 
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Ihorotrast-lnduced Spindle Cell Sarcoma and Hepatic Ch"»f"grtT-
carcinoaa in Syrian Hamsters. 
by 
T. Noriz), T. Ocanoto, H. Umeda, K. Salto and H.Okensian 
z) Second Department of Pathology. Yokohama City Dhiveraity 
School of Medicine, Tokohaaa, Japan. 
Abstract 
By injecting Ihorotraat into the submucosa of the cheek 
pooch of Syrian hamsters, spindle cell sarcoma »ere induced at 
the site of injection. It »as also possible to induce hepatic 
cholangiocarcinoma in Syrian hamsters by systemic Ihorotraat ad-
ministration. Both of the induced tumors were transplantable, and 
could also be converted into the ascitic form. In addition, the 
former was established as a stable strain through culture in vi-
tro. 
Histopathological and radiological examination of the tu-
nors demonstrated that the carcinogenesis of the former proceeds 
from Ihorotraat foreign body inflammation to thorotraatoma for-
mation to spindle cell sarcoaa development, and that of the lat-
ter from Ihorotraat deposition in the liver to adenomatous proli-
feration of intrahepatic bile ducts to the development of hepatic 
cholangiocarcinoaa. In both tumors, shortening of the period from 
Ihorotraat administration to tumor recognition «aa observed as the 
Ihorotraat doae m a increased. Also abnormal proliferation of al-
veolar epithelial cells of the lung vas observed following syste-
mic Ihorotraat. 
268 
Introduction. 
Ihorotrast-induced human malignancies, of which a number of 
reports (1,2,3,4,) have been accumulated to date, may be roughly 
divided into those developing at Ihorotrast injection sites, such 
as fibrosarcoma, and those resulting from systemic Ihorotrast ad-
ministration, such as malignant hepatic tumors. 
Various animal experiment] have been undertaken to study 
the pathogenesis of these malignancies. In experiments using mice 
(5), rats (6,7), rabbits (8) and guinea pigs (9), the occurences 
of various malignant tumors following Thorotrast administration 
have been reported. 
The authors (10) in their own previous animal experiments, 
were able to induce fibrosis of the liver, spleen and lymph nodes 
in mice, rats and rabbits by systemic Ihorotrast administration, 
but failed to induce clearly recognizable malignant tumors. 
In the present study, however, using Syrian hamsters as ex-
perimental material, the authors succeeded in inducing spindle 
cell sarcoma (11, 12) by local Ihorotrast injection and hepatic 
cholangiocarcinoma by systemic administration. This paper descri-
bes the results obtained. 
Material. 
Ihorotrast used in the present study was manufactured by 
Fellow Testagar, Inc., of the U.S. 
In the local administration experiment Syrian hamsters 
aged 3 months with body weight ranging between 120 and 150 grams 
were used. In the systemic administration experiment they were 
aged 2 months with body weight ranging between 90 and 110 grams. 
In both expe~!uents males and females were used in equal numbers. 
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All the animals vere raised on pellet food under identical condi-
tions. 
Methods and Heaults. 
1. Local Tnorotrast Injection Experiment. 
Twenty healthy Syrian hamsters were divided into four equal 
groups. To the animals of each group, 0.1, 0.2, 0.4 or 0.6 ml of 
Thorotrast was given in single injection into the submucosal soft 
tissue of the left cheek pouch. As controls, 20 untreated ham-
sters of the same kind were used. 
Both the experimental animals and the controls were kept 
till death due to tumors or till natural death. Immediately follo-
wing death, the animals were dissected for macroscopic and micro-
scopic examinations. 
Hematoxylin and eosin-staining was performed on all samples. 
Where deemed necessary, other staining aethods vere addetionally 
employed. Further, in some cases, examination by means of elec-
tron microscopy and micro-autoradiography was conducted in con-
junction with measurement of radiation dose by use of a gas-flow 
Geiger Wilier counter. 
Development of tumors at injection sites was observed in 3 
out of the 5 animals which survived more than 250 days in the ex-
perimental group given 0.1 ml of Thorotrast, in 2 out of the 4 
survivals in the group given 0.2 ml, and in 2 out of the J survi-
vals in the group given 0.4 ml. In the group given 0.6 ml, how-
ever, 2 animals survived over 250 days without indicating any 
signs of tumor development. 
All told, tumors developed in 7 out of the 14 animals which 
survived more than 250 days. The number of controls surviving mo-
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re than 250 days was 18. Tumor development was not detected in 
any of the latter (Table 1). 
Time interval between Thorotrast injection and macroscopic 
recognition of tumor formation ranged from a minimum of 295 days 
to a maximum of 472 days. Breakdown by the amount of Thorotrast 
administered gave the time interval at 445 - 472 days (average 
455 days, standard deviation 12.28 days) for the group given 0.1 
ml, 375 - 390 days (average 383 days, standard deviation 7.48 
days) for the group given 0.2 ml, and 295 - 370 days (average 
288 days, standard deviation 33.63 days) for the group given 0.4 
ml. Thus it was learned that increase in the amount of Thoro-
trast administered resulted in shortening of the injection-to-tu-
mor recognition period. Time interval between tumor recognition 
to death ranged between 33 and 48 days, exhibiting little varia-
tion in relation to the amount of Thorotrast administered (Table 
I). 
Nacroscopically, the tumors developed were mostly well-de-
marcated, were about the size of a walnut, and elastic-hard in 
consistency. On the eut surfaces, they were white-grey with yel-
lowish central zone of necrosis. X-ray photographs revealed dot-
like dense shadows in the tumors corresponding the Thorotrast 
granules deposited. (11). 
Microscopically, the tumors consisted of interwoven bundles 
of long fiber-like spindle cells having ovoid or spherical nuclei 
with abundant chromatin, and projecting cytoplasm, which was po-
sitive by collagen and reticulum staining methods. In other words, 
they presented a typical image of spindle cell sarcoma of fibro-
blastic origin (Photo 1). 
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Sir electron micrographs, the tuaor cells were shown to hare 
centrally located ovoid nuclei and cytoplasmic processes at the 
cell surface, poorly developed organellas, i.e. scanty endoplas-
mic reticulum and ribosome granules, which lie at randoa in the 
cytoplasmic aatrices. Reduced number of mitochondria and abundant 
intracytoplasmic fibrilles indicated the fibroblastic origin of 
the tumor cells (11). Metastases of these tumors were found in 
the lung, liver, kidney and lymph nodes. 
The tumor cells could be roughly divided into those contai-
ning near diploid and tetraploid chromosome nuaber. Homotransplan-
tation of the tumors was made into the submucosal tissue of the 
cheek pouch, dorsal subcutis, peritoneal cavity, or heaatogeneous-
ly via vein, the transplantation was auccesful in 100)1 of the ea-
ses. Number of cells required for successful transplantation waa 
6 3 3 i 10 to 1 x 10 . Successive transplatation, carried out subcu-
taneously and intraperitoneally also proved successful. 
In intraperitoneal transplantation, ths authors were able 
to convert the tumors into aacitic form (11). The transplantabl-
lity of the tumor ascites was 100%, whether Bubcutaneoualy, intra-
peritoneally or hematogeneusly. 
Following transfer of the ascitic tumor cells to culture in 
vitro, a stable strain was established. 
In order to examine the process of tumor-inducing by Thoro-
trast, changes taking place with the passage of time in the or-
gans wsre examined for hamsters given 0.2 ml of Thorotrast both 
histopathologically and microautoradiographically for periods 
from 30 minutes to 15 months after Thorotrast administration. 
Thirty minutes after injection, most of Thorotrast still 
272 
remained in its colloidal state and was retained by loose connec-
tive tissues of the subaucosa. Thorotrast ingestion by reticulo-
endothelial cells had hardly begun by this tine. 
Three dayB after injection, Ihorotrast was found to have 
deposited in submucosal tissues as granules. Ingestion by macro-
phagocytes had started by this time. Congestion edema and other 
manifestations of foreign body inflammation were observed. 
Seven days after injection, edema of submucosal tissues had 
disappeared, and most of the smaller Ihorotrast granules had been 
ingested by macrophagocytes. Foreign body inflammation was found 
subsiding. 
Thirty days to six months after injection, some of the Iho-
rotrast ingesting cells necrosed, forming granules measuring 20 
to 20 microns in diameter. The granules resulting from this in-
tercellular Thorotrast ingestion formed closely conglomerated ag-
gregates, over which connective tissue capsules were found devel-
oped, thus presenting a typical image of Thorotrastoma. In the 
subsequent period, no further changes were observed except in the 
cases developing malignancies. Thorotrastoma thus induced in the 
animals closely resembled Thorotrastoma in humans. 
Incidentally, about six months after injection, transloca-
tion of Thorotrast granules to the liver, lung and spleen began 
in very small amounts, with deposition becoming detectable in 
these organs. 
2. Systemic Thorotrast Administration Experiment. 
Three experimental groups consisting of 10 animals each 
were respectively given 1.0, 1.9 and 2.S ml of Thorotrast via in-
jection into the sublingual vein. 
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The method of administration was single injection for the 
group given 1.0 ml of Thorotraat, two separate injections for the 
group given 1.5 ml, and three separate injection for the group 
given 2.5 ml with one week intervals. As controls, twenty ham-
sters of the same kind were used. In other respects, methods of 
experimentation and examination were the same as in the local 
Thorotraat injection experiment. 
9 animals survived more than 150 days in the group given 
1.0 ml, of those animals five developed adenoaatous proliferated 
bile ducts in the liver and one developed hepatic cholangiocarci-
noma. Among the four survival in group given 1.5 ml, three cases 
of adenomatous proliferation in the liver and one case of hepatic 
cholangiocarcinoma were recognized. In the group given 2.5 ml one 
of the two survivals developed adenomatous proliferation in the 
liver and the other developed hepatic cholangiocarcinoma. 
In all, 9 cases of adenomatous proliferation in the liver 
and 3 cases of hepatic cholangiocarcinoma were found among the 
15 animals which survived more than 150 days. It was also found 
that increase of the injected dose of Thorotrast was accompanied 
by a decrease in the number of animals surviving more than 150 
days and a rise of the incidence of adenomatous proliferation 
in the liver and hepatic cholangiocarcinoma (Table 2). 
latent period of hepatic cholangiocarcinoma was 525 days 
in the group given 1.0 ml of Thorotrast, 59C days in the group 
given 1.5 ml and 207 days in the group given 2.5 ml. This showed 
that increase of the amount of Thorotrast administered resulted 
in remarkable shortening of the latent period (Table 2). 
Hacroscopically, the hepatic cholangiocarcinoma thus devel-
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oped was white-grey in cut surface, measured approximately 1.5 x 
1.2 en, and were elastic-hard in consistency. 
Histologically, it presented a typical image of adenocarci-
noma with relatively large glandular lumens (Photo 2). 
The tumor cells were atypical and varied in size, and were 
characterized by chromatin increase. Stroma increased was pro-
nounced in these tumors, and large amounts of intrastrooal thoro-
trast deposits were observed. Metastatic foci were found in the 
lung, kidney and lymph nodes, giving rise to peritonitis carcino-
matosa in one case. 
Homotransplantation of the tumor cells was made into dorsal 
subcutle and peritoneal cavity. Transplantability was 100^ in 
subcutaneous transplantation and 9054 in intraperitoneal transplan-
tation. 
Successive transplantation, both intraperitoneal and hemato-
genous proved successful. Intraperitoneal transplantation was 
successful in converting solid tumors Into the ascitic form. 
Aiming at the examination of the process of tumor-Induction, 
the changes taking place in the organs with lapse of time were 
examined by histopathological and autoradiographical methods, 
for periods ?0 minutes to two years following injection. Thirty 
minutes after injection most of the Ihorotrast administered still 
remain as colloid in the blood vessels (Photo 3). After a lapse 
of 24 hours following Thorotrast administration, the presence 
of Thorotrast in the blood stream was hardly recognizable because 
of ingestion by reticuloendothelial cells. Ihorotrast phagocyto-
sed by Kupffer cells of the liver ånd reticulum cells of the 
spleen was clearly In evidence. Seven days after Injection, Iho-
rotrast-ingesting cells were found to accumulate and form cell 
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aggregates. 
Thirty days to three months after injection, these aggrega-
tes of Thorotrast-ingesting cells grew increasingly larger (Photo 
4) with small round cell infiltration and collagen fiber prolife-
ration occuring around the aggregates. 
In the liver, proliferation of pseudo-bile ducts was also 
observed (Photo 5). After a lapse of 6 to 15 Months, localized 
fibrosis appeared in the liver, suggssting cirrhotic changes. 
Adenomatous proliferation of the intrahepatic bile ducts and the 
development of hepatic cholangiocarcinoma were also observed 
(Photo 6). This cholangiocarcinoma closely resembled that occur-
ring in humans. 
In the lung, abnormal proliferation of alveolar wall cells 
came to be frequently observed at the deposition sites of Thoro-
trast granule aggregates, while in the kidney small infarctions 
were seen presumably attributable to embolisms due to Thorotrast 
granules. 
Dosimetry by use of a gas-flow Galger Miller counter indi-
cated that a cumulative radiation dose from Biorotrast administra-
tion to occurrence of tumors were ca. 1.500^2.200 rad on average 
at the injection site in local Thorotrast administration and of 
the liver in systemic Thorotrast administration. 
Discussion. 
Despite the spate of reports on Thorotrast cancer-induction 
experiments, there has thus far been little documentation of such 
experiments with the Syrian hamster. 
In the present study, the authors have suceeded in inducing 
spindle cell sarcoma by local Thorotrast injection and hepatic 
276 
cholangiocarcinona by systenatic Thorotrast administration In 
hamstere. The period from Thorotraat administration to tumor for-
mation becomes shorter as the Thorotraat dose is increased. 
By examining the process of tumor formation, the authors 
have found that in the cases locally given Xhorotrast, carcinoge-
nesis proceeds from foreign body inflammation at injection site 
tc Ihorotrastoma, thence to the developnent of spindle cell sar-
coma. In systemic Zhorotrast administration, carcinogenesis pro-
ceeds from Ihorotrast deposition in the liver to adenomatous pro-
liferation of intrahepatic bile ducts, thence to the onset of he-
patic cholangiocarcinona. 
Cumulative radiation dose at injection sites or in the liver 
from Thorotrast injection to tumor formation was observed to ca. 
1.500 - 2.200 rad on the average. As 95^ of the radiation energy 
emitted by Thorotrast is alpha-ray energy, measurement of the do-
se in the area adjoining Thorotrast granules becomes of particu-
lar importance in dosimetry. According to Kato. Y. (13) the dose 
at the distance of the 10 micron from a large Thorotrast granule, 
20O nicron in diameter,is 48.000 rad/year, and that at the same 
distance from a medium sized Thorotrast granule, 20 microns in 
diameter, is 9.500 rad/year. These doses are considered to be suf-
ficiently large to cause necrosis or atypical proliferation in 
Thorotrastingesting cells or adjoining cells. 
Concerning other organs, alveolar wall proliferation of the 
lung and multiple small infarctions in the kidney following Thoro-
trast administration were observed but are considered specific to 
the Syrian hamster, as these reaction have not been obtained thus 
far in experimental studies using mouse, rat, rabbit or guinea 
pig. This »peoifielty in the Syrian hamster may be related to the 
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authors previous finding (10) that Thorotrast deposition rate in 
the lung and kidney is greater in the Syrian hamster than in 
other animals. 
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figures. 
Pig. 1.Spindle cell sarcoma with interwoven bundles of spindle 
cells. In the stroma a large number of Thorotrast granules. 
Fig.2.Cholangiocarcinoaa of liver 13 months after i.v. Ihorotraat 
1.5 ml. 
Fig.3.Thorotrast as intravascular colloid 30 minutes after i.v. 
injection. 
Fig.4.Thorotrast in phagocytic H.B.cells in liver 1 month after 
i.v. injection of 1.5 ml. 
Pig.5.Multiple pseudo bile duct proliferation 6 months after i.v. 
Thorotrast 1.5 ml. 
Fig.6.Adenomatous proliferation in liver 10 months after i.v. 
Thorotrast 1.5 ml, a precarcinomatous condition? 
273 
ate la ir tmt 
•1 
1.0 
1.5 
8.5 
» 0 . 
10 
10 
10 
ftorvlnl 
190 «V* 
9 
4 
2 
.5-2=. 
5 
5 
1 
XatUMM tf 
«Mia»jl«-
1 
1 
1 
•K 
A-l 
»•1 
0-1 
S 
9fO 
m 
liwlM 
iFIIMi 
y» * iso.5 
280 
• - • * / * • : 
^&S3 
281 
Mon-Radiation Effect« of Thorotreat 
and other Colloidal Substanceg 
by 
V.Riadel, B.Mttller, A.Kaul 
Klinik fur Radiologic und Nukleamedizin 
- Nukleansed. Phyaik und Strahlenschutz (Biophysik) -
KlinikuB) Steglits der Freien Universitttt Berlin 
Abetract 
In a review of the current literature the pathogenetic 
effects of son* non-radioactive colloidal substances in sni-
vels are preeented. 
The effects of these substances suggest the supposition 
that apart fron the radioactivity other etiological factors 
operate in the pathogenesis of Thorotrast. 
Three recent papera devoted to this special probles are 
quoted. 
Our experimental project le designed to Investigate the 
role of the foreign body effect present in the pathogenesis 
of Thorotrast. 
Soae ZrO.-aquaaols wsre prepared according to the coaewn 
peptization and condensation aethods. Up to now we failed to 
obtain a Tborotrast like particle sizs distribution. 
Thorotrast was produced following the aethod of the foraer 
aanufacturar. 
A possibility of the enrlchaent of Thorotrast by Th-230 is 
described. 
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Introduction and Review of Literature 
Tha question whether only tha radiation of Thorotraat io reepon-
sible for tha lone tam affacta aftar administration of tha 
colloid »or whether the foreign body or tha chemical propartiaa 
ara alao to ba takan into consideration ma poasible etiological 
factors in tha tumor genesis,is discuaaad first by Quimaroa and 
Lamerton • 
Pro« tha chemical point of viav Thorotraat should ba indiffe-
rant. Beneted and Croofcall *, however, praauna a csrtain cheml-
l) 
cal toxicity of Thorotraot from tha raault of Roth"",who had 
obsarvad thraa tumor caaas in a group of 25 vineyard workara 
with chronic araanic poisoning,which could not ba dlatlngulahed 
from Thorotraat tumors. The find ins* of Rowlay ' that vascular 
injuria* wars presumably indue ad by 5-hydroxitryptamine and 
histamine ralaasad from damaged nast calls,alao auggoot tha 
supposition that distinct pharmacological affscts nay ba attri-
buted to Thorotrast. 
Tha occuranca of malignant tumors induced by othar radio-
active colloidal substances, however, points to tho radioacti-
vity of Tho rot rast aa tha sain etiological factor in tunor 
genesis. 
Upton, Furth and Burnett ' failed to observe any liver tumors 
in nice intravenously injected with non-radioactive colloidal 
gold. However, these authors ware able to produce hepatoses in 
two groups which had received different doaaa of Au-19& laballed 
gold-sol. 2 and 5 hepatomas, respectively, of 7 and 20 snisjals 
have bean recorded. 
Comparable results were published by Xoletsky and Oust afson '. 
On the other hand, a review of current literature indicates 
that these tissue reactions are not different froa those of 
other non-radioactive macroaolocular colloidal substances 
underlying no or little metabolic degradation and which have 
been parenterally administered as aquasolst 
Comprehensive animal experiment* on the effects of solutions of 
some synthetic substances as polyvinylpyrrolidone (FYP), dex-
tra n, polyvinylalcohol, polynethyl- and polyethylcellulose, 
parenterally administered to rats, mice and rabbits ware pub-
lished by Hueper7,8' 
Although the used PVP and dextran varied in molecular 
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size (PVP n.tt. 10 OOO - 300 OOO; dextran m.w. 37 500 - 3O0 000 
partly branchad) tha experiments failad to alicit an evident 
dopandanca of tha tumor incidanca on tha nolecular alse. Tha 
tunor incidanca appaars to ba nora dapandant on tha aninal 
species supported by following information. A tumor frequency 
of 0 - 10 i and 10 - »O % respectively M I observed in arf.ce 
and rats, respectively! compared with 0,7 % in mice and 10 % 
in rats as controls. 
The PVP induced tumors ware classified according to their 
periodic incidence in the following groups i Reticulum-cell ear-
coma of the lymph nodes* Kupffer-cell sarcoma, carcinoma of 
uterus, skin, ovary and breast. 
Although mora than 500 OOO patients received PVP in the farm 
of a 3,5 % solution (Plaamoaan ) aa plasma substitut no lang 
term effects in man havs bean reported in tha lit era turs so far 
have received. 
In contrast to the findings of Hueper7' ', Haddow and Homing ' 
did not observe any tumors after subcutaneous injection of 0,2 ml 
of 20 % solution of daxtran into mice in weekly doses for 16 and 11 
months, respectively. 
Likewise no pathologic changes have bean observed by Lvndim ' 
after application of the Thorotrast stabilising agent dextrin 
41 to rats. However, Rowley ' suggeeted that the dextrin component 
is responsible for tba mast cell damage and increases vascular 
permeability after intravenous injection of Thorotrast into 
rats. 
Imferon and Ferri gen as dextran and dextrin stabilised sols 
colloidal nature. The particle sine of tl 
Imferon which was succesfully used in the treatment of iron 
deficiency anemia is of coure*rather large compared with that 
of ThO_ particles. Molecular weight has been determined to ba 
as high aa 160 000. 
12) First Richmond ' found Imfaron to be carcinogenic in rats. 
Haddow and Horning ' confirmed theae resultsi 
Massive weekly repeated doses subcutaneously administered to 
mice and rats dsveloped sarcones, fibrosarcomas and histiocy-
toma at the site of injection. 
After aubcutansoua application of 0,5 »1 Iaferon in weakly 
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deeea ta 20 aale crau hmt»r», however, only ana aalaal 
developed a aarcena aftar lataat parlod of 9 »ontha. Ha tiaaera 
•tara racordad In a aarla af 30 boasters siuilerly traatad. 
Two aarlaa of 12 and 20 ebinaaa banatara which received doaaa 
of 0,1 and O.] al laTerea, reapectively, exhibited relatively 
high aartallty dna ta an extraordinary hlfh frequency of daaege 
and hyperthrophy af tha Hvor and tn sone eaaaa dna to cholan-
gieaee and hepateaee. No tuaora vara ebeerved at tha alta af 
Injactlan. 
Tao greupe af 8 and 10 guinea plga received 1 ni Xnfaron 
oacb week ror 7 non tha. Only 5 and 3 anlaala eurvlved 1 yaar 
and no tiawirs vara racordad. Six rnbbita vara alaa injected 
intrenuecularly, but wlthaut evident pathological afraeta aftar 
16 nantha. Lundia ' generally confinsed tha raaulta by Intra* 
•uaeular Injactlan af lafaron into rata with, rining weekly deaaa 
over a parlad af % aonthe (total doeei 350 er 255 ag Fa). 
Ferrlgea aaa (Ivan la tha aaaa way. Tha tuaar oceuronca In 
bath laf aron groups and In thalr higher Forrigen daaa (roup 
proved ta bo caaaarabla (25/27, 26/31 and 25/30 reapectively 
tuaara wara racardad). However, tha group traatad with a lawar 
Forrigen daaa, developed a auch lawar fraquancy af tuaara af 
16/31. Ha tuaara wara racardad aaong tha controla. 
In view or tha high lncidanca of tuaara at tha alta af in-
jection. It la remarkable that no tuaara developed in tha lirer 
or apleen before the experiaente were diacentlnoed. Lundin did 
net øboerve any proliferation af hepatic connective tieeue. 
Langvad -" daacrlbad the production of haenanglo-endothello-
aae af the liver eaeng ather tuaara, auch ae fibraaarcoaaa at 
the aite of injection in alce eubcutaneeualy adainietered with 
laferon. Ko correlation between the tuner eccurence and the 
injected doae norene ebviaua. 
Concerning the aechanl aa af the geneeie of those ao-called 
•polyner tumors- aaaa investigators fevered the view that »pa-
cific chealcal er phyalcochoedcel prapertiee of these aacre-
aolecular agent« (such a« complex foraation ef aaereaolecular 
aubatancea with proteins or the presence of lapurltlsa e.g. 
traces of the catalyst used in the production of these aacre-
aolecular substances) are responsibis far tha pathogenic process. 
In the opinion of ether authere tha tuner genesis la a noa spa-
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cific tru* foreign body effect, analogues to the sarcogenesis 
obtained around the various synthetic insoluble polymers and 
natal disks following their subcutaneous implantation. Such 
implantations induce the formation of granulomatous tissue of 
a fibrous capsule which is generally present in subcutaneous 
sarcomatas . However, it is absent in the cases of experimen-
tally induced liver tumors. Thus this subcutaneous tumor may 
perhaps be regarded as an example of the "Oppenheimer effect**. 
However, it is rather- difficult to invoke this mode of action 
Ik) in the case of liver tumors 
The problem: radiation or foreign body effects of Thorotrast 
was approached experimentally first by Bensted and Crookall '. 
These investigators injected intravenously into 18 male mice 
a dextrin stabilized non-radioactive ZrO.-sol (zirconotrast) 
containing 13 % w/v ZrO« as wall as Thorotrast into 16 mice. 
They observed in the Thorotrast group and not well established 
in the zirconotrast group one haemangio-endothelioin which has 
been suggested by Looney to be a Thorotrast specific tumor. 
The relevance of these experiments is somewhat reduced as also 
in 18 controls .5 liver tumors occured . Moreover, the particle 
size of the used ZrO_-sol of 50 - 100 nm exceed that of Thoro-
trast by an order of magnitude (see fig. l). In further experi-
14) 
ments Bensted obtained numerous vascular tumors of the spleen 
but not of the liver only in the Thorotrast group and not in the 
zirconotrast group, since this type of tumor tends to occur very 
late and the survival of the animals was poor in the zircono-
trast group, 
Mori ' injected intravenously into mice, rats and rabbits 
different doses of Thorotrast and of the following control me-
dia: colloidal carbon as Indian ink. the diazo dye-stuff try-
panblue and the Al-complex of carmine acid carmine. The both 
latter compounds may not be considered as true colloids. How-
ever, trypanblue is known to b* firmly bound with plasma albumin 
being stored in the r.e.s. ', and it is responsible for the 
development of reticulum-cell tumors in rats after parenteral 
17) 
repeated administration as a 1 % solution . 
Hori ' observed diffuse and rather conspicous retrograde 
cellular damage of the parenchymal tissue increasing in sever-
ity according to the doses. 
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Fig. 1 Electron micrograph of ZrO.~p.rti cl es of the sol 
used by Bensted and Crookali 
1|jm 
?•*-•' 
* « 
by peptization 
« i MUTKLé DHM£te» • 
Fie.3 Particle size distribution of commercial Thorotrast 
Indian ink a;id ^ carmine caused only slight and temporary 
histological changes. 
Ovn Experimental Project, and Preliminary Results 
Our experimental project considers the following tine setiuence 
studies: 
1st, Tn continuation of Bensteds investigations production and 
application to animals of ZrO - and HfO -aquasols as non-
radioactive colloids possessing Thorotrast like particle 
size distributions: studies of the biological effects of 
these colloids. On account of the identical chemical pro-
perties of these elements the biological effects should 
be similar, 
2nd, Production and application to animals cf Zr-95 and Hf-lSl 
labelled sols (radiozirconotrast, radiohafniotrast); studies 
of the distribution and retention of these radiocolloids 
in different organs and in the whole body and calculation 
of absorbed doses; comparison of biological effects due 
to the radiocolloids and non-radioactive colloids of zir-
conium and hafnium dioxide. 
3rd, For the same purpose a further animal group will receive 
Th-230 enriched Thorotrast according to the suggestion of 
Dudley and applied by Bensted and Taber in their hitherto 
unoublished works. 
Animal which will receive Thorotrast from own production 
and non treated animals are provided for controls. 
For the production of ZrO« aquasols the common procedure con-
sisting in the peptization of freshly precipitated hydroxids 
and the cationic condensation of Zirconyl-salts was employed. 
18) According to a dutch patent the peptization ensues after at 
least 2k h cooking of the zirconium hydroxide coagulate under 
reflux afterwards the pH-value was adjusted to the range bet-
ween 0,6 and 2 by moans of cone. HC1. 
Figure 2 shows the electron micrographs of the particles of 
the ZrO.-sol as obtained according to the preceding method. 
We failed to obtain the particle diameter distribution of 3 to 
20 nn as quoted by the dutch patent and determined by x-ray 
diffraction, and which is comparable to that of Thorotrast 
(see fig. 3). Our particle diameters extend the range between 
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Fig.k Electron micrograph of ZrO--sol particles obtained 
by condensation 
4"\ '\5!li»i. 
b * «»•'• J l •••. v a» 
Fig.5 Electron micrograph of ThO. particles of commercial 
Thorotrast (v. Heyden Co«) 
fflmmam 
Fig,6 Electron micrograph of ThO, particles of Thorotrast 
from our own production 
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25 and 75 nm (see fig. 2 ) . 
The condensation of hydrolyzed ZrOCl. in presence of dextrin 
as protective colloid after successive addition of a weak basic 
exchange resin yielded better results with regard to the par-
tiel* size distribution. The particle sizes of a sol e.g. con-
taining as much ZrOCl2 as equivalent to 12 £ ZrO? cover the 
range of 10 to 70 nm for the diameter (see fig. 4 ) . 
Particle diameters between 3 and 7 no should be expected if 
19 20) the condensation would be carried out by electrodialysis '. 
These experiments are underway. 
Due to the identical chemical properties of hafnium and zir-
conium the aquasols of hafnium dioxide can be produced by the 
same method. 
Thorotrast has been produced according to the procedure 
21) given by the former manufacturer v. Heyden Co. . 
The first step is the production of a stock sol containing 
about 50 % Tb°2 O D t * t n 9 d D v peptization of freshly prepared 
TbX>2 by means of 0,2 n HCl as peptize tor. The Th0 2 used has been 
produced by thermal decomposition of Th(C„0. )0» 6 H-0 at 530 C 
22) in an electric .furnace. ThfC-O.) • 6 H_0 was precipitated out 
of a nitric acid solution of Th(NO-)^- 5 HgO (p.a. quality rec. 
from Merck Co., Germany) by addition of oxalic acid in excess. 
The concentration of the stock sol was adjusted to 37*5 $ 
and than stabilized by successive addition of yellow dextrin 
(Kartoffelflocken- und Starkefabrik eGmbH, Schrobenhausen, 
Germany) In portions. The pH-level of this stabilized sol was 
repeatedly adjusted by addition of 25 £ NaOH to 8,3 since the 
pH-value changed after heating for half an hour at 120 C. 
Finally the sol was diluted to 25 % Th0 2 w/v. 
The particle size distribution of the sol obtained in the 
described manner has proved to be in agreement with that of 
commercial Thorotrast (see fig. 5 and 6 ) . 
For the production of Th-230 enriched Thorptrast* Th-230 
being only available as Th0 2 must be transferred into soluble 
form in a sodium pyrosulphate melting. The resolved melting 
may b* precipitated as oxalate together with the calculated 
amount of 2 3 2Th(N0-) 1 |. 
In order to obtain alpha energy emission-rates being on* 
hundrad tines higher than those of commercial Thorotrast an 
activity ratio Th-230/Th-232 of about 800 is necessary. 
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The effect of Thorotraat enriched with Th . 
by 
H. Faber 
The Finsen Laboratory, 
The Finsen Institute, 
Copenhagen, Denmark. 
2^0 Ihorotrast enriched with Th ' to an a-activlty 7 to 49 times 
normal when injected into Rabbits in a high dose (10 ml) and 
a low dose (0,3 ml) showed a shortened latency period for haem-
angioendotheliomas compared with commercial Thorotrast, demon-
strating the significance of the radiation in carcinogenesis. 
29S 
The chronic irradiation delivered by Thorotraat differs 
from other chronic internal radiations by the fact that the 
scource of the radiation is present as particles• and that 
these particles stay unchanged in the body apart from an in-
crease in.particle else with time (vuimaraes and Lamerton). 
This gives a possibility for two different carcinogenic mecha-
nisms, the radiation and the particle action. 
In order to permit an evaluation of the cancer mortality 
in Thorotraat injected patients as a pure radiation effect it 
is necessary to separate the action of the two carcinogens, 
in order to be sure that the particles only represent a minor 
factor in carcinogenesis. It ia not possible to produce radio-
activity without the granules, but a change in the specific 
activity of the granules should be able to give part of this 
information. 
Such an increase could be produced by introducing a 
Thorium isotope into the Thorotrast and Th ' with a halflife 
•w 226 
of 80 z \<y years which as daughter produces Ba with a 
22 halflife of 16 years would appear ideal. 
Through the help of dr. Dudley, IAB1, Th 2 3 0 was procured 
and fresh Thorotrast was produced through the kind help of dr. 
Wiedemann at the Beyden Chemical Co., Munich. 
The Th2'2 used was prepared f m old Thorotrast. In this 
way the daughters released during storage would be reduced due 
to their adherence to the glass of the ampules in which they 
had been stored (Bundo). In actual fact the Thorotrast produ-
29« 
ced had an a-activity of 1/4 of the expected if the In2'2 
had been in equilibrium. 
three preparations were produced. One oontained the de-
pleted Th ^  only. In preparation 2 th *^ was added to give 
an increase in o-activity by a factor of 7> in preparation 3 
this activity was raised to a factor of 49. this was obtained 
by adding 1 uCi Th250 per g Th2'2 in preparation 2 and 7 iiCi 
Th per g in preparation 3. 
All aniaal experiments were performed on rabbits, and 
a number of experiments were visualised. * medium dose which 
would permit an adequate deviation in the results in a not 
too distant future was selected on the basis of previous rab-
bit experiments (Pig. 1) to be 10 ml per rabbit. 
the first three experiments were performed using the 
depleted and the two enriched Thorium preparations in combina-
tion with a fourth using fresh commercial Thorotrast from 
another scource. these experiments were later extended by an 
experiment where a dose of 0,3 ml of the most enriched Thoro-
trast was injected in order to study the effect of a low che-
mical dose - tat a radiation dose comparable to the dose from 
control injections in the first set of experiments. 
A summary of the first four experiments is given in Pig. 
II and Table I. 
Shortly after the injections it became evident that the 
group 3 Thorotrast had too high an activity. The animals died 
during the first year of observation from liver insufficiency. 
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partly icteric, and with a liver which histologically showed 
clear signs of a radiation produced liver cirrhosis with re-
generating nodules free of Thorotrast surrounded by connective 
tissue containing degeneration cells and with the Thorotrast 
in general in phagocyting cells. The weight of the liver had 
decreased to approximately half the normal liver weight (Table 
II). The largest decrease in size was found in those animals 
who died first. In this group only one haemangioendothelioma 
developed 94 weeks after injection. 
The rabbits from the three other groups showed a beha-
viour comparable to the previous control material. The mean 
age at death from tumors in group 2 was 103 days. In those 
injected with.depleted Thorotrast the age was 147 days. The 
two control groups, one from the old study and the other with 
commercial Thorotrast showed mean ages at tumor death of 151 
and 126 days. This means that the last three groups had a du-
ration of life until death from tumor longer than was the case 
for the Th ' containing Thorotrast in group 2. It has not 
been possible in these experiments to demonstrate a difference 
between the depleted Th and the two commercial preparations. 
As both of these were prepared by a manufacturer different 
from the one preparing the experimental samples these diffe-
rences may have had a number of reasons. It is known that the 
•ode of production and the carbohydrate used to stabilize the 
colloid are different from the ones used in the experimental 
batches. 
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When the ren>jlrement for space in the animal house was 
decreasing through death of the animals the fifth experiment 
was started. In this only 0,3 ml Sr. 3 Thorotrast was used. 
The results of the experiment can be seen in Fig. Ill and Table 
III. The mean time between injection and death of tumor was 
found to be 249 weeks. If this should be an effect due to the 
effect of normal Thorotrast, it could be expected from the 
line drawn in Fig. I through the tumor cases produced by dif-
ferent Thorotrast doses that the tumors should appear some 
700 to 800 weeks after injection, or after the death of the 
rabbit, which according to our experience should take place 
before 550 weeks without tumors as can be seen from the 0,6 ml 
experiment, If we disregard all differences in selfabsorption, 
differences in distribution and lack of daughter shifts etc. 
and only consider the absolute a-activity, the latency period 
could be expected to compare with the 15 ml experiment, where 
the mean latency is less than the 150 weeks found for the 10 
ml experiment. 
In actual fact the 0,3 ml enriched corresponds closely 
to the 4,5 ml experiment where the mean was found to be 239 
weeks. 
The reason for this fit to a lower Thorotrast dose can 
not be given. It requires a full understanding among other 
things of the relative change in size of the granules with timi. 
and of the differences in relative distribution of Thorium in 
liver and spleen, factors which are not known. 
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There can, however, be no doubt as to the significance 
of the radiation for the production of the haemangioendothe-
liomas in the rabbits both when high doses of Thorotrast 
were used and in the low dose experiment as far as the latency 
period of the effect is concerned. This is most aarked in the 
low dose experiment where the decrease in latency period hat, 
brought the tumor manifestation inside the lifespan of the 
rabbit. 
It is of course regrettable that the high dose experi-
ment was performed with too high a dose, an effect which was 
made more evident because both the experimental preparation 
and a commercial one tended to act with latency periods shor-
ter than the previous experiment from which the doses were 
estimated. 
It is evident that a comparison between incidences of 
haemangioendotheliomas among the different groups is of no 
value. In the group 3 experiment the rabbits died from non-
specific liver damage before a tumor could develop and in the 
0,3 ml experiment as in the other long lasting experiments 
uterine cancer was the most common cause of death when a haeaan-
gioendothelioma was not present. 
The question as to whether a theoretical non-radioactive 
Thorotrast might have a carcinogenic effect can not be answe-
red through these experiments. 
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TABLE I. 
The 10 ml Experiments. 
Type of Thorotrast used o r 
Enriched Gr. 3 1/17 
Enriched Gr. 2 15/20 
Depleted Gr. 1 9/17 
Testagar 12/23 
Previous series 17/22 
incidence 
* 
6 
75 
53 
52 
77 
Mean 
latency 
period 
weeks 
94 
103 
147 
136 
151 
Gr. 1 
Gr. 2 
Gr. 3 
Testagar 
0,3 ml Gr.3 
TABLE 
Weight 
Mean Weight 
e 
132 
122 
66 
123 
107 
of 
II. 
' Liver. 
Spread 
g 
59-233 
80-174 
39-114 
69-195 
65-245 
Type of Thorotrast 
Normal 
Normal 
Normal 
Enriched Gr. 3 
T 
Amount 
ml 
7 
4,5 
1,5 
0,3 
4BLE III 
Tumor : 
16/19 
18/22 
1/8 
13/22 
incidence 
* 
84 
82 
13 
59 
Latency 
period 
weeks 
187 
239 
315 
249 
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The Stability of Leukemogenic Risk in Human Marrow 
Irradiated by a Rays 
L. D. Marlnelli 
Center for Human Radlobloloqy 
Radiological and Environmental Research Division 
Argonne National Laboratory 
Argonne, Illinois 60439 
Abstract 
Comparison between the latent period of leukemias and the corres-
ponding man-years at risk In the Thorotrast-lnlected patients of Denmark 
suggests that the leukemogenic risk per unit absorbed dose of chronically 
delivered a-radlatlon remains constant in time. This result Is In contrast 
with the decline observed in leukemias Induced by x radiation in thera-
peutically treated spondylitics. 
Key Words: Thorotrast 
Leukemia 
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Data on Irradiated spondylitics show a decline in leukemia incidence 
five to ten years after therapeutically administered x-ray radiation."' 
Atomic bomb survivors of Hiroshima and Nagasaki^) irradiated with a mix-
ture of neutrons and y rays also show a similar general trend, but the rela-
tively small number of cases at hand precludes drawing any conclusion as 
to whether the decline observed in delayed leukemogenesis depends on the 
LET of the radiations. A preliminary test of the permanence of a leukemo-
genic risk induced by high LET radiation delivered at low dose rates can be 
made, however, by examining the results published by Faber^ on the epi-
demiology of patients injected with Th02 (Thorotrast) for cerebral angio-
graphy. 
The test of the hypothesis proceeds as follows: Let n be the number 
of leukemia s appearing within t years post-injection, and let D be the 
average dose rate to the marrow of the population N (about 0.3 to 0.5 
rads/year/cc injected). If one assumes that the number of leukemias in-
duceo per unit dose per man year at risk is constant in time, then the 
increment, dn, in the number of leukemia cases observed in an increment 
of time, dt, at the end of t years, is given by 
dn = t Dt N dt, (1) 
where c is the (constant) leukemogenic efficiency. We have taken D to be 
constant with time although, per cc injected, it decreases somewhat in the 
first few years after injection. tt»5) In Eq. (1) the product N dt is seen to 
be the number of man-years at risk during dt at accumulated dose 6t. 
Integration of Eq. (1) leads to the number of cases, n(0,T), accumu-
lated during a period from 0 to T years after injection as follows: 
n(0,T) = i D J t N(t) dt . (2) 
If N(t) is constant, the accumulated number of cases of leukemia would be 
expected to increase as the square of time after injection, since 
T
 • T2 
n(0,T) = t D f t N dt = c D N Y . (3) 
0 
If N(t) does not vary according to some known function of time, a 
closed expression for n(0,T) cannot be obtained. In this situation we may 
sum the dose man-year contributions in small intervals of time. Expressing 
Eq. (1) in finite steps, we have 
in = i D t N i t 
and 
n(O.T) = £ an - t D? t N At . (4) 
1=1 i=l 
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In Eq. (4). D t"t is the average accumulated dose in interval i, and N at is 
the number of man-years at risk during i t . ' ' 
Assuming that_N changes linearly during short time intervals, the 
appropriate value of t"t Is the time from injection to the middle of the time 
Interval. Thus. Eq. (4) becomes 
n(O.T) D V (, - - i 
1-1 2 > V
l i (5) 
A straightforward test of whether Faber's observations are consistent 
with the hypothesis of constant leukemogenic efficiency consists in verifying 
whether the following is true [from Eq. (5)1: 
n(0,T) 
z v 
1=1 * 
T , M t M i 
(6) 
where m » T/at. This test has been applied to the data of Faber. exclud-
ing the man-years accumulated by patients dead (mostly of neurological 
diseases) within the first three years after Thorotrast injection. The latent 
periods of the deaths from leukemias and the number of man years at risk 
accruing to the total population until the death of each case are shown in 
the first three columns of Table 1. 
TABLE 1 
Leukemia in Danish Series of Thorotrast-lnjected Cases. 
Relationship between Number of Accumulated Cases 
and Sum of Accumulated Man-Years at Risk. 
(number of 
leukemias) 
T 
(latent 
Period, vr) 
T/at at 
fVT'V ' i no'3) 
Thorotrast 
injected, 
(a), 
8.85 
10.15 
14.1 
17.1 
19.5 
21.5 
21.8 
27564 
35649 
64803 
91046 
123940 
133540 
143390<a> 
3.63 
5.61 
4.63 
4.39 
4.03 
4.49 
4.86 
•> 
2!) 
48 
50 
30 
24 
•> 
Average 4.49 ± 0.45 a.d. 
This case died during the year following completion of the follow-up. 
The corresponding man-years at risk have been computed assuming that 
all the 475 patients alive by that date were still alive when this patient 
died of leukemia. 
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The values of c' shown in column 4 of Table 1 are indeed remarkably 
constant, considering the small number of leukemia cases and the long 
interval of time involved. Note must be taken, however, that the analysis 
above may be considered meaningful only insofar as the average injected 
dose to the patients remaining at risk remains constant with time. Although 
this epidemiological detail is lacking in the data, one may assume that D 
cannot vary very much on the average because 76% of the population at risk 
has remained alive in the time interval luring which all seven cases of 
leukemia have appeared. The influence of dose rate and total dose is strongly 
suggested by two observations, namely a) that the known average dose in-
jected in leukemia cases is definitely higher (34.4 cc) than the average of 
all injections (23. 3 cc), and b) that irrespective of the average time at risk, 
which is unknown for each dose category, the incidence of leukemia in-
creases with dose as follows: 0% of the 349 cases injected with less than 
20 cc, 0. 26% of the 324 cases injected with 20 to 29 cc, 1.1% of the 
91 cases injected with 20 to 39 cc, and 2.4% of the 84 cases known to have 
been injected with more than 40 cc (Faber, (3) Tables 6 and 7). These figures 
are not individually significant, but the trend with dose is compelling. 
It is obvious that a more precise analysis of these questions could 
be made if, in addition to the data submitted, additional dosimetric inform-
ation were given, such as the average dose injected in patients at equal 
intervals of risk, and conversely, if the average time at risk were cal-
culated for each group injected with approximately the same amount of 
Thorotrast. Obviously, of greatest Interest would be an extension of the 
data already published by da Silva Horta and Cayolla da Motta, O to include 
dosimetric information concerning the detailed distribution of both injected 
dose and man-year at risk within the injected population. 
In conclusion, it may be stated that, contrary to evidence for low 
LET radiation (at high dose rates), the leukemogenic risk induced by 
a-radlation (delivered at low dose rates) can be interpreted to be a constant 
for intervals ranging up to more than 20 years post-injection. This resu' 
is in accord with the general radiobiological findings that there is little or 
no recovery from the effects produced by high LET radiation. 
Acknowledgments 
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Dose e f f ec t relations in hepatic ctrclr.a-renesis. 
»y 
H. Faber 
The Piosen Ii*bor?itory. 
The Finsen I n s t i t u t e , 
Copenhagen, Oerjrark. 
The re la t ive s ignif icance of radiation ftnd physical tox ic i ten 
of Thorotrast has to be solved in num. An ittempt to give a 
risk es t iaate on the basis of cuculat«d doses to the l i v e r i s 
presented. The r e s u l t s f i t s the published risk estimates for 
other types of radiation induced tumors. The procedure for the 
calculat ion of absolute risk i s given. The risk i s c-%lcul»ted 
to be 0,42/10 "persons"/year/Rem. 
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The preoccupation with Thorotrast induced tumors has a 
number of reasons quite apart from the nosological description 
of a chronic toxic state. 
The patients injected represent one of the largest pools 
of information on the effect of chronic irradiation of paren-
chymatous tissue with a high LET radiation. 
As mentioned previously in this meeting one of the more 
significant problems is to what extend the toxic effect is due 
to the presence of Thorotrast granules and to what extend the 
radiation can be the cause. We have previously in animal experi-
ments demonstrated that the radiation is of definite significan-
ce as far as the latency period of the induction is concerned 
and in this way probably of significance also for the rate of 
appearance of tumors. 
It would however be of interest to study whether the in-
formation collected from a human population could contribute 
to this question. 
If we look at the influence of the amounts of Thorotrast 
injected in the three types of malignancies due to Thorotrast 
and compare with the doses Injected Into non Thorotrast can-
cers and into the total material we get the results seen in 
Table I. It is evident that the number of patients with the Tho-
rotrast dependant malignancies who have received doses in the 
upper reaches is higher than both in non-Thorotrast malignanci-
es and in the general Thorotrast population. This could indica-
te that higher doses Increase the risk for tumors, but give no 
quantitative guidance. 
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The radiation from Thorotrast contains both a- and ppar-
ticles. The calculation of a correct radiation dose is however 
complicated by a number of other factors. Of these the selfab-
sorbtion in the Thorium dioxide granules, the shift of break 
down daughters out of the granules and their disintegration with 
emission of a- and ^partieles at other places have been thoroug-
ly studied (Kundo (l), Kaul (2)) and can to a large extend be 
corrected for in the calculations. It is however at present not 
possible to correct for the temporary uptake of Thorium dioxide 
in the hepatocytes, for the perpetual shift in the place of de-
position of at least part of the Thorium and for the place of 
final deposition in connective tissues which will then prolife-
rate and bring the nepatoeytes at least partly outside the range 
of the a particles. 
In the further treatment of the dose dependency only the 
cumulative doses to the liver shall be considered. The dose has 
been calculated for each case taking the amount injected and the 
time of stay in the body into account by means of the curves for 
cumulative a and f doses published by Kaul (3). Patients who had 
died less than 7 years after the injection were excluded. - This 
excludes less than 30 cases and only a single case of leucemia. 
The resulting cumulative doses for the different grou-
pings in the material have been collected in Table II and the 
mean cumulative dose per patient has been estimated. A compari-
son between the groups shows some interesting differences. It 
was expected that the cumulative dose to the liver was lowest 
in the patients dying from non-cancer diseases. A somewhat hig-
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her mean cumulative dose was found in the patients dying from 
non-Thorotrast malignancies, and the highest dose was delive-
red in the patients dying froa Thorotrast malignancies. Among 
these the dose was highest in the haemangioendotheliomas. 
These results fit reasonably well with the picture given 
by the amount of Thorotrast injected into these groups. 
If we however look at the dose delivered to the liver up 
till now in the patients still living we find that this dose is 
the largest of all. 
This result can not be unexpected. If the distribution 
of injected doses in the Danish material is taken into conside-
ration where most of the patients have received 20 ml or less, 
this distribution with the load on the smaller doses will in the 
calculations of. the radiation dose tend to give much weight to 
the duration of the carrier state. This is also of importance 
when the dose to patients dead froa Thorotrast cancers is consi-
dered. Due to the long latency period it has been possible for 
these patients to accumulate a larger radiation dose before 
death than if no latency period was present. 
The spread of the radiation doses to the liver is in ge-
neral limited when longevity is not the reason. Until further 
information is present the patients must be considered as having 
been exposed to a single mean dose only. A separation as the one 
which was possible in the radium carriers as described by Kow-
landes et al. (4) is not possible for the Thorotrast patients. 
From the results so far it is still difficult to evaluate 
the significance of radiation as a carcinogenic agent in this 
human group. 
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It might therefore be useful to study the risk for can-
cer and then to compare the ripU as a dose effect relationship 
with what is known from other types of human radiation exposures 
which have recently been summarised in the U.S. National Academy 
of Sciences (5) report. 
The risks can be calculated in a number of ways. 
The risk expressed as the increase in percentage of tu-
mors per 100 rads delivered to that organ of the patient which 
is under study, in this case the liver is suggested by Pochin 
(6). 
This can be calculated on the whole of the material to be 
0,88$, a figure which would correspond to the one expected from 
other human materials, if we take into consideration that the 
BBE of the predominant radiation may be up to 10. 
It is however possible that a better doseeffect relation-
ship could be obtained if only that period of time was conside-
red when the tumors actually occured. With an observed minimal 
latency period for leucemias of 5 years and for the solid tumor 
of 15 years a compromise at 7 years has been made which corre-
sponds to the time when the curve for the dose to the liver 
flattens out and becomes horizontal. If this line is used as 
basis for the calculations the relative risk will rise to 1,24$, 
a perhaps more reasonable expression for the risk. 
Both figures correspond well to the figures cited by 
Pochin of 0,1 - 0,5 for different types of tumor. 
In the 0.8. K.A.3. (5) Report three types of risk estima-
tes are used. The simple Relative risk of °jj?* will for the 
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liver tumors give 56. 
From this the % increase in relative risk per Rem can 
55 be calculated to be dose i a Rem. For the two possible 
mean doses this will give 1,27 and 1,80. Again these figures 
are in reasonable accordance with the figures cited in the Re-
port which in most tumors and leucemias cites values below 0,20. 
For all cancers in the A-bomb cases, and in a number of the Ra-
dium series give higher figures. 
The probably most interesting calculation in the estima-
te of absolute risk expressed as cases/10 persons/year /Rad. The 
formula generally used „ 0 o{ p e r s o n _ ^ ; ; {££ ; J. 1™ t l 3 s u e 
The problem in the calculation will be to give a meaning-
ful definition of the concept: person years when it is the re-
sult of a chronic irradiation which is under study. The Thoro-
trast patients should be well suited for such a calculation. 
Certain assumptions have however to be made. 
It would be useful if we could make the assumption that 
the yearly increase in radiation induced tumors after a given 
acute radiation is constant when the latency period has been 
passed. It is doubtful whether this is the case, but for a cal-
culation with a primary interest in orders of magnitude of ef-
fects this assumption can be considered acceptable. In the case 
of the Thorotrast patients this may even appear to be correct 
when it is considered that early and late radiation effects are 
manifest at the same time. 
It would be of help if the dose delivered each year to 
the organ would be constant. In the Thorotrast cases this can be 
considered as funfilled according to the dose calculations of 
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Kaul (3) if we disregard the first 7 - 8 years. As these years 
correspond to the latency period this procedure would be accep-
table and would probably lead to correct estimates. 
The third assumption is that the dose delivered each 
year can be treated as a single acute irradiation which in its 
effects will act without interference from the doses from other 
years as far as carcinogenesis is concerned. This model would 
appear probable but has not been proved. 
If we then consider the yearly dose as the radiation 
unit and the cumulative number of years of observation after 
each such year as the person years in the formula we reach a 
figure of 0,42
 l 6 ^ \ ' ^ x 10 
Again a figure of a dimension which fits well with the 
results obtained in other radiation induced tumors where the de-
livery of the radiation ia acute and in a single dose. 
The results of these calculations all point to one con-
clusion. It is with the present knowledge of dose calculations 
possible to reach a figure for the dose to the liver through 
which it is possible to correlate the effects observed in Thoro-
trast cases with effects seen in man after other types of ioni-
sing radiation. 
The results must furthermore be taken as a strong indica-
tion that the effect of Thorotrast in man is due to the radia-
tion and that the colloid although serious histological effects 
can be seen in the tissues as far as carcinogeneeity is reaso-
nably inert. 
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Table I. 
Relative distribution of injected 
dose of Thoriua dioxide solution. 
Injected 
a l 
5 - 9 
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50 
unknown 
A l l 
* 
1 
43 
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3 
8 
cases 
æan 
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4«8t«t*jQf Collaboration relating to Follow-up-studies 
•7 
H.Immich 
Department of Ke>lical Documentation and Statistics of The 
University od Heidelberg, D-69 Heidelberg,Federal Republic 
of Germany 
Abstract 
The necessity of international collaboration in order to pet 
relevant and valid information on the thorotraat carrier 
group is out of doubt. Some reasonable conditions must be 
observed. Usual statistical models are not suitable for eva-
luation of data obtained by foll«w-up-studies. Only that is 
the reason why the publication of original dpte should be re-
commanded. 
As Dr. Faber says in the invitation paper for the present 
meetimg:"The thorotrast carrier group is slowly dying out. 
This state requires an international collaboration in order 
to get as much relevant information as possible fro« the 
study of this population." I should like to call your atten-
tion to sone aspects of this important requirement. 
2i2i2HS-S225ili2S£_2i_22ll£i2££5i2S 
The scheme of the investigation technique must be homogene-
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ous as well as the data recording system. It seems to he de-
sirable from experience to develop a standardized hesie pro-
gram as snail as possible, concentrated only on relevant in-
formetion.In this way we are able to avoid an overwhelming 
influence of different physicians, different laboratory and 
radiological techniques in the various countries.The develop-
ment of such a basic program needs further discussion, espe-
cially under the aspect: Which information is relevant? Which 
information is valid? 
International collaboration may also be influenced by the 
proportion of the total number of thorotrsst-administered 
patients, which is under investigation in the different coun-
tries. i£véry effort must fee made to increase this proportion, 
where and if necessary. 
All_Follow-ug-studies_will_be_Cohort-studies 
Although nearly essential, the assumption is unrealistic 
that follow-up-studies could be carried out together with 
one or more control-groups. You can convince a health per-
son one time, to undergo a health-check-up of the whole bo-
dy, in extreme cases twice; but you cannot hope to find po-
pulations like the Freminghem one in order to perform thoro-
trast follow-up-studies on the international level. This 
fact leads directly to so called cohort- or profile studies , 
or,from the statistical point of view, to one sample studies 
over the time with implications as follows: 
(i) You can test hypotheses with the respective data of the 
various countries only. E.g.: You can compare the incidence-
rate of any riven malignancy in the thorotrast-group with the 
incidence-rate of the respective population under the assump-
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tion tket the incidence-rate of tke populatioa is kotk a eoa-
stsat Bad • well-known parameter. However,this essuaptioa is 
unrealistic very often. 
(ii) If you «isk to auks estiaatioae, e.g. prognostic calcu-
lations for expected toaor incidences, the question i>rises: 
Mast is tke uaderlyiag statistical aodel for estiaetioa? 
Usually we do assume tkat all elaaeats of tke saaple are ia-
depemdeat. Tkis assuaptioa is true, if yon estiaate ky aeaas 
of a cross-sectioa-study. Estiastioas ky aeaas of follow-np-
atudiea are dangerous. Because tke estiaatioa two, four or 
six years later tkea tke onset of tke study are coaditioaal 
estiaatioas at best.However,the FreaiBghaa-study is a typi-
cal exaaple, what happens, if you aake estiaetioas from aa 
universe, which eleaeats are aot iadepeadeat oae froa each-
other. 
(iii) la tkis position we are akle to use the ao called li-
fe takle aetkod, either for tke survival tiae or for tke ti-
ae uatil tke first aaaifestatioB of aay aeligaaacy. However, 
tkia aethod depends firstly of tke length of iatervsl ke-
tweaa two ekeek-ups. Tkis interval will ke ia practice at 
least two years, ia teres of tke life takle aethod a very 
loaf tiae. Secondly,tke evaluation is toucked ky tke auaker 
of drop out-aeabers of tke cohort during any gives interval. 
I usiag the life takle aethod, considerable efforts aust ke 
aade ia order to keep tke drop out as saall as possible. 
(iv) These tkree iaplicstipas lead to the conclusion: We ha-
ve to avoid all highly sophisticated statistical aetkods 
aid havs to observe and record oaly, what happens every two 
years with our cohorts. The need of collecting relevant and 
valid iBforaetioh if out of discussion. But in ay feeling we 
•re obliged to publish all original data, that aeans, to 
aake a descriptive evaluation oaly. 
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Expected I*te Effects In Thorotreat Patients ») **) 
H. MUTH 1 \ B. OBERHAUSEN 1'f R. KUNKEL *> w U. HERZFELD Z' 
1) Institut fttr Biophysik der UtaiversitSt des Saarlandes* 
Homburg (Saar) 
2) Department of Clinical Radiology, University of Heidelberg 
Abstract 
The paper reports the results of biophysical examinations ot 
about 5^ *0 thorotrast patients« Measurements vere made of the 
total-body radioactivity and of the thoron concentration in 
the exhaled air. Taking into account the results of special 
animal experiments and using the results of the direot mea-
surements on the patients A. XAUL has calculated both the 
dose rate as a function of the age ot the thorotrast burden 
and the accumulated radiation dose in different organs of 
the patient. The average values as veil as the upper limits 
of the radiation exposure of the different organs (liver, 
spleen, marrov-free skeleton, bone marrov and lungs) are 
given. Using these data and the most probable values for risk 
coefficients published, the expected radiation induced late 
effects (leukaemia, bone tumours, lung tumours and liver 
*) Sponsored by Euratom and the Bundesminister fttr Bildung 
und Vlssenschaft of tbe Federal Republic of Germany. 
**) Dedicated to Prof. Dr. 8. Rajevsky on his 80th Birthday 
321 
tumours) in a thorotrast group were estimated and discussed. 
The results shov qualitatively the importance of follow up 
studies of thorotrast patients for gathering optimal and use-
ful radiobiological data. 
Key words: 
Thorotrast 
Radiation dose 
Risk coefficients 
Late effects 
Follow up studies 
Introduction 
In this paper are summarized some more or less speculative 
ideas concerning possible late effects to be expected in tho-
rotrast patients. 
So far it is the general opinion fl] that the following late 
effects of thorotrast must be taken into considerationt (l) 
granuloma and tumours at the site of injection; (2) tumours 
of the liver and (3) leukaemia; whereas the formation oft 
(k) lung tumours and (5) bone tumours is questionable. 
Concerning the late effects of (l) and (2) and to a certain 
degree of (3)» there is not only the effect of ionizing ra-
diation but the effects of other factors (for example chemi-
cal and mechanical effects) which may be partially respon-
sible for the carcinogenic properties of thorotrast [JQ . 
Horeover, with respect to the effects of (1) and (2) there 
are no groups of persons with whioh to compare the same late 
effects caused by other sources of radiation and in other 
dose ranges. These reservations do not exist for the effects 
°f (3)* (^ ) *nd (5). The investigation of thorotrast patients 
may therefore -above all- provide results with respect to a 
relationship between the effective radiation dose and the in-
cidence of leukaemia, lung tumours and bone tumours. At the 
same time It should be pointed out that a negative statement, 
322 
which means no significant increase of tumour Incidence com-
pared vith the spontaneous incidence, may be as important as 
a positive one. 
Results of Whole-Body Measurements and Estimation of the Ra-
diation Dose in Liver, Spleen and pone of Thorotrast Patients 
The measured total body burden of Tl of the thorotrast pa-
tients varies betveen about 10 nCi and about 1000 nCi. Vith 
the knowledge of the excretion rates of the different decay 
232 232 
products of Th the total body burden of Th can be calcu-
232 lated. From the ipecific Th-activity of the colloidal 
ThOp-solution then the total amount of thorotrast injected 
can be estimated vith an accuracy of 10 - 15 jt for patients 
without paravascular deposits and of 20 # fox* patients vith 
paravascular deposits Q)] . The lover limit of measured Tl-
activity of 10 nCi corresponds to an injected amount of thoro-
trast of about 1 ml. The upper limit of 1000 nCi corresponds 
to about 110 ml. 
Fig. 1 gives the distribution (#) of the injected primary tho-
rotrast solution (ml) for 53** cases. Only 11 jL of the pa-
tients were injected vith more than **0 ml vith an average of 
50 ml corresponding to a measured Tl-activity of about kZO 
nCi. 
For purposes of estimation of radiation dose in the different 
organs of interest a mean value of 15 ml thorotraat primarily 
injected seems to be a reasonable figure. According to the in-
vestigations of KAUL |7Q (VJ radiation dose rates and cumula-
tive doses can be estimated. The calculated mean radiation 
doses from alpha particles in liver, spleen, bone marrow and 
skeleton are summarized in Table I, assuming an average of 
15 ml and an upper limit of 50 ml thorotrast solution injec-
ted. The contribution of beta and gamma radiation to the total 
absorbed dose only amounts to betveen about 5 $ and 10 96 and 
can be neglected. The mean exposure time of all patients exa-
mined was 30 years. The dose rates of alpha radiation after 
injection of 20 ml thorotrast are in the order of 0,5 rad/week 
(liver), 1 rad/veek (spleen) and 0,01 rad/veek (skeleton) \jy}. 
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TABLE I . ABSORBED DOSE IB BADS PROM ALPHA PARTICLES 
IB PlilUUIII OBCABS OP THOROTRAST PATIERTS OVER A 
PERIOD OP JO TEARS 
ORGAN 
LIVER 
SPLEEB 
ROBE HARBO« 
SKELETOM 
AVERAGE 
(15 il) 
too 
iboo 
2»0 
20 
UPPER LIMIT 
(90 ail) 
• 100 
J0O0 
900 
70 
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Results of Measurements of Thpron Concentration in the Exhaled 
Air and Estimation of the Radiation Dose Distribution in the 
Lungs of Thorotrast Patients 
The thoron concentration of the exhaled air of each thorotrast 
patient was measured vith a special equipment and method deve-
lopped at our institute |j]. It varied between 1 x 10~ Ci/ 
litre and 60 x 10~ Ci/litre. According to the procedures and 
results given by R. GRILLMAIER in a paper at this meeting 0 0 
[9J , the absorbed dose : in the lungs of thorotrast patients 
from alpha particles of thoron and its short-lived daughters 
were estimated for an average injected amount of 15 ml and an 
exposure time of 30 years. The results are given in Table II. 
TABLE II. EXPOSURE OF LUNGS OF THOROTRAST PATIENTS 
(EXPOSURE TIME TO YEARS AFTER A 15 ML-INJErTION 0* 
THOROTRAST) 
PART OF THE EXPOSED LUNfi 
BRONCHI 
MAIN BRONCHI 
TRACHEA 
ABSORBED DOSE FROM 
ALPHA PARTICLES (RAI)S) 
50 
230 
370 
It is known that after inhalation of Rn-decay products by 
uranium miners the maximum radiation exposure and the induc-
tion of lung cancer occurs in the region of the bronchi. ¥ith 
thorotrast patients the absorbed dose in the bronchi is only 
50 rad. In comparison, the absorbed dose in the main bronchi 
amounts to more than ZOO rad and the maximum dose of about 
400 rad is in the trachea. 
325 
Expected Late Effects 
Bone tumours i 
The mean alpha radiation dose of marrov-free bone of thorotrast 
patients is about 0,7 rad per year corresponding to the absor-
bed alpha ray dose from about \(k of the maximum permissible 
body burden of Ra (0,1 [iCi Ra: 3 rad per year). The lack 
of any statistically significant increase in bone tumours rate 
of thorotrast patients relative to a suitable control group 
QO] may be considered as an important additional support for 
the maximum permissible body burden of 0,1 *iCi for Ra, as 
recommended by ICRP and for the corresponding limits for all 
other bone-seeking radionuclides related to Ra. 
According to the new data reported by A. KAUL in one of his 
papers, read at this Meeting [Ti] the mean dose in marrov-free 
skeleton probably is higher than 0,7 rad per year (about 2 rad 
per year for an injected amount of 15 si thorotrast), correspon-
ding, to 2/3 of the alpha ray dose from 0,1 ^Ci Ra. Even by 
taking into account these higher values, our general conclu-
sions concerning the possible incidence of bone tumours are not 
changed. 
The paper given by R. E. ROWLAND |12) , has pointed out some 
new aspects of this problem by comparison with the findings 
of SPIESS and MAYS with Ra-injected patients fi 3! . The 
accumulated dose from translocatable Ra to bone surfaces 
of thorotrast patients estimated by ROWLAND and RUNDO is about 
60 rad in 30 years for an injection level of 50 ml. It is evi-
dent that this dose is only a fraction of the mean dose of the 
marrow-free skeleton calculated by KAUL (about 220 rad in 30 
years) H i ) * We need further follow up studies of thorotrast 
patients to decide, whether only bone surface dose is respon-
sible for tumour incidence. 
Leukaemia t 
The mean dose-equivalent of the bone marrow is about 90 ram 
per year (Table I) assuming a quality factor of 10 for alpha 
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particles. On the assumption that a single exposure of the 
bone marrow causes an increase of the incidence of leukaemia 
during the subsequent 10 years with an average increase of 2 
cases of leukaemia per rem per 10 persons each year, the re-
commended value of the risk coefficient would be 20 per 10 
man-rem |f*», 15, 16, Ty . On the assumption that a continuous 
exposure of the bone narrow caused by thorotxast is as effec-
tive as a single whole body exposure (see Qol Q7J ) a mean 
dose-equivalent of 900 rem (exposure time 10 years) would be 
responsible for an increase of leukaemia incidence, That 
means, that about 2 additional cases of leukaemia have to 
occour among 1000 thorotrast patients per year. Within a fol-
low-up time, for example of 10 years, altogether 20 cases of 
leukaemia among 1000 thorotrast patients would be registered 
compared with about one spontaneous case of leukaemia within 
this time. This estimated figure is in good agreement with 
23 fatal blood dyscrasias from the Portuguese thorotrast popu-
lation of 998, traced by SILVA HORTA, ABBATT and others gOj . 
Lung tumours: 
The spontaneous incidence of lung tumours is 7 • 10~ N/year 
(where N is the number of persons). The risk coefficient for 
radiation-induced lung cancer generally recommended today is 
10 per 10 man-rem {lb, 15, 1*3 • To obtain statistically sig-
nificant results the number of radiation induced lung tumours 
should be greater than 36"* of the spontaneous incidence ( $**« 
j7 • 1 0 ~ 4 N ) . With a follow-up time of 10 years and an average 
dose equivalent of 1O0O rem (Table Il)» the minimum number of 
patients that would have to be examined is about 700. Undoub-
tedly an increased incidence of lung cancer with thorotrast pa-
tients would be a pure radiation effect, if we do not take into 
consideration possible special smoking habits of the thorotrast 
group. However in the Portuguese population of about 1000 cases 
up to now no significant increase of lung tumours rate could be 
demonstrated (only 2 cases of carcinoma of the bronchus occu-
ring 1 and h years after thorotrast injection) [}(S| . 
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Liver tumours i 
The spontaneous incidence is about 2 • 10 N/year (Ns number 
of persons). Concerning liver tumour incidence, the non radia-
tion effects of thorotrast may be important. Nevertheless the 
folioving estimation is based on a pure radiation effect. As-
suming a mean radiation dose of 2000 rem in 10 years (Tabe i) 
and a risk coefficient of 8 per rem 10 persons per year tø5) 
ve estimate 16 additional cases vith liver tumours per IOOO pa-
tients per year compared vith less than 1 spontaneous case per 
year. For comparison: in the Portuguese group up to nov 52 li-
ver tumours could be demonstrated nOj . 
For conclusion it must be pointed out, that these are very 
rough and speculative estimations. Many of our assumptions are 
problematic (for example: the generally adopted RBE-value of 
10 for alpha particles, pure radiation effects, the risk co-
efficients used, which are mainly derived from single exposure 
vith relative high doses). 
But even these simple considerations show qualitatively the 
importance of follow up studies of thorotrast patients for 
gathering optimal and useful radiobiological data. Compared 
vith the efforts and expenses for the recording and the first 
clinical and biophysical examination of the patients, the 
follow-up studies are relative simple (only a routine medical 
examination). We therefore believe that recording and first 
examination of the patients must be combined with systematic 
follow-up studies within a time of at least 10 years. 
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Concluding discussion. 
Professor J.8. Mitchell opened the session by giving a 
survey of the meeting and its results. 
The meeting has been successful in bringing forward new 
information on practically all the points under discussion. Fur-
thermore the papers has made it possible to place the Thorotrast 
study at its proper place in relation to other radioactive conta-
minations especially plutonium and perhaps radioactive drugs. 
The dosimetry is getting better but »e have now got as far 
as ve can on a first approximation of the general dose. He must 
now study the effects of inhooogeneous distribution in both liver 
and in bone. This leads us to studies of mechanisms of action 
which have only been briefly touched upon. The significance of 
biological findings such as the cytogenic effects, the possibili-
ty of multiple tumors and of the latency period, are all fields 
mentioned in the presented papers. The problem of hormone action 
and immunology has been touched upon and even the basic problems 
of the cell type at risk have been discussed without a clear an-
swer. Probably the most important points has been that ve have 
met one another as a possible start for further collaboration, 
and here it is important that both WHO and IAEA have been present. 
On this basis and on the discussion during the meeting the 
following four main points of interest could be drawn up. 
1. Dosimetry. 
2. Biology of Thorotrast and its carcinogenic effect. 
3. Follow up studies. 
4. International coordination and collaboration. 
331 
In the discussion following this survey. The significance 
of refined dosimetry was brought up by professor Muth on behalf 
of the German study group. He summarized the dosimetric questions 
as follows: In relation to liver tumors it is apart from radiati-
on - non radiation effects the inhomogenity of the dose distribu-
tion which is of interest. Concerning the bone tumors - which so 
far have not materialised - there are questions concerning Th ' 
content of bone, Ra /Ra distribution on bone surface and 
Th distribution ratios in relation to daughters. In general 
these points were accepted by the following discussion. 
The continuation of the follow up studies are necessary. 
This is especially the case where the national materials so far 
have been too small to give definitive answers. In these areas 
an international cooperation is necessary, not only to supply 
enough material but also to make it possible to transfer data and 
clinical diagnosis between the groups. The form could not be de-
finitely defined. The different groups are far ahead in their own 
type of study and may not wish to change the procedure too much 
as this may introduce serious breaks in the collection of data. 
However some attempt at more uniformity would be useful. For this 
purpose some sort of written communication would be necessary. 
The possibility of data sheets where new information of cases 
<iying, new advances in dosimetry, experiments started etc could 
be printed for information to the groups was mentioned as one of 
the possible solutions. 
Dr. Seelentag on behalf of KHO outlined a number of fur-
ther possibilities for collaboration, but a start required some 
discussion. He suggested that the groups if possible should be 
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invited to send written suggestions on collaborative procedures 
to professor Faber for distribution to the participants as basis 
for further discussion. 
The necessity of a protocol for minimal information on 
the cases was stressed by Rowland. Suggestions for this protocol 
should be sent to professor Faber. The necessity for coordinati-
on in pathology and diagnosis was stressed by Faber, and the dif-
ficulties, especially the need for a fairly rigid framework for 
the collaboration by Ihwlley. Finally the importance of studying 
the eventual children from Thorotrast patients was stress by 
Rowland, Kaick and Tarares. 
The possibility for a new meeting was discussed and both 
Geneva, Lisbon and Heidelberg was suggested as meeting places. 
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Cages of Bone Tvmors in Thorotrast injected Patients. 
Portuguese Material, ( la ter informations). 
Age at 
Injection 
19 
17 
34 
Sez 
F 
F 
H 
Amount 
inj.ml 
20 
24 
>60 
Latency Period 
years 
29 
27 
25 
Location 
Femur 
Femur 
Maxilla 
Diagnosis con-
firmed by 
clinical + 
X-ray diagnosis 
clinical + 
X-ray diagnosis 
clinical 
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